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ABSTRACT OF DISSERTATION 
 
 
TARGETING METHYLGLYOXAL AND PPAR GAMMA TO ALLEVIATE NEUROPATHIC 
PAIN ASSOCIATED WITH TYPE 2 DIABETES 
  
 Neuropathic pain affects up to 50% of the 29 million diabetic patients in the United 
States. Neuropathic pain in diabetes manifests as a disease of the peripheral and central 
nervous systems. The prevalence of type 2 diabetes is far greater than type 1 (90%), yet 
the overwhelming focus on type 1 models this has left the mechanisms of pain in type 2 
diabetes largely unknown. Therefore I aimed to improve the current mechanistic 
understanding of pain associated with type 2 diabetes using two preclinical rodent 
models: Zucker Diabetic Fatty rats and db/db mice. In addition, I highlight the 
translational importance of simultaneous measurement of evoked/sensory and non-
evoked/affective pain-related behaviors in preclinical models. This work is the first to 
show a measure of motivational-affective pain in a model of type 2 diabetes. 
 
 I used methodological approaches including: (1) immunohistochemical and calcium 
imaging to assess stimulus-evoked sensitization; (2) measurement nociceptive 
behaviors and evoked sensory thresholds as well as pain affect using novel mechanical 
conflict avoidance and conditioned place preference/aversion assays; (3) 
pharmacological and genetic manipulation of methylglyoxal, TRPA1, AC1, and PPARγ. 
 
 I hypothesized that the thiazolidinedione class of peroxisome proliferator-activated 
receptor gamma (PPARγ) agonists would reduce neuropathic pain-like behavior and 
spinal neuron sensitization in traumatic nerve injury and type 2 diabetes. As PPARγ is a 
nuclear receptor, and already targeted clinically to promote cellular insulin sensitization 
to reduce hyperglycemia, sustained changes in gene expression are widely believed to 
be the mechanism of pain reduction. In two separate research aims, I challenged this 
view and tested whether the PPARγ agonist pioglitazone would (1) rapidly alleviate 
neuropathic pain through a non-genomic mechanism and (2) reduce painful sensitization 
in nociceptive and neuropathic pain models independent from lowering blood glucose.  
 
 I aimed to investigate the contribution of the glucose metabolite methylglyoxal to 
painful type 2 diabetes. I tested the hypothesis that methylglyoxal produces nociceptive, 
evoked, and affective pain that is dependent on activation of the sensory neuron cation 
channel TRPA1 and the secondary messenger enzyme AC1. I also tested whether 
pioglitazone or the novel methylglyoxal scavenging peptide GERP10 could alleviate 
painful type 2 diabetes.  
 
  
 
Ryan B. Griggs 
KEYWORDS: painful type 2 diabetes, pioglitazone, chronic neuropathic pain, 
methylglyoxal, TRPA1, PPAR gamma 
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1 
CHAPTER 1:  Background 
 
1.1  Hypothesis and specific aims 
 My overall hypothesis is that type 2 diabetic neuropathic pain is alleviated by either 
administration of thiazolidinedione PPARγ agonists or inhibition of the methylglyoxal-
TRPA1-AC1 pathway. To test this hypothesis I designed and performed many 
experiments to investigate the following specific aims:  
1) Determine whether the known analgesic gabapentin alleviates motivational-
affective pain in the spared nerve injury model of neuropathic pain. The purpose 
of this aim was to validate the use of conditioned place preference testing to 
assess a preclinical measure of affective pain.  
2) Test whether the rapid antihyperalgesic action of TZDs is dependent on a non-
genomic mechanism.  
3) Determine whether astrocyte mechanism are involved in rapid pioglitazone 
antihyperalgesia.  
4) Characterize the neuropathic pain phenotype of the Zucker Diabetic Fatty rat 
model of type 2 diabetes and determine whether spinal nociresponsive neuron 
sensitization is associated with pain-like behavior in this model.  
5) Determine whether pioglitazone alleviates pain and spinal sensitization in type 2 
diabetes independent from its reduction of hyperglycemia.  
6) Test whether methylglyoxal is sufficient to produce nociceptive, evoked, and 
affective pain-like behavior and determine whether the methylglyoxal scavenging 
peptide GERP10 alleviates type 2 diabetic hyperalgesia.  
7) Determine the contribution of TRPA1 and AC1 to methylglyoxal-mediated pain in 
type 2 diabetes. 
  
2 
1.2  Overview of Pain Physiology and Psychology 
 The phenomenon of pain is a complex physiological and psychological experience 
defined by the International Association for the Study of Pain (IASP) as “An unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage.” Importantly, pain can exist in the absence of any 
noticeable injury and as such, current medical practice treats a patient’s pain, even when 
there is no obvious injury. This fact alone makes the treatment of pain in humans very 
difficult, because in many cases physiological symptoms of pain may not exist or are not 
detectable and caregivers must rely on subjective reports only. In this line of thinking, the 
ability of preclinical researchers to utilize animal (non-human) models to develop 
treatments (i.e. drugs, or pharmacological agents that act on one or multiple biological 
targets to effect physiological change) for psychological pain is virtually impossible 
because animals lack the ability to verbally self-report. However, I argue that there are 
very similar ways for both patients and preclinical rodent models (it should be recognized 
that there are other animal models used in pain research such as dogs, rabbits, and 
non-human primates) to self-report the presence or absence of the sensory-
discriminative and affective-motivational dimensions of pain (see 1.7.2 and Chapter 2: ).  
 
1.2.1  Terminology, or notes on the words and terms used to describe pain 
 It is difficult to rationalize using the term pain to apply to an unpleasant experience in 
rodent models used in pain research, as only an inference can be made whether or not 
the animal is experiencing unpleasantness. I should note that many times I ascribe pain 
to conclusions that I make from this research in discussion; but, the use of the term pain 
in this case is simply an inference. To avoid confusion, and to help delineate discussion 
of human patients and rodent models, several terms defined by IASP exist to define the 
3 
phenomena we can measure and study in rodents. These terms can be found in the 
Appendix. 
 Several terms defined by IASP are inherently flawed if used to describe rodent 
research because they include the word “pain”. However, if “pain” is replaced with 
“response” then terms such as allodynia, hyperalgesia, and neuropathic pain can be 
reasonably applied to describe a pain-like experience in rodents. We have used the 
words allodynia, hyperalgesia, and hypersensitivity almost interchangeably, but it is 
important to note that each term describes a slightly different aspect of somatosensation. 
Here, allodynia refers to when an animal responds to a stimulus (e.g. von Frey filaments 
or acetone) that does not produce a response prior to injury in that animal or in control 
animals. Hyperalgesia is used to describe either a decrease in the response threshold or 
an increase in the magnitude of a response to a given stimulus. Hypersensitivity is a 
term that encompasses both allodynia and hyperalgesia while escaping the inherent 
flaws in the definitions ascribing pain to preclinical models.  
 
1.2.2  The dimensions of pain 
 The emotional and unpleasant experience of pain begins with the sensory-
discriminative, or the ability to sense a potentially tissue damaging stimulus and to 
discriminate its location on the body. The somatosensory system has the ability to 
distinguish both the quality (e.g. chemical, thermal, mechanical) and quantity (e.g. non-
noxious versus noxious) of the stimulus. Several types of primary afferents containing 
nerve endings innervate the skin, viscera, internal organs, and blood vessels to function 
in a sensory-discriminative capacity. These include C, Aδ, and Aβ fibers that are 
distinguished by their neurophysiological properties including conduction velocity, 
degree of myelination, size (cross sectional area), length, action potential threshold, and 
expression of receptors. Reception is the process of detecting an exogenous (such as 
4 
mechanical touch or thermal changes) or endogenous (such as cytokines, chemokines, 
or lipid metabolites) stimulus. This typically occurs via protein receptors expressed on 
the plasma membrane of afferents with free nerve endings or by larger, more 
complicated structures such as Merkel discs, Meissner’, or Pacinian corpuscles. 
Transduction is the process of converting that extracellular stimulus to an intracellular 
message, which typically occurs by depolarization of the neuron. A stimulus that is great 
enough to overcome the activation threshold of the neuron results in the initiation of an 
action potential. Transmission is the process by which the neuron propagates the action 
potential along its axon toward the first synapse at the junction between the primary 
afferent and the second order neuron in the central nervous system. Second order 
neurons for the limbs in humans and rodents are located in the spinal cord, which is the 
focus of most of the work herein, because typical behavioral tests in rodents involve 
measuring the sensitivity of hindpaws to mechanical, chemical, and thermal stimuli. 
Integration is the process by which CNS neurons compile signals from one or many 
primary afferents and relay this information to third and fourth order neurons that 
transmit signals through spinal and brainstem pathways to the thalamic integration 
center and cortical areas involved in the motivational-affective and  cognitive-evaluative 
dimensions of pain. It should be noted that the stimulus-evoked signals can be 
modulated at several locations of the transmission process by inhibitory neurons, other 
excitatory neurons, neurons integrating other simultaneous stimuli, and descending 
modulation that is regulated by specific areas of the brain. These will not be investigated 
in the current work.  
 Motivational-affective describes the unpleasantness (affect) and the inherent drive to 
avoid pain (motivation). Motivational-affective pain can be independent from a sensory 
experience. This is evident by the fact that even the threat of pain can be perceived as 
painful and produce negative affect and avoidance. Conversely, the negative 
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reinforcement of ongoing pain is rewarding and therefore subjects will seek this pleasant 
experience. This extension of the pain experience beyond its sensory component 
increases the complexity of studying pain, as objective research is attempted to define a 
subjective experience. We and others report that some therapies may benefit the 
sensory aspect of pain (i.e. evoked hypersensitivity) without reducing the subjective 
affective component in preclinical models. This is highlighted by the small number of 
effective therapies developed by preclinical research, beyond the repurposing (e.g. 
gabapentin) or refinement (e.g. opioids) of “old” drugs. Here we describe and validate 
conditioned place preference, a preclinical assay used as a tool to assess the 
motivational-affective dimension of pain in rodents (1.8 ) and apply this tool to assessing 
affective pain in diabetes (section 5.4.1 ). For review of these dimensions of pain see 
(Auvray et al, 2010). 
 
1.3  Painful diabetic neuropathy (aka painful diabetes) 
1.3.1  The burden of chronic diabetic pain 
 According to the World Health Organization, almost 350 million people or ~5% of the 
population worldwide have diabetes. In the U.S. the prevalence is a bit greater at 9% 
(Center for Disease Control), or 29 million people. The cost of diabetes in the U.S. in 
2012 was estimated to be $245 billion, with $176 billion in direct costs and $69 billion in 
lost productivity. Type 2 diabetes accounts for the majority of diabetes cases at 90%. 
This is shocking given the fact that the gold standard for type 2 diabetes prevention and 
treatment is diet and exercise.  
 Approximately 50% of diabetics will experience peripheral neuropathy at some point 
during the disease natural history (Vincent et al, 2011). Peripheral neuropathy is likely 
due to microvascular complications associated with the metabolic deficits and 
inflammation that result in insulin insensitivity, hyperglycemia, decreased motor and 
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sensory nerve conduction velocities, macrophage infiltration, loss of intraepidermal 
nerve fibers, and altered somatosensation, including painful hyperalgesia/allodynia as 
well as painless or insensate neuropathy. Here we focus on the neuropathic pain that 
occurs in approximately one-third of diabetic patients (Davies et al, 2006; Abbott et al, 
2011; Lee-Kubli et al, 2014), a condition commonly referred to as painful diabetic 
neuropathy (PDN) (Vincent et al, 2011). As the current work focuses only on the pain-
related behaviors associated with type 2 diabetes and not necessarily the overt 
dysfunction of sensory and motor neurons that is neuropathy, we suggest that the term 
painful diabetes is a suitable substitute for painful diabetic neuropathy. The 
pathogenesis of pain in rodent models of diabetic neuropathy is reviewed by several 
groups (Kapur, 2003; Tirabassi et al, 2004; Calcutt and Backonja, 2007; Obrosova, 
2009).  
 The majority of preclinical painful diabetes studies focus on the streptozotocin (STZ) 
model of type 1 diabetes (Calcutt et al, 2009). However, as we further discuss below, 
STZ is an inappropriate model to study PDN because it produces a natural history of 
diabetes that does not model the human condition (Fox et al, 1999). Instead, we use two 
genetic models of type 2 diabetes: Zucker Diabetic Fatty rats (ZDF) and db/db mice 
(db/db). Figure 1-1A illustrates the dearth of pain publications in these two models of 
type 2 diabetes, compared to the explosion of STZ pain publications within the past 
couple decades. Figure 1-1B further illustrates the disparity between the very few 
numbers of preclinical studies investigating painful type 2 diabetes compared to 
exponential increases in publications on type 2 diabetes pain in patients. Figure 1-1C 
shows that the prevalence of diabetes in the United States has quadrupled in the past 15 
years. Clearly more work is needed to benefit the growing problem of type 2 diabetes 
and associated pain. 
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Figure 1-1. Publications and prevalence of diabetes. 
I performed a Pubmed (http://www.ncbi.nlm.nih.gov/pubmed) search on September 
22, 2015 and quantified the number of publications per year from 1973-2015. The 
number of publications are shown using the following search terms. (A) Preclinical 
models of type 1 diabetes pain (“streptozotocin pain”) and type 2 diabetes pain 
(combined publications from “zucker diabetic fatty rat pain” and “db/db pain” 
searches). (B) Clinical condition descriptors of “type 1 diabetes pain” and “type 2 
diabetes pain”. (C) The number of diagnosed diabetes (type 1 and type 2 combined) 
cases per year from 1980-2012. 
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1.3.2  Current treatments available for painful diabetes 
 Analgesic treatments are only effective in a small subset of PDN patients (Smith and 
Argoff, 2011). Maintaining blood glucose in the normal range is the first line of defense 
against PDN (Veves et al, 2008), and this can be accomplished with a lifestyle change to 
incorporate diet and exercise. However, in late-stage type 2 diabetes obesity and pain 
may prevent adequate management by diet and exercise. Therefore adjuvant 
pharmacotherapies may be needed to manage painful diabetes. Only duloxetine, a 
selective serotonin and norepinephrine reuptake inhibitor, and pregabalin, a 
gabapentinoid anxiolytic, are approved by the Food & Drug Administration for diabetic 
pain treatment (Smith and Argoff, 2011), but are only moderately effective in a subset of 
diabetic patients. PDN treatment is complicated by the fact that diabetes decreases the 
efficacy of opioid analgesics. The function and antinociceptive effects of opioids are 
diminished in both db/db mice (Kamei et al, 1997; Takeshita and Yamaguchi, 1998) and 
ZDF rats (Otto et al, 2011) as well as in STZ (Shaqura et al, 2013).  
 Ongoing clinical trials are testing the efficacy and safety of new 
pharmacotherapeutics but treatment options for PDN are still lacking (Javed et al, 2015). 
A non-exhaustive list of potential therapies for PDN include: the lipophilin ligand FK1706 
(Yamazaki et al, 2012), taurine (Li et al, 2006), aldose reductase inhibitors (Schemmel et 
al, 2010), Poly-ADP-ribose inhibition (Drel et al, 2010), and TRPA1 antagonists (Wei et 
al, 2009; Wei et al, 2010; Barrière et al, 2012; Eberhardt et al, 2012; Koivisto et al, 2012; 
Andersson et al, 2013). One potential problem with the future success of these therapies 
for the treatment of painful type 2 diabetes is that they were developed using the 
preclinical STZ model. Here we use mouse and rat models to investigate both the 
mechanisms of and potential treatments for painful type 2 diabetes to combat the 
growing problem of diabetic neuropathic pain.  
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1.4  Neuropathic pain sensitization 
 Sensitization is defined as the increased responsiveness and/or decreased threshold 
of activation of peripheral or central neurons. Peripheral and central sensitization in 
rodents and humans is a major contributor to the transition from normal, protective, 
evolutionarily advantageous pain to pathological pain that hinders function and quality of 
life. It is the prevailing belief that peripheral sensitization mechanisms contribute to 
central sensitization (Baron et al, 2013) and mediate the shift between acute pain, which 
typically has a distinguishable stimulus (e.g. tissue or nerve injury, exogenous stimulus), 
and chronic pain, which may or may not have a recognizable cause. Our goal is not to 
re-review or redefine the mechanisms on central sensitization, but only to provide a brief 
overview as rationale for investigating the spinal mechanisms of painful diabetes and 
PPARγ-directed therapies for neuropathic pain.  
 Central sensitization is characterized by both functional studies and changes in the 
expression of sensitization markers. One prevailing theory is that peripheral injury leads 
to central sensitization in the form of long term potentiation (LTP) in the spinal cord 
dorsal horn (Sandkuhler and Gruber-Schoffnegger, 2012). A recent study showed that 
this plasticity that contributes to chronic pain could be reduced by reconsolidating the 
nociceptive event, effectively erasing the pain memory (Bonin and De Koninck, 2014). In 
addition, neuropathic pain models result in increased responses to peripheral input in 
dorsal horn neurons (Ji et al, 2003; Doolen et al, 2012), increases in the expression of 
astrocyte (Svensson and Brodin, 2010) and microglial (Beggs and Salter, 2007; Zhuo et 
al, 2011) markers, and exaggerated phosphorylation of extracellular signal-regulated 
kinase (pERK) and Fos (Gao and Ji, 2009), which acts as a marker for neuronal 
activation. Indeed, the above mechanisms are shown to contribute to spinal sensitization 
in models of type 2 diabetes (Cheng et al, 2010; Liao et al, 2011; Dauch et al, 2012; Xu 
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et al, 2014; Schuelert et al, 2015). For further review of painful central sensitization 
generalized to many types of pain see (Ji et al, 2003; Woolf, 2011; Baron et al, 2013).  
 Stimulus evoked phosphorylation of extracellular signal-regulated kinase (pERK) is a 
marker of central sensitization (Ji et al, 1999). Activation of peripheral nociceptors 
increases pERK in the spinal cord dorsal horn (Ji et al, 1999). Light-touch stimulation of 
the hindpaw in a traumatic nerve injury model of neuropathic pain leads to increased 
pERK in the dorsal horn of injured subjects (Zhuang et al, 2005; Morgenweck et al, 
2013). Noxious hindpaw stimulation also induces pERK in spinal neurons (Ji et al, 2002). 
In injured animals, ERK is activated (i.e. phosphorylated) within ten to thirty minutes, 
indicating a relatively rapid increase in the responsivity of spinal neurons in response to 
peripheral stimulation, making pERK is a suitable marker for central sensitization (Gao 
and Ji, 2009). Further supporting the role of spinal ERK activation in neuropathic pain, 
intrathecal delivery of pERK inhibitors such as U0126 reduces hypersensitivity in 
diabetic pain models (Daulhac et al, 2006; Tsuda et al, 2008; Daulhac et al, 2011; Xu et 
al, 2014). 
 The mechanisms of central sensitization in painful type 2 diabetes are not well 
known, as only a few preclinical studies have investigated central sensitization in painful 
type 2 diabetes. Type 2 diabetic subjects exhibit increased expression of markers of 
central sensitization, including pERK (Daulhac et al, 2011; Dauch et al, 2012; Xu et al, 
2014) and the astrocyte marker GFAP (Liao et al, 2011; Ren et al, 2012). To our 
knowledge, Schuelert et al were the first to show functional electrophysiological 
evidence of central sensitization in type 2 diabetes, indicating that spinal neuron 
responses to peripheral non-noxious mechanical stimulation were increased (Schuelert 
et al, 2015). Here we evaluate stimulus-dependent pERK in type 2 diabetic rats and 
mice to investigate the role of spinal nociresponsive neurons in type 2 diabetes. We also 
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test the hypothesis that sensitization of these neurons contributes to the pathogenesis of 
PDN.  
 
1.5  Specific mediators involved in the regulation of pain 
1.5.1  Peroxisome proliferator-activated receptor gamma (PPARγ) 
 Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor 
that regulates the gene expression related to insulin signaling, glucose and fatty acid 
metabolism, adipogenesis, neurological disease, and pain (Feinstein, 2003; Evans et al, 
2004; Kota et al, 2005; van Neerven and Mey, 2007; Maeda and Kishioka, 2009; 
Ahmadian et al, 2013; Yonutas and Sullivan, 2013). The endogenous ligands for PPARγ 
include 15-Deoxy-Delta-12,14-prostaglandin J2 (15d-PGJ2), poly-unsaturated fatty acids 
(PUFA), and arachidonic acid and some of its metabolites. The exogenous ligands for 
PPARγ include thiazolidinedione (TZD), non-TZD molecules, and natural derivatives. 
TZDs include older molecules such as ciglitazone and troglitazone and newer molecules 
such as rosiglitazone and pioglitazone, in addition to some TZD-derivatives under 
development. Non-TZD PPARγ agonists include MDG548 (Lecca et al, 2015), PAM-
1616 (Kim et al, 2010), MBX-102 (Gregoire et al, 2009), FK614 (Minoura, 2007), and 
other partial agonists such as PEA (Costa et al, 2008). Ligands are also derived from 
natural sources such as the compound monascin (Hsu et al, 2013). Studies using 
antagonists of PPARγ such as T007, BADGE, and GW9662 (2-chloro-5-
nitrobenzanilide) suggest PPARγ-dependent effects of agonists. However, the excellent 
review from Luconi et al indicate a multitude of ways PPARγ agonists could exert their 
effects, including both PPARγ-dependent and independent pathways (Luconi et al, 
2010). Germline PPARγ knockout is embryonic lethal but several conditional or tissue 
specific transgenic mutations have been reported in mice (Sarruf et al, 2009; Wu et al, 
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2009; Lu et al, 2011), including a nestin-Cre neuronal knockout (de Guglielmo et al, 
2014) that could prove very useful in future studies investigating PPARγ analgesia.  
 The FDA has approved rosiglitazone (Avandia®) and pioglitazone (Actos®) for the 
treatment of type 2 diabetes. These TZDs act as insulin sensitizers to lower blood 
glucose. It should be noted that their safety in humans has come under scrutiny. For 
example, pioglitazone may contribute to the development of bladder cancer following 
long-term administration (Lewis et al, 2011). The FDA has released safety precaution 
warnings for both TZDs with regard to cardiovascular risks; however, both drugs are still 
used in mono and combination therapy for the treatment of type 2 diabetes.  
 Over the past thirteen years, a growing body of preclinical evidence indicates that the 
PPARγ agonists 15d-PGJ2, rosiglitazone, and pioglitazone reduce central (Park et al, 
2007), inflammatory (Taylor et al, 2002; Morgenweck et al, 2010; Hasegawa-Moriyama 
et al, 2013), nociceptive (Oliveira et al, 2007; Napimoga et al, 2008; Pena-Dos-Santos et 
al, 2009; Griggs et al, 2015), and neuropathic (Churi et al, 2008; Costa et al, 2008; Iwai 
et al, 2008; Maeda et al, 2008; Fehrenbacher et al, 2009; Jain et al, 2009; Jia et al, 
2010; Takahashi et al, 2011; Hasegawa-Moriyama et al, 2012; Jain et al, 2013; Jain et 
al, 2013; Jia et al, 2013; Morgenweck et al, 2013; Paragomi et al, 2014; Zanardelli et al, 
2014; Griggs et al, 2015) pain. PPARγ is expressed in key areas of pain processing 
including the brain (Cullingford et al, 1998; Cristiano et al, 2001; Zander et al, 2002; 
Dello Russo et al, 2003; Moreno et al, 2004; Park et al, 2004; Victor et al, 2006; Sarruf et 
al, 2009), spinal cord (Diab et al, 2002; Moreno et al, 2004; Churi et al, 2008; Maeda et 
al, 2008; Shibata et al, 2008), and peripheral nerves (Yamagishi et al, 2008). PPARγ 
agonists reduce many factors associated with behavioral hypersensitivity including: (1) 
proinflammatory TNFα, IL-1β, and NF-κB in the spinal cord and peripheral nerve (Park et 
al, 2007; Maeda et al, 2008; Jia et al, 2010; Jain et al, 2013; Jia et al, 2013); (2) M1 
macrophage polarization with simultaneous promotion of M2 in peripheral nerve (Park et 
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al, 2007; Takahashi et al, 2011; Hasegawa-Moriyama et al, 2012; Hasegawa-Moriyama 
et al, 2013); (3) microglial (Park et al, 2007; Iwai et al, 2008; Takahashi et al, 2011; 
Morgenweck et al, 2013) and astrocyte (Park et al, 2007; Jia et al, 2013; Morgenweck et 
al, 2013; Griggs et al, 2015) activation in the spinal cord; and (4) Fos and pERK markers 
of neuron activation in the spinal cord and brain (Morgenweck et al, 2010; Morgenweck 
et al, 2013; Griggs et al, 2015). Here we investigate the mechanism of action of 
pioglitazone in both nerve injury and type 2 diabetic pain models.  
 
1.5.2  Transient receptor potential cation channel A1 (TRPA1) 
 Subtypes of the transient receptor potential (TRP) superfamily of cation channels 
include ankyrin (A), vanilloid (V), melastatin (M), and canonical (C). TRP receptors are 
can be polymodal, responding to chemicals found in food as well as hot, cold, and 
mechanical stimulation. Here we use capsaicin, a compound found in chili peppers, to 
activate TRPV1 in order to model nociception in the rodent primary afferent. In addition, 
we investigate the activation of TRPA1 by the glucose metabolite methylglyoxal. See 
review on TRP channels in pain for more information on these well-studied receptors 
(Julius, 2013).  
 TRPA1 is activated by cold (Story et al, 2003) and mechanical (Kwan et al, 2009) 
stimuli, as well as chemicals (Bautista et al, 2005; McNamara et al, 2007; Trevisani et al, 
2007; Eberhardt et al, 2012; Gregus et al, 2012) such as methylglyoxal (MG). 
Sensitization of TRPA1 in peripheral neurons is suggested to fine tune mechanical 
sensitivity (Kwan et al, 2009; Brierley et al, 2011). In mice, TRPA1 is expressed in small, 
unmyelinated, peptidergic peripheral DRG neurons (C-fibers) and predominantly 
colocalizes with TRPV1 (Story et al, 2003; Bautista et al, 2005; Kobayashi et al, 2005; 
Garcia-Anoveros and Duggan, 2007). The proportion of DRG neurons that express 
TRPA1 varies depending on the species used (rat or mouse) and between publications, 
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with a range of 20-40% in rat and 3-56% in mouse (Kobayashi et al, 2005). Functional 
studies indicated that MG produces a calcium response in 72% of capsaicin (prototypical 
TRPV1 agonist) responsive DRG neurons (Andersson et al, 2013), suggesting that 72% 
of TRPV1 fibers also express TRPA1. This expressional and functional evidence 
suggests that TRPA1 may play a role in mediating diverse stimulus modalities, and 
supports our investigation of spontaneous nociceptive as well as both mechanical- and 
heat-evoked hypersensitivity by the novel agonist methylglyoxal (Eberhardt et al, 2012). 
Important to note, there is little evidence to support the expression of TRPA1 on 
postsynaptic neurons in the dorsal horn, suggesting that presynaptic TRPA1 contributes 
to the activation of these nociresponsive neurons in the spinal cord.  
 TRPA1 is implicated in several pain conditions. The TRPA1 antagonist A-967079 
reduces nociresponsive behavior after administration of mustard oil (TRPA1 agonist) as 
well as attenuating cold allodynia in the monoiodoacetate model of osteoarthritis. 
Inhibition of TRPA1 may reduce pain-related behaviors by blocking CGRP release in the 
DRG (Chen et al, 2011). Interestingly, A-967079 did not inhibit mechanical 
hypersensitivity in nerve injury (CCI/SNI) or inflammatory (CFA) pain models (Chen et al, 
2011). However, an alternative TRPA1 antagonist (which we have used in the current 
studies) HC-030031 attenuated nociresponsive behavior after AITC administration 
(TRPA1 agonist) as well as mechanical hypersensitivity in both nerve injury (SNL) and 
inflammatory (CFA) pain models (Eid et al, 2008). Neither of these antagonists affected 
locomotor coordination, body temperature, heart rate, or naïve heat sensitivity (Eid et al, 
2008; Chen et al, 2011). A third antagonist, Chembridge-5861528, reduces mechanical 
hypersensitivity after peripheral administration of TRPA1 agonists, in models of 
neuropathic pain such as STZ-induced type 1 diabetes or SNI, and in a post-operative 
pain model (Wei et al, 2009; Wei et al, 2010; Wei et al, 2012; Wei et al, 2013). 
Antagonist studies further implicate the contribution of spinal TRPA1 to peripheral 
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hypersensitivity in various pain models (Wei et al, 2011). Here we investigate the role of 
spinal and/or peripheral TRPA1 in the maintenance of pain in type 2 diabetes.  
 The structural-functional relationships (Paulsen et al, 2015) of the TRPA1 channel as 
well as the new development of selective antagonists (Preti et al, 2015) provide valuable 
information as to the mechanism of TRPA1 activation by endogenous and exogenous 
agonists. The mode of activation of TRPA1 by putative (functional) agonists may be due 
to covalent modification of specific, thermodynamically available, reactive protein 
residues such as cysteines (Macpherson et al, 2007). In various pain models, 
endogenous TRPA1 agonists are produced (Stucky et al, 2009) and this may mediate 
ongoing hypersensitivity associated with these models. Indeed, functional 
characterization of TRPA1 in DRG neurons indicated that an endogenous agonist 
activates TRPA1 via modification of cysteines (Takahashi et al, 2008). The release of 
endogenous TRPA1 agonists in a pathological pain condition (i.e. injury) or after 
peripheral stimulation (such as by mechanical stimulation of the hindpaw (McGaraughty 
et al, 2010) helps to explain the putative contribution of spinal TRPA1 to pain-related 
behaviors. In other words, our current results and other studies indicate that spinal 
administration of a TRPA1 antagonist blocks peripherally evoked hypersensitivity; 
therefore, either the pain model or the stimulation itself must result in the release of 
TRPA1 activators at the first synapse in the dorsal horn. This is explored in section 
5.4.3.  
 
1.5.3  Adenylyl cyclase, isoform 1 (AC1) 
 Calcium activated adenylyl cyclase 1 (AC1) (Xia and Storm, 1997) is a key signal 
transduction protein and modulator of pain plasticity in the central nervous system 
(Zhuo, 2012). AC1 (and AC8 to some extent) acts to facilitate N-methyl-D-aspartate 
receptor (NMDAR) mediated nociceptive transmission in the spinal cord dorsal horn, an 
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effect that is modulated by both 5-HT activity and forskolin-stimulated cAMP production 
(Wang and Zhuo, 2002). AC1 knockout and systemic administration of the AC1 inhibitor 
NB001 inhibited the late acute response and chronic hypersensitivity associated with 
administration of intramuscular formalin, while the immediate nociresponsive effects 
were unchanged by modulation of AC1. Similarly, knockout of AC1 does not reduce ERK 
activation in spinal neurons evoked by glutamate, capsaicin, or formalin in naïve 
animals, but does reduce persistent spinal long term potentiation (LTP) (Wei et al, 2006). 
These results suggest that AC1 mediates central sensitization of spinal nociceptive 
neurons but not rapid/acute responses to noxious stimulation in a naïve state. 
Supporting an AC1 role in central sensitization, a potentiated AC1 system in the spinal 
cord is revealed by the reinstatement of pain after recovery from an inflammatory injury 
(Corder et al, 2013). We hypothesized that AC1 mediates persistent hyperalgesia in type 
2 diabetes that is dependent upon activation of TRPA1.  
 
1.5.4  Methylglyoxal and glyoxalase 1 
 Methylglyoxal is a highly reactive cellular metabolite of glycolysis that accumulates in 
type 2 diabetic hyperglycemia (Bierhaus et al, 2012; Kender et al, 2014; Kong et al, 
2014; Allaman et al, 2015; Dornadula et al, 2015). Figure 1-2 illustrates the biosynthetic 
and biodegradation pathways of methylglyoxal. Methylglyoxal contains both aldehyde 
and ketone moieties that result in protein modification at lysine/arginine residues and 
facilitates cysteine-cysteine disulfide bonds (Rabbani and Thornalley, 2012). 
Methylglyoxal forms other protein adducts such as advanced glycation end-products 
(AGEs) (Shipanova et al, 1997; Oya et al, 1999; Berner et al, 2012), which result in 
diabetic complications (Westwood and Thornalley, 1995; Desai and Wu, 2007; Matsui et 
al, 2010; Sohn et al, 2011). Figure 1-3 illustrates two methods of measuring 
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methylglyoxal-derived AGEs or free methylglyoxal in biological samples and depicts the 
structure of methylglyoxal.  
 Methylglyoxal is metabolized by the glyoxalase (GLO) system involving both GLO1 
and GLO2 enzymes and requiring reduced glutathione (GSH) as an oxidizing agent. An 
excellent review of the history of discoveries related to MG and GLO1 is available 
(Rabbani and Thornalley, 2014). Potential polymorphisms in GLO1 can affect enzyme 
function (Peculis et al, 2013), thereby rendering an organism more susceptible to 
changes in glucose metabolism. This is exemplified in different mouse strains, where 
BALB/cByJ mice are protected from STZ-induced diabetic neuropathy compared to 
BALB/cJ mice, in which GLO1 expression is decreased tenfold (Jack et al, 2012). Both 
aging (Fleming et al, 2013) and diabetes (Jack et al, 2011; 2012; Skapare et al, 2013) 
are associated with reduced GLO1 activity thereby rendering greater risk for the 
detrimental effects of MG. Studies overexpressing GLO1 implicate methylglyoxal in: the 
production of anxiety-related behavior (Distler et al, 2012), reduction of seizures after 
administration of epileptic seizure agents (Distler et al, 2013), and inducing hyperalgesia 
in type 1 diabetes (Bierhaus et al, 2012). Conversely, chronic inhibition of GLO1 by Sr-p-
Bromobenzylglutathionecyclopentyl diester (BrBz) produces evoked behavioral 
hypersensitivity (Andersson et al, 2013). This indicates that the endogenous levels of 
MG, which are inversely correlated with GLO1 activity (Thornalley, 1996), regulate pain 
sensitivity. We propose that overexpression of GLO1 activity in type 2 diabetes could 
reduce PDN as a future study (section 6.3.2 ).  
 Methylglyoxal is implicated in the pathogenesis of several neurological disease 
conditions. Methylglyoxal induces the release of glutamate in human neuroblastoma SH-
SY5Y cells that is dependent on NMDA-R activation and results in the depolarization of 
neocortical pyramidal cells producing neurotoxicity through necrotic and reactive oxygen 
species mechanisms (de Arriba et al, 2006). Both calcium imaging and patch clamp 
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electrophysiology experiments indicate that DRG neurons are activated by methylglyoxal 
(300 μM), suggesting methylglyoxal might modulate peripheral nociceptor sensitivity to 
produce pain (Koivisto et al, 2012). Methylglyoxal generates anxiogenesis (Hovatta et al, 
2005; Distler et al, 2012) and epileptic seizure activity that is regulated by GLO1 activity 
(Distler et al, 2013). Furthermore, methylglyoxal may be the common factor linking 
associations between Parkinson’s and type 2 diabetes (R. Hipkiss, 2012) and GLO1 
variations are loosely associated with autism spectrum disorder (Kovac et al, 2014). 
Methylglyoxal is reported to activate ion channels involved in pain processing such as 
GABAA (Distler et al, 2012), Nav1.8 (Bierhaus et al, 2012), and TRPA1 (Eberhardt et al, 
2012; Koivisto et al, 2012; Ohkawara et al, 2012; Andersson et al, 2013; Koivisto et al, 
2013). Here we investigate the activity of MG at TRPA1 receptors to produce painful 
type 2 diabetes.  
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Figure 1-2. Biochemical pathways of methylglyoxal production and 
degradation. 
Adapted from (Allaman et al, 2015). 
Methylglyoxal is produced from (A) glycolysis and (B) lipid and protein metabolism 
and is (C) detoxified (i.e. metabolized) by the glyoxalase system using glutathione 
(GSH) redox cycling coupled to (D) NADPH production from pentose phosphate. 
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Figure 1-3. Methods to measure MG-related entities. 
(A) Methylglyoxal-derived advanced glycation end-products (AGEs) can be 
measured using a competitive ELISA that recognizes hydroimidazolone MG-H1 
protein residues where methylglyoxal covalently modifies arginine residues. (B) Free 
methylglyoxal (chemical structure is shown) circulating through the blood or within 
tissues can be measured by high-pressure liquid chromatography followed by 
tandem mass spectrometry. A representative mass spectrometry trace is shown for 
vehicle or methylglyoxal (MG) infusion. Mass spectrometry data courtesy of Dustin 
Carroll. 
 
1.6  Modeling pain conditions in rodents 
 In order to study the human condition of pain we need preclinical models. Bioethical 
and practical considerations preclude the ability of the researcher to perform 
experimental manipulations on humans. For example, it is not feasible or reasonable to 
expect a patient to allow a researcher to transect a piece of their sciatic nerve in order to 
study the pain of traumatic nerve injury. However, as described later in section 1.6.2.1  
we have used this technique to investigate neuropathic pain mechanisms in rats.  
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 Animal models are important because they can be readily manipulated by the 
experimenter and constant variables (e.g. genetics, environment, time, location, etc.) 
can be well-controlled. In addition, reproducibility of results can be tested across 
experiments, labs, and institutions. Common animal models in the field of research are 
mice and rats, of which there are thousands of different strains and genetic backgrounds 
available through commercial vendors. The past twenty years of research has advanced 
biotechnology and genetic engineering so that specific pieces of DNA can be 
manipulated to create transgenic or knockout mice or rats. In this work we have utilized 
germline knockout mice to investigate the role of specific proteins involved in painful 
diabetes. 
 Manipulations other than genetic changes are also useful in pain research. The 
following sections describe two categories of animal pain models utilized in this 
research: Nociceptive, which we define as chemical activation of primary afferent 
nociceptors to produce immediate pain-like behavior that lasts only about one hour; and 
Neuropathic, which we define as a direct lesion to the peripheral (and to some extent, 
central) nervous system that results in pain-like behavior that lasts days to weeks to 
even an indefinite duration.  
 
1.6.1  Nociceptive 
1.6.1.1  Capsaicin 
  The prototypical agonist of TRPV1 is capsaicin, a compound found in chili 
peppers that contributes to the taste of spicy foods (Caterina et al, 1997). Intraplantar 
injection of capsaicin activates TRPV1-positive primary afferents (i.e. nociceptors) that 
are mostly small, unmyelinated C-fibers. These C-fibers typically respond to chemical 
(e.g. capsaicin) or thermal (e.g. heat) stimuli. TRPV1 is a cation channel whose open 
probability increases when a ligand such as capsaicin is bound. Increased open 
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probability allows a greater number of cations, such as sodium and calcium, to enter the 
neuron (as compared to the resting state with no ligand) resulting in depolarization of the 
neuron. When the stimulus is great enough, as is the case with injection of even low 
doses of the potent capsaicin agonist, the action potential threshold is reached and the 
nociceptor begins to relay “pain” information to the first synapse within the spinal cord 
dorsal horn. This activation of nociceptors by the capsaicin chemical stimulus leads to 
nociceptive responses in the form of paw licking, flinching, and lifting.  
 Intraplantar capsaicin injection has been used as a model of nociceptor activation. 
For example, capsaicin activates nociceptive neurons in the spinal cord dorsal horn as 
evidenced by both superfusion in physiological slice studies (Wei et al, 2006) and 
immunohistochemical analysis of the dorsal horn after peripheral administration (Griggs 
et al, 2015). As such, it is convenient to label these dorsal horn neurons as 
nociresponsive, since they respond to the stimulation of nociceptors. In addition, 
capsaicin also induces expression of both Fos and pERK in the dorsal horn, which 
provides for a relatively simple quantifiable measurement of nociresponsive neuron 
activation after peripheral nociceptor stimulation (Griggs et al, 2015).  
 
 
Figure 1-4. Intraplantar capsaicin evokes pERK in the spinal cord dorsal horn. 
Intraplantar capsaicin (50 μg in 50 μl) was injected beneath the plantar skin of the 
left hindpaw in Sprague-Dawley rats. Animals were perfusion-fixed 10 min following 
intraplantar injection and spinal cords were harvested for immunohistochemical 
analysis. Representative images of the ipsilateral lumbar dorsal horn after (A) 
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vehicle or (B) capsaicin administration. (C) Quantification of the number of cell 
profiles positive for pERK (n=3-4).  p<0.05 vs. VEH. 
 
1.6.1.2  Methylglyoxal (acute administration) 
 Akin to activation of TRPV1, evidence is building that methylglyoxal (MG) activates 
TRPA1-positive nociceptors to produce spontaneous nociceptive behavior (Eberhardt et 
al, 2012; Koivisto et al, 2012; Andersson et al, 2013; Koivisto et al, 2013; Oguri et al, 
2014). Similar to activation of TRPA1 afferents by formalin (McNamara et al, 2007) or 
15d-PGJ2 (Cruz-Orengo et al, 2008), we tested the hypothesis that intraplantar 
administration of MG would induce nociception and activation of spinal neurons (see 
Figure 5-2). This model of chemical induced nociception allowed us to further investigate 
the role of TRPA1 and spinal sensitization in MG-mediated nociceptive pain.  
 
1.6.2  Neuropathic 
 The IASP defines neuropathic pain as “pain caused by a lesion or disease of the 
somatosensory nervous system”. We distinguish the difference between nociceptive and 
neuropathic pain in that neuropathic pain becomes pathological even in the absence of 
an obvious exogenous stimulus (such as capsaicin or methylglyoxal administration). 
Much work has been completed to elucidate the mechanisms of neuropathic pain after 
traumatic nerve injury, post-herpetic neuralgia, chemotherapeutic neuropathy, trigeminal 
neuralgia, or diabetes. Here we used three different models of neuropathic pain to 
investigate the mechanisms of PPARγ analgesia as well as the contribution of 
methylglyoxal to diabetic neuropathic pain. For reviews of neuropathic pain mechanism 
see the following references (Campbell and Meyer, 2006; Scholz and Woolf, 2007; 
Sandkühler, 2009; Jensen and Finnerup, 2014).  
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1.6.2.1  Traumatic (Spared) Nerve Injury 
  There are several models of traumatic nerve injury utilized in rodents. Most 
involve either ligation, by tying sutures around a nerve to induce neuroinflammation and 
associated sensitization, or ligation followed by transection, where a piece of the nerve is 
removed. There are two major nerves utilized in these types of studies: trigeminal and 
sciatic. Here we focus on manipulation of the sciatic nerve to induce neuropathic pain. 
Spared nerve injury (SNI) is a method by which the branches of the sciatic nerve 
trifurcation (tibial, common peroneal, sural) are differentially ligated and/or transected. 
Transection of one or more of these branches results in hypersensitivity and 
sensitization of the intact, or spared, nerve. In our studies, we transect the tibial and 
common peroneal branches of the sciatic nerve and spare the sural nerve. The 
procedure (Decosterd and Woolf, 2000) and innervation territories of these nerves in the 
spinal cord dorsal horn (Corder et al, 2010) are described previously and elaborated 
upon in section 3.3.2  
 
1.6.2.2  Diabetic neuropathic pain 
  Models of both type 1 and type 2 diabetes exist in the pain research community. 
The most common model of diabetes and associated pain-like behavior is induced by 
streptozotocin (STZ), a glucose analog and pancreatic beta cell toxin. STZ induces beta 
cell destruction resulting in the loss of insulin production and hyperglycemia. STZ 
models a type 1 diabetic-like phenotype. Here we focus on models of type 2 diabetic 
pain for reasons described in section 4.2  We use both rat (Zucker Diabetic Fatty; ZDF) 
and mouse (Leprdb/db; db/db) genetic models of type 2 diabetes. These rodents develop 
a type 2 diabetic phenotype because of an inbred genetic mutation that produces a non-
functional leptin receptor. At early stages of diabetes, ZDF and db/db exhibit behavioral 
hypersensitivity to noxious mechanical and heat stimuli. However, as diabetes 
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progresses the animals become hyposensitive. This allows for investigating the 
mechanisms of both painful and insensate neuropathy in diabetes. Here we focus on the 
period of hypersensitivity in order to study painful diabetic neuropathy (PDN), or the 
neuropathic pain associated with type 2 diabetes.  
 The Zucker Diabetic Fatty (ZDF) rat originated from a colony harboring a mutation in 
their leptin receptor causing a truncated, non-functional protein product. Inbreeding of 
ZDF rats resulted in a reliable model of genetically induced spontaneous type 2 
diabetes. ZDFs develop type 2 diabetes by age 2-3 months (Pickavance et al, 1998; 
Shibata et al, 2000; Li et al, 2006; Brussee et al, 2008; Sugimoto et al, 2008). Control 
Zucker Lean (ZL) rats are heterozygous for the leptin receptor mutation and are not 
diabetic. Thermal hyperalgesia in ZDF rats is present from age 14 weeks (Li et al, 2006; 
Donahue et al, 2012) and can last up to age 28 weeks (Oltman et al, 2008). Mechanical 
hyperalgesia occurs as early as age 14 weeks (Zhuang et al, 1997; Li et al, 2006; 
Romanovsky et al, 2008; Sugimoto et al, 2008) while mechanical allodynia develops at 
age 25 weeks and can last up to age 29 weeks (Otto et al, 2011). Our lab was unable to 
see evidence of tactile allodynia in ZDF rats up to age 24 weeks (Donahue et al, 2012). 
ZDF rats develop motor and sensory nerve conduction velocity deficits by age 16 weeks 
(Brussee et al, 2008; Oltman et al, 2008). Hypoalgesia is a common symptom of 
diabetics in later stages of disease progression and this condition also has been shown 
in ZDF rats (Oltman et al, 2008); however, this proposal aims to characterize the 
hypersensitivity seen after diabetes develops but before progression to hypoalgesia.  
 
1.6.2.2.1  Methylglyoxal (chronic administration) 
 Several studies suggest that chronic administration of methylglyoxal (MG) may be a 
suitable model of diabetic complications (Dhar et al, 2011; Dornadula et al, 2015; Illien-
Junger et al, 2015). These groups showed that chronic MG administration in the drinking 
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water, via repeated systemic injection, or minipump induces mild hyperglycemia, 
mitochondrial dysfunction, and neuroinflammation. However, pain-like behavior in a 
chronic MG model has not been investigated. Here we show that acute administration of 
MG produces pain-like behavior. We attempted to induce chronic neuropathic pain by 
using minipumps to administer MG in naïve, wild-type mice. However, experimental 
complications limited our conclusions from this study (see Figure 6-5). Therefore a future 
aim of this work is to develop a chronic neuropathic pain model induced by long-term 
administration of MG in mice and/or rats (see 6.3.1 ).   
 
1.7  Measuring preclinical “pain” in rodents 
 It is virtually impossible to measure pain in rodents when considering the true 
definition of pain, which includes the words unpleasant and emotional. We simply cannot 
ask the rodent subject whether they hurt, or whether a particular stimulus is unpleasant 
or induces negative emotion. We can only observe behavior and make inferences based 
upon these observations. Instead of ascribing the word pain to behavioral observations 
that may or may not be unpleasant or emotional, we can refer to these behaviors as 
pain-like. A majority of pain research has used stimulus-evoked measures of pain-like 
behavioral hypersensitivity. New assays, or the repurposing of previously described 
behavioral assays from the fields of psychology and addiction, are now available to go 
beyond assessment of the sensory-discriminative dimension of pain.  
 
1.7.1  Stimulus-evoked measures 
 Sensory organs and receptors in the skin allow animals to discern both quality and 
quantity of a potentially painful stimulus. Stimulus modalities include mechanical, 
thermal, and chemical. Primary afferents that innervate the skin and sensory organs 
express various proteins that each contribute to sensing stimuli in different modalities. 
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Here we investigate two such receptors: TRPV1, the primary heat receptor that is 
activated by capsaicin; and TRPA1, primarily a cooling receptor that is activated by 
methylglyoxal. Both TRPV1 and TRPA1 can contribute to mechanosensation in naïve 
and pathological pain conditions.  
  Stimulation of primary afferent terminals in the periphery can result in activation of 
nociceptive neurons in the spinal cord dorsal horn. These spinal neurons act as relay 
neurons that transmit pain information to circuits within the spinal cord as well as to third 
and fourth order neurons in the brainstem, thalamus, and cortex. This first (and 
potentially second) synapse in the spinal cord can be modulated by inhibitory and/or 
excitatory interneurons in the spinal cord or by descending projections from structures 
within the brainstem. However, a growing body of evidence suggests that the sensory 
aspects of stimulus-evoked pain-like behaviors are predominantly spinally mediated 
reflexes, and therefore do not reflect the affective-motivational or cognitive-evaluative 
aspects of pain. Nonetheless, the methods of assessing stimulus-evoked pain-like 
behavior in rodents are often quite similar to those used in humans, and therefore may 
still have translatable value. However, we argue that simultaneous assessment of both 
stimulus-evoked and non-evoked measures of pain in rodents is necessary in studies 
aiming to evaluate the clinical utility of drugs that may potentially relieve pain.  
 Assessment of stimulus-evoked pain-like behavior is accomplished by measuring the 
threshold of stimulation at which the animals responds, or withdraws from the given 
stimulus. Conversely, the magnitude of the response, as is the case for chemical-
induced nociception by capsaicin or methylglyoxal, can be measured. Here we use von 
Frey filaments and a modified Randall-Selitto pressure method to determine the force at 
which animals withdraw/respond to non-noxious or noxious stimulation, respectively. 
Similarly, we use a hotplate to subject animals to a heat stimulus and measure the 
latency, or the duration of time until the animal withdraws/responds. For mechanical or 
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heat stimulation, a decrease in the withdraw threshold or latency indicates 
hypersensitivity. To measure cold sensitivity we either evaluate the duration of withdraw 
response after stimulation with acetone (presumably evaporation results in a cooling 
sensation) or quantify the number of responses in animals subjected to a coldplate.  
 
1.7.2  Stimulus-independent measures 
1.7.2.1  Chemical-induced nociception 
 Activation of primary afferent nociceptors by endogenous and exogenous moieties 
produces pain-related behaviors. Compounds (e.g. capsaicin, formalin, carrageenan, 
methylglyoxal) are administered subcutaneously beneath the epidermis (intradermal). 
We refer to this as an intraplantar injection (i.pl.) because compounds are given into the 
ventral plantar surface of the hindpaw. Chemical activation of receptors on the free 
nerve endings of nociceptors results in spinally mediated reflex withdraw behaviors 
including licking, lifting, and/or flinching of the affected limb. We deem these 
spontaneous measures of nociception or nociresponsive behaviors because the effect is 
immediate, typically short-lived on the order of minutes, and does not require repeated 
stimulation (i.e. administration of the compound of interest) as is the case for stimulus-
evoked mechanical or thermal hyperalgesia. Quantification of the pain-related behaviors 
allows us to test how various manipulations (e.g. a receptor antagonist) affect the 
specific peripheral nociceptive pathway and/or how modulation of the spinal neuron 
reflex system changes nociception.  
 
1.7.2.2  Mechanical conflict avoidance 
 A novel Mechanical Conflict Avoidance System (MCS) was recently developed by 
our colleagues (Lau et al, 2012) to incorporate cognitive processing in the measurement 
of preclinical motivational-affective pain in rodents. MCS gives the subjects a choice to 
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remain in an environment containing an aversive light stimulus or to enter an 
environment that contains an aversive mechanical stimulus in the form of height-
adjustable, blunted metal probes. By navigating through the mechanical stimulus 
environment the subjects are rewarded with access to a darkened environment without 
probes. If animals chose to leave the light chamber and cross the probes in the stimulus 
chamber, they then had the option to enter a darkened reward chamber. This method is 
described in detail in section 4.3.4  and used to test the hypothesis that type 2 diabetes 
is associated with affective pain in ZDF rats (section 4.4.1 ).  
 
1.7.2.3  Conditioned Place Preference/Avoidance 
 Assessment of clinical and preclinical pain is not always performed using the same 
assays, which contributes to the lack of clinical efficacy of drugs that reverse reflexive 
pain in rodents (Vierck et al, 2008). Alternatively, Bennett suggests that the lack of 
success in clinical trials is not due to measuring the wrong outcome in animals (i.e. 
evoked sensitivity), but that clinicians are evaluating imprecise endpoints in patients 
(Bennett, 2012). Therefore, assays that go beyond evoked measures and that can be 
performed using similar experimental designs in both rodents and humans are needed. 
 Conditioned place preference (CPP) is used to measure the rewarding (Bardo and 
Bevins, 2000) and pain relieving (Sufka, 1994; King et al, 2009) effects of experimental 
drugs in rodents and humans. CPP has gained attention as an approach to unmask the 
affective dimension of pain in preclinical rat (King et al, 2011) and mouse (He et al, 
2012) models of peripheral nerve injury. The CPP approach harnesses the fact that an 
animal presumably in pain will be motivated to seek out an environment previously 
associated with pain relief. Since pain is aversive, negative reinforcement of the aversive 
stimulus is rewarding. Animals are trained by the unconditioned stimulus (i.e. the 
behavioral effects of analgesic drug administration) in an environment with distinctive 
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sensory cues that serves as the conditioned stimulus. After conditioning animals are 
allowed to choose whether or not they prefer to spend more time in the drug-paired 
environment in the absence of any drug administration. Pairing the affective 
consequences of analgesic drug administration takes into consideration the motivational 
aspects of pain and allows for measurement of preclinical analgesia in the absence of an 
exogenous stimulus (Tzschentke, 2007). One caveat to CPP/CPA is that diseases that 
affect memory may confound results from this assay, as memory is needed to recognize 
the environment where pain relief was received. We validate the method of CPP in a 
model of nerve injury (see 1.8 ) and use this assay to determine the effect of 
methylglyoxal on motivational-affective pain. 
 Several reports indicate dissociation between decreased evoked hypersensitivity and 
negative reinforcement of pain (i.e. CPP) after analgesic drug administration. After injury, 
rodents exhibit CPP to inhibition of spinal or peripheral nerve transmission by local 
injection of lidocaine (King et al, 2009; King et al, 2011). This suggests that ongoing 
activity from peripheral neurons in the pain pathway contributes to aversive aspects of 
supposed pain after injury. However, pharmacological inhibition of TRPV1 (Okun et al, 
2011), COX2, or TRPA1 (Okun et al, 2012) does not reverse ongoing pain (i.e. eliminate 
a preference for peripheral nerve block after injury) but alleviates evoked 
hypersensitivity. In the streptozotocin model of painful diabetic neuropathy, inhibition of 
TRPA1 reversed mechanical hypersensitivity, but not spontaneous pain as assessed 
using the CPP paradigm (Wei et al, 2013). The failure of TRPA1 and TRPV1 inhibitors in 
producing CPP preclinically is mimicked by the limited ability of TRPA1 or TRPV1 
antagonists to reduce pain in humans (Brederson et al, 2013). These studies highlight 
the importance of measuring both sensory/discriminative and affective/motivational 
outcomes in preclinical models in order to better predict clinical utility of analgesic drugs. 
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1.8  Preface 
 My current results reflect six years of work investigating chronic neuropathic pain 
using preclinical rodent models. I began this work by validating models for nociceptive 
pain (e.g. capsaicin and methylglyoxal), traumatic nerve injury (e.g. spared nerve injury), 
and painful type 2 diabetes (e.g. db/db mice and Zucker Diabetic Fatty rats). I used 
various methods to characterize and evaluate pain-related behaviors in rodents, 
including validating the use of conditioned place preference testing to assess the 
motivational-affective component of pain in Chapter 2: . In Chapter 3:  I elucidated the 
rapid antihyperalgesic effect of PPARγ agonists and determined that the inhibition of 
spinal sensitization by pioglitazone is mediated through a non-genomic, anisomycin-
insensitive, astrocyte-related mechanism. Next in Chapter 4: and Section 6.4.2 I 
simultaneously characterized models of painful diabetic neuropathy (i.e. ZDF and db/db) 
and determined that pioglitazone, a drug approved by the FDA for treating type 2 
diabetes, inhibits painful type 2 diabetes independent from its effect on decreasing blood 
glucose. I also validated a second method for measuring pain-like negative affect using 
a novel mechanical conflict avoidance, showing that diabetic ZDF rats exhibit 
motivational-affective pain-like behavior. Finally, in Chapter 5:  I extended findings from 
the overgeneralized streptozotocin model of painful diabetes, providing strong evidence 
implicating TRPA1 in sustained diabetic hypersensitivity in a superior model, type 2 
diabetic db/db mice. Using this model along with exogenous administration of the 
glucose metabolite methylglyoxal, I will show that MG is sufficient to produce behavioral 
hypersensitivity and affective pain (i.e. conditioned place aversion) through activation of 
peripheral TRPA1 and subsequent sensitization of spinal neurons through a TRPA1-
AC1 mechanism. Furthermore, I investigate the inhibition of methylglyoxal-induced pain 
by the methylglyoxal scavenging peptide GERP10 and pioglitazone. 
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 My results are the first to report evidence of affective pain in a model of type 2 
diabetes as well as the reduction of painful type 2 diabetes GERP10 and pioglitazone. 
My long-term goal for this work is to inform the initiation of future clinical studies 
investigating the analgesic properties of pioglitazone and/or GERP10. In Chapter 6:  I 
evaluate my results alongside the available literature to synthesize new insights into the 
mechanism(s) by which PPARγ mediates its antihyperalgesic effects in neuropathic pain 
conditions. I also discuss evidence suggesting that targeting TRPA1, AC1, or GLO1 may 
alleviate painful type 2 diabetes. Future studies discussed in the following content 
chapters and the overall discussion in Chapter 6:  are proposed to extend our knowledge 
of the involvement of MG, GLO1, TRPA1, AC1, and PPARγ in mediating and inhibiting 
chronic neuropathic pain associated with type 2 diabetes.  
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CHAPTER 2:  Gabapentin alleviates affective pain after traumatic nerve injury 
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2.1  Abstract 
 Gabapentin reduces behavioral signs of stimulus-evoked allodynia and hyperalgesia 
in preclinical studies of traumatic nerve injury, but its effects on more clinically-relevant 
measures of stimulus-independent pain are unclear. To address this gap, we determined 
whether gabapentin would relieve affective pain after spared nerve injury (SNI). Twelve 
days after sham or SNI surgery, we administered gabapentin over three consecutive 
conditioning days and then evaluated conditioned place preference (CPP). Gabapentin 
produced CPP and reversed mechanical hypersensitivity in SNI but not sham rats at a 
dose (100 mg/kg) that did not change open field activity. These results show for the first 
time that gabapentin provides relief from affective pain without producing locomotor 
sedation, and adds to a limited clinical literature suggesting that its use can be extended 
to treat pain arising from traumatic nerve injury. 
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2.2  Introduction  
 Preclinical research targeting discovery of novel treatments for neuropathic pain 
primarily rely on mechanical or thermal stimulus-evoked behavioral outcomes. However, 
this approach fails to mimic the affective and spontaneous aspects of chronic pain that 
are most relevant to pharmacotherapy in humans, as indicated by the high failure rate of 
analgesic drug candidates in clinical trials. The use of conditioned place preference 
(CPP) to assess non-evoked pain, originally described two decades ago (Sufka, 1994), 
has re-emerged as a leading measure of affective neuropathic pain (King et al, 2009) 
and has the potential to address the disconnect between preclinical and clinical efficacy 
(King and Porreca, 2014). The use of CPP to measure preclinical pain relief is 
advantageous because the test is performed in the absence of an exogenous stimulus 
(Tzschentke, 2007), incorporates the motivation to seek reward (Bardo and Bevins, 
2000), and evaluates the affective (King et al, 2009) pain relieving effects of analgesic 
drug administration (King and Porreca, 2014). 
 Gabapentin (Neurontin®) is a primary treatment for neuropathic pain (Attal et al, 
2010) in patients with trigeminal neuralgia (Lemos et al, 2011), post-herpetic neuralgia 
(Rowbotham et al, 1998), painful chemoneuropathy (Caraceni et al, 2004), and painful 
diabetic neuropathy (Backonja et al, 1998; Vincent et al, 2011). Reverse translation 
studies in rodents indicate that gabapentin attenuates affective pain produced by 
cisplatin (Park et al, 2013) or streptozotocin (Wagner et al, 2014), as well as the evoked 
hypersensitivity associated with traumatic nerve injury (Xie et al, 2014). However, no 
study has evaluated whether gabapentin reduces affective pain after traumatic nerve 
injury. To address this question, we performed gabapentin CPP in rats with spared nerve 
injury (SNI), a widely used preclinical model of traumatic nerve injury (Decosterd and 
Woolf, 2000). 
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2.3  Methods 
2.3.1  Animals 
 Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) weighing 
200-250 g at the time of surgery and 300-350 g at the time of behavioral procedures 
were housed 2 per cage on a 12-hour light/dark cycle (7am lights on / 7pm lights off) in a 
temperature (68-72º F) and humidity controlled room with food and water provided ad 
libitum. All efforts were made to minimize animal suffering, to reduce the number of 
animals used, and to utilize alternatives to in vivo techniques, in accordance with the 
International Association for the Study of Pain and the National Institutes of Health Office 
of Laboratory Animal Welfare Guide for the Care and Use of Laboratory Animals. All 
behavioral procedures were carried out between 8am-6pm and approved by the 
Institutional Animal Care and Use Committee (IACUC) at University of Kentucky. 
Behavioral measurements were performed by an observer blinded to experimental 
treatments. 
 
2.3.2  Spared Nerve Injury (SNI) surgery 
 Sham and SNI surgeries were performed as previously described (Decosterd and 
Woolf, 2000). To generate surgical sham control subjects, all steps were performed 
except ligation and transection of the common peroneal and tibial nerves. The day of 
sham or SNI surgery is referred to as day 0.  
 
2.3.3  Measurement of pain-like behavior and open field activity 
 Animals were acclimated in individual Plexiglas boxes (4” x 8” x 4”) on top of a raised 
stainless steel mesh grid for 1 h. Mechanical hypersensitivity was assessed using von 
Frey filaments (Stoelting, Inc., Wood Dale, IL) using a modified up-down method (Dixon, 
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1980; Chaplan et al, 1994) as previously described (Morgenweck et al, 2013). The 
calculated 50% withdraw threshold is reported. 
 A photobeam activity system (PAS; 16 x 16 array; San Diego Instruments, San 
Diego, CA) was used to measure exploratory locomotion in a clear, square box 
surrounded by the photobeam array. Saline or gabapentin (100 mg/kg) was 
administered i.p. prior to placing the rat into the open field chamber. The total number of 
photobeam breaks was automatically quantified by the PAS software for 30 min in 5 min 
bins in the absence of any observer.  
 
2.3.4  Conditioned Place Preference 
 The use of conditioned place preference (CPP) as a tool to measure the ongoing 
aversiveness (i.e. affective pain) after injury or preference for rewards has been well 
established (Sufka, 1994; Bardo and Bevins, 2000; King et al, 2009; Wei et al, 2013). 
Eight rat CPP boxes (Med Associates, St Albans, VT) were used to assess chamber 
preference before and after the drug conditioning phase. The experimental timeline and 
details of the CPP apparatus are illustrated in Figure 1. Rats were able to discriminate 
the drug- versus vehicle-paired chamber using visual (wall color), tactile (flooring), and 
olfactory (Lipsmackers Chapstick, Bonne Bell, Westlake, OH) cues. Preliminary 
experiments indicated no preference for vanilla (white chamber) or kiwi (black chamber) 
chapstick olfactory cues in sham or SNI rats. To reduce time spent in the gray chamber 
lighting in the white and black chambers was adjusted to 25% of that in the grey 
chamber. Manual guillotine doors were used to isolate the white and black pairing 
chambers from the grey chamber during conditioning. Each individual CPP box was fully 
contained in a sound and light attenuating enclosure. Time of testing, animal handling 
method, and cleaning of the CPP boxes were held constant. 
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 Preconditioning. The CPP procedure spanned six consecutive days. On Day 1, 
subjects were acclimated to the CPP boxes for 30 min, with open access to each of the 
three chambers. On Day 2 (preconditioning), animals were placed in the grey middle 
chamber, and then we determined time spent in the white or black pairing chambers for 
15 min. Animals that spent <20% or >80% time in the black and/or white chamber (i.e. 
showing an apparatus bias or initial, unconditioned preference) during preconditioning 
were removed from the experiment (King et al, 2009). By these criteria, ten animals were 
removed from von Frey and CPP analyses.  
 Conditioning. On Days 3, 4 and 5 (conditioning), we used a biased assignment 
approach to drug pairing: saline was paired with the preferred chamber in the morning, 
and gabapentin was paired with the non-preferred chamber in the afternoon. Our biased 
approach was chosen for five reasons: 1) increases assay sensitivity; 2) allows for a 
within subjects design and statistical analysis (Cunningham et al, 2003; Tzschentke, 
2007); 3) of all CPP studies in 2001, 30% used a biased approach and 42% analyzed 
results using a difference score (postconditioning minus preconditioning) (Cunningham 
et al, 2003); 4) a biased approach was very recently used  to assess gabapentin CPP in 
the streptozotocin model of painful diabetic neuropathy (Wagner et al, 2014); 5) 
Cunningham et al demonstrated that if the CPP apparatus is not biased (time spent in 
the white chamber = time spend in black chamber when average across all subjects, as 
in the current study) , then the use of either a biased or unbiased chamber-assignment 
approach does not affect the ability to produce CPP (Cunningham et al, 2003).  
 Conditioning consisted of the following sequential steps: i.p. injection, return of the 
animal to its home cage for 5 min, and then placement within the white or black chamber 
for 30 min (injections were never paired with the grey, middle chamber). We used a 30 
min conditioning time based on reports that gabapentin maximally reduced mechanical 
hypersensitivity at 30-60 min after injection (Park et al, 2013; Wagner et al, 2014). We 
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chose 3 d of gabapentin conditioning because 1 d was not sufficient to produce CPP in a 
mouse model of chemoneuropathy (Park et al, 2013). 
 Postconditioning and analysis. On Day 6 (postconditioning), animals were placed 
into the grey chamber and we evaluated time spent in either the white or black chamber. 
The difference score for each subject was calculated by subtracting the time spent in the 
saline- or gabapentin paired chamber before pairing (during preconditioning) from the 
time spent in each chamber after pairing (postconditioning), and then averaged within 
each group.  
 
 
Figure 2-1. Experimental timeline and diagram of the conditioning place 
preference (CPP) apparatus.  
(Top) Baseline von Frey thresholds were measured on d -1 prior to Sham or Spared 
Nerve Injury (SNI) surgery on d 0. Mechanical hypersensitivity (von Frey) was 
measured on d 9 (pre CPP) and d 16 (post CPP). The Conditioned Place Preference 
(CPP) assay was performed on d 10 – 15 (open arrows) and consisted of 
acclimation, preconditioning, conditioning, and postconditioning. Open field activity 
was determined on d 17. (Bottom) The CPP apparatus consisted of: (left) a white 
chamber with grid flooring, vanilla chapstick, and 25% light intensity; (middle) a grey 
chamber with solid flooring, no olfactory cue, and 100% light intensity; (right) a black 
chamber with bar flooring, kiwi chapstick, and 25% light intensity.  
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2.3.5  Experimental Design 
 Evoked mechanical sensitivity was measured prior to sham or SNI surgery (day 0), 9 
d after surgery (pre CPP), and after completion of the CPP procedure on d 15 (post 
CPP). The CPP assay was performed on days 10 – 15. Following post CPP 
measurement of von Frey withdraw thresholds to confirm the sustained presence of 
mechanical hypersensitivity, saline or gabapentin (100 mg/kg) was injected i.p. and von 
Frey thresholds were recorded 15, 30, and 60 min later. A 24 h timepoint was taken to 
determine whether the anti-hypersensitivity effects of gabapentin endured from one 
conditioning day to the next. Open field activity after i.p. saline or gabapentin 
administration was performed at the conclusion of von Frey and CPP experiments on d 
17.  
 
2.3.6  Drugs 
 Gabapentin (Spectrum Chemical, Gardena, CA) was dissolved in 0.9% saline 
immediately prior to injections and administered i.p. in a volume of 0.5-1.0 ml (final dose 
= 100 mg / kg body weight). 
  
2.3.7  Statistical Analysis  
 A paired t-test was used to compare the effect of sham or SNI surgery on 
mechanical sensitivity prior to CPP, preconditioning versus postconditioning time spent 
in CPP chambers, and CPP difference scores. Gabapentin effect on behavior in the von 
Frey assay was compared for significant differences over time using repeated measures 
two-way ANOVA followed by Holm-Sidak multiple comparison correction. An alpha value 
of α = 0.05 was used to determine statistical significance. All data were analyzed and 
graphed using Prism 6.0 (GraphPad, La Jolla, CA) and are presented as mean ± SEM. 
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2.4  Results 
2.4.1  SNI produces evoked mechanical hypersensitivity 
 Spared nerve injury (SNI) evokes mechanical hypersensitivity that begins a few days 
after surgery and lasts for at least 6 months (Decosterd and Woolf, 2000). To compare 
evoked mechanical hypersensitivity and affective pain, we performed von Frey testing 
prior to surgery (baseline), before CPP (pre), after CPP (post), and for 60 min following 
i.p. gabapentin administration in sham and SNI rats. CPP conditioning occurred at day 
12-14 during established mechanical hypersensitivity. As illustrated in Fig 2A, SNI 
produced hypersensitivity to von Frey mechanical stimulation at the pre CPP timepoint [p 
< 0.0001]. There was no change in mechanical thresholds in sham animals [p > 0.05].  
 
2.4.2  Gabapentin reverses SNI-induced evoked mechanical hypersensitivity 
 After CPP testing, we assessed inhibition of SNI-induced mechanical hypersensitivity 
by measuring von Frey withdraw thresholds after systemic administration of gabapentin 
at the same dose used during CPP conditioning (100 mg/kg). Fig 2B illustrates that 
gabapentin significantly attenuated evoked mechanical hypersensitivity in rats with SNI 
at 30 [p < 0.05] and 60 [p < 0.05] min after i.p. injection [drug x time; F (3, 36) = 17.5; P < 
0.0001]. Mechanical withdraw thresholds were slightly, but insignificantly, increased at 
15 min. Sham animals did not exhibit evoked mechanical hypersensitivity (compared to 
baseline) [p > 0.05] and von Frey withdraw thresholds were unaltered by gabapentin 
[drug x time; F (3, 18) = 0.015; P > 0.05].  
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Figure 2-2. Gabapentin reverses evoked mechanical hypersensitivity 
associated with nerve injury.  
(A) Mechanical thresholds are shown at baseline (before surgery) and d 9 (pre CPP) 
after sham or spared nerve injury (SNI) surgery prior to conditioned place 
preference testing. SNI (n=17) decreased mechanical thresholds relative to sham 
(n=8) controls. (B) On d 16 (post CPP), mechanical thresholds remain decreased in 
SNI but not sham animals. Gabapentin (100 mg/kg; i.p.) increased mechanical 
thresholds in SNI (n=11) but not sham (n=5) animals. Saline did not change 
mechanical thresholds in sham (n=3) or SNI (6) animals. (A),  “SNI” at the pre 
CPP timepoint significantly different from all other groups. (B),  “SNI – 
Gabapentin” significantly different from “SNI – Saline”. 
 
2.4.3  Gabapentin produces CPP in rats with SNI but not sham surgery 
 To confirm that animals do not prefer one chamber over another, we assessed time 
spent in each. This was done prior to drug-pairing during conditioning. In sham rats, time 
spent in the white [355.1 ± 16.0 s] and black [363.2 ± 18.8 s] chambers was similar [p = 
0.37]. In SNI rats, time spent in the white [336.2 ± 15.6 s] and black [346.1 ± 18.6 s] 
chambers was also similar [p = 0.34]. These data indicate that there is no initial bias for 
the CPP apparatus and that injury did not alter preconditioning preferences. 
 To determine whether gabapentin alleviates affective pain after traumatic nerve 
injury, we assessed CPP in sham and SNI rats. Fig 3A illustrates our biased conditioning 
approach: preconditioning time spent in the saline-paired chamber was greater than time 
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spent in the gabapentin-paired chamber in both sham [p < 0.05] and SNI [p < 0.0001] 
rats. Biased drug pairing remained counterbalanced, where half the animals received 
gabapentin in the white chamber and half in the black chamber. Conditioning to 
gabapentin produced an increase in time spent in the gabapentin-paired chamber in SNI 
[p = 0.0043] but not sham rats [p = 0.2]. When compared to saline difference scores, Fig 
3B illustrates a significantly higher gabapentin difference score in SNI [p < 0.0001] but 
not sham [p = 0.70] rats. These results indicate that gabapentin produces CPP in SNI 
but not sham rats at 2 wks after injury. A previous study indicates that the 
antihyperalgesic effect of gabapentin varies over time after nerve injury (Hama and 
Borsook, 2005). Future studies could investigate the ability of gabapentin to produce 
CPP at later timepoints. 
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Figure 2-3. Gabapentin attenuates affective pain associated with traumatic 
nerve injury. 
To determine affective pain relief we performed CPP with three days of conditioning 
(saline or gabapentin; 100 mg/kg; i.p.). (A) Time spent in the saline-paired chamber 
during preconditioning was greater than time spent in the gabapentin-paired 
chamber as a result of our biased drug-pairing approach. In sham rats (n=8), there 
was no change in preference during postconditioning (“Post”) when compared to 
preconditioning baselines (“Pre”). In SNI rats (n=17), gabapentin produced an 
increase in time spent in the gabapentin-paired chamber when compared to 
preconditioning baseline. (B) Saline and gabapentin difference scores were 
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significantly different in SNI but not sham rats. These results taken together indicate 
gabapentin induces CPP thereby relieving affective pain in rats with traumatic nerve 
injury. # Significantly different from preconditioning saline-paired in SNI. $ 
Significantly different from preconditioning gabapentin-paired in SNI.  Significant 
difference between indicated groups. 
 
2.4.4  Gabapentin did not change locomotor activity in sham or SNI rats  
 Gabapentin produces adverse effects in humans including somnolence, dizziness, 
peripheral edema, infection, and ataxia (Rowbotham et al, 1998). To address the 
potential effect of gabapentin on exploratory or somatomotor activity, resulting in 
confounding alterations in mechanical thresholds or CPP, we assessed open field 
activity. Fig 4A indicates that gabapentin did not change locomotor activity in sham 
[drug; F (1, 6) = 0.18; P > 0.05] or SNI [drug; F (1, 8) = 0.005; P > 0.05] rats. 
Furthermore, there was no difference in activity between sham and SNI animals treated 
with saline [injury; F (1, 8) = 0.02; P = 0.89] indicating that SNI did not change locomotor 
function.  
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Figure 2-4. Gabapentin does not alter locomotor activity.  
(A) The number of beam breaks in sham or SNI animals treated with saline or 
gabapentin (100 mg/kg; i.p.) was not different in an open field photobeam activity 
assay (n=5-6). 
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2.5  Discussion 
 Here we present the first data indicating that gabapentin relieves affective pain (i.e. 
produces CPP) associated with traumatic nerve injury in a preclinical model. Our current 
results are consistent with recent findings in other rodent models of neuropathic pain. 
For example, gabapentin produces CPP in mice following chronic cisplatin treatment 
(Park et al, 2013) or in the streptozotocin model of type I painful diabetic neuropathy 
(Wagner et al, 2014). Xie et al reported that gabapentin reversed mechanical 
hyperalgesia associated with spinal nerve ligation (SNL), without measuring its effect on 
affective pain using CPP (Xie et al, 2014). Repetition of our study in an alternative model 
of traumatic nerve injury such as SNL or using a dose response could provide additional 
support for our conclusion that gabapentin alleviates affective pain generalized to 
multiple types of neuropathic conditions. 
 The current study shares important experimental design characteristics with Park et 
al and Wagner et al (Park et al, 2013; Wagner et al, 2014), but in the setting of traumatic 
nerve injury. First, a systemic dose of 100 mg/kg was administered over three 
conditioning days. Second, gabapentin produced CPP rapidly, within 30 min of 
administration. Third, gabapentin did not produce CPP in control animals, ruling out the 
possibility that gabapentin is intrinsically rewarding. This is in contrast to rewarding 
analgesic drugs such as morphine, which produce CPP in naïve or uninjured subjects, 
thus complicating interpretation of effects on affective pain (Sufka, 1994; Tzschentke, 
2007). Fourth, gabapentin reduced both evoked and affective measures of pain. This is 
striking in light of recent reports indicating that other analgesic drugs such as TRP 
antagonists (Brederson et al, 2013) inhibit evoked but not affective pain in preclinical 
models of inflammation (Okun et al, 2011), osteoarthritis (Okun et al, 2012), type I 
diabetes (Wei et al, 2013), and SNI (Wei et al, 2013).  
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 We conclude that gabapentin alleviates affective pain after SNI in rodents, and 
suggest further studies to determine the clinical efficacy of gabapentin for the treatment 
of chronic pain associated with traumatic nerve injury. Indeed, a randomized, double-
blind, placebo-controlled, cross-over, multicenter clinical trial involving patients with 
peripheral nerve injury due to trauma or surgery reported that, compared to placebo, 
gabapentin provided better pain relief and increased the number of subjects with a pain 
reduction of at least 30% (Gordh et al, 2008). In addition, our results highlight the 
importance of measuring the affective component of pain in preclinical studies to better 
predict clinical efficacy of pain-relieving drugs. 
 
2.6  Supplemental Discussion 
2.6.1  Gabapentin reduction of neuropathic pain in humans and rodents 
 Gabapentin (Neurontin®) is an anticonvulsant drug that is a primary treatment (Attal 
et al, 2010) for neuropathic pain in patients with diabetes (Vincent et al, 2011), trigeminal 
neuralgia (Lemos et al, 2011), cancer (Caraceni et al, 2004), traumatic nerve injury 
(Gordh et al, 2008), and post-herpetic neuralgia (Kukkar et al, 2013). Gabapentin also 
decreases evoked measures of pain-like hypersensitivity in rodent models of painful 
diabetic neuropathy (Field et al, 1999; Zhang et al, 2013), orofacial nerve injury (Nakai et 
al, 2014), spinal cord injury (Kitzman et al, 2007; Rabchevsky et al, 2011), hindlimb 
nerve injury (Luo et al, 2002; Yezierski et al, 2013), and chemoneuropathy (Park et al, 
2013). Gabapentin likely produces analgesia by reducing neuronal excitability through 
inhibition of α2δ1 subunits presynaptic calcium channels (Brown et al, 1998; Kukkar et 
al, 2013). Relief from pain-like hypersensitivity is associated with decreased Fos 
expression in the spinal cord and PAG after nerve injury (Morgado et al, 2010), 
attenuation of fMRI BOLD signals in the cortical pain matrix in nerve injured mice 
(Takemura et al, 2011), and attenuated overexpression of Nav1.7 and pERK in 
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streptozotocin-treated rats (Zhang et al, 2013). Because gabapentin is currently 
recommended for the treatment of neuropathic pain patients (Attal et al, 2010), and it is 
unknown whether gabapentin attenuates preclinical spontaneous pain, we performed a 
reverse translation study to assess gabapentin induced CPP. Our finding that 
gabapentin decreases affective pain in rodents with traumatic nerve injury highlights the 
ability of the CPP approach to predict clinical efficacy. Future reverse translation studies 
could investigate whether gabapentin relieves affective pain in a preclinical model of 
painful type 2 diabetes, such as db/db or ZDF.  
 Evoked mechanical hypersensitivity in SNI, but not sham, animals begins to subside 
at 15 min, is significantly reduced at 30 min, and is maximally reversed at 60 min after 
systemic administration of gabapentin. This efficacy time course is similar to that of Park 
et al, where mechanical hypersensitivity alleviation and production of CPP occurs within 
30 min of gabapentin administration in cisplatin-treated mice (Park et al, 2013).  
 Rapid attenuation of both evoked and spontaneous pain-like behavior after injury is 
likely due to gabapentin acting on α2δ calcium channel subunits to reduce neuronal 
excitability (Kukkar et al, 2013). Our results suggest that 30 min is enough time for 
gabapentin to affect α2δ channels at presynaptic terminals. The finding that gabapentin 
does not produce CPP or change mechanical thresholds in sham animals may be due to 
the finding that expression of α2δ subunits is increased after peripheral nerve injury (Luo 
et al, 2002; Nieto-Rostro et al, 2014). Furthermore, we found no effect of gabapentin on 
locomotor activity suggesting that adverse effects related to motor and exploratory 
activity are not present at the current dose. Effects on exploratory behavior would 
confound our conclusion that production of CPP indicates alleviation of spontaneous 
pain-like behavior after SNI. This is an important measure that is easily obtained by 
monitoring activity during CPP conditioning.  
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2.6.2  Methodological considerations in CPP 
2.6.2.1  Production of CPP to systemic gabapentin after injury 
 To our knowledge, Park et al (2013) were the first to investigate CPP to gabapentin 
with the notable difference that the neuropathic pain-like model was generated by 
administration of the chemotherapeutic cisplatin. Additionally, the authors report that two 
but not one day of gabapentin pairing was necessary to produce a preference in cisplatin 
but not control mice. Gabapentin was administered systemically (i.p.) at the same dose 
used in the current study. They achieved CPP only after two days of conditioning with 
vehicle pairing in the morning and drug pairing in the afternoon. In another very recent 
study, gabapentin produced CPP in streptozotocin (STZ) diabetic but not naïve mice 
indicating, contrary to other reports, that STZ induction of type 1 diabetes produces a 
state of ongoing pain (Wagner et al, 2014). Production of CPP to gabapentin in STZ 
mice required three conditioning sessions and the authors used a biased approach (i.e. 
pairing gabapentin to the least-preferred chamber) because the CPP apparatus showed 
initial bias after the preconditioning test. We also used a biased approach while Park et 
al counterbalanced their pairings.  
 It should be noted that even though we used a biased approach, pairings were 
indeed counterbalanced because half of the rats received gabapentin in the white 
chamber while half were paired with the black, an approach also used by Wagner et al. 
Cunningham et al demonstrated that when there is no apparatus bias (i.e. on average, 
animals spend equal time in the black and white pairing chambers as in the current 
study), then the use of a biased or unbiased chamber-assignment approach does not 
affect the ability to produce CPP (Cunningham et al, 2003). Furthermore, the lack of 
gabapentin CPP in sham rats (current results) or vehicle-treated mice (Park et al, 2013) 
indicates that gabapentin is not intrinsically rewarding. This is important given the abuse 
48 
potential of analgesic drugs such as morphine that produce CPP in naïve, uninjured 
animals (Sufka, 1994; Tzschentke, 2007) and Figure 2-5. 
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Figure 2-5. Morphine produces conditioned place preference in rats.  
Difference scores (postconditioning minus preconditioning time spent in chamber) 
for animals that were conditioned with saline vehicle in both chambers (left) or 
vehicle in one chamber and morphine in the other (right). Systemic administration of 
morphine induced a significant place preference in rats.  
 
2.6.2.2  Constant experimental conditions are critical to yield consistent CPP results 
 Neither SNI nor sham surgery altered baseline initial preference indicating that our 
CPP apparatus is unbiased, which is an important methodological consideration to 
eliminate experimental confounds. We were able to replicate very similar baseline values 
in SNI animals between Experiment 1 and Experiment 2 even though these studies were 
performed six months apart. Our CPP setup includes different tactile cues in the white 
and black pairing chambers; therefore, it is important to note that injury alone did not 
produce a preference to either tactile cue (grating versus bars) as evidenced by equal 
baseline preferences for the white and black chambers. Additionally, preference for a 
vanilla (white chamber) or kiwi (black chamber) chapstick olfactory cue was equal in 
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sham and SNI rats in both experiments (see Figure 2-6). We were extremely careful to 
handle the animals in the same manner within and between experiments and in the 
different injury groups. We used eight different CPP boxes and were able to achieve 
consistent average baselines between experiments. Although not directly tested, we 
should stress that experimental variables such as time of day of testing, handling 
method, the way animals are placed into the neutral grey chamber, cleaning boxes 
before and after each CPP session, etc. should be highly controlled to achieve 
consistent baselines as reported here. Carefully controlled variables will allow easier 
replication and increase the predictive value (i.e. sensitivity) of the CPP approach. 
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Figure 2-6. Baseline preferences with the addition of a chapstick olfactory cue. 
Counterbalanced addition of vanilla and kiwi chapstick to the pairing chambers in 
the conditioned place apparatus did not introduce a scent bias, as evidenced by 
equal time spent in each vanilla- or kiwi-scented chamber. 
 
2.6.2.3  Minimization of time spent outside the pairing chambers 
 We cannot ignore the fact that, for whatever reason, conditioning the animals in both 
experiments resulted in an increase in time spent in the grey neutral chamber. It is 
possible that the stress of vehicle or gabapentin pairing (e.g. i.p. injections, handling, 
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cage manipulations) resulted in a slight aversion to the black and white chambers after 
conditioning, resulting in increased grey time in postconditioning. However, the negative 
reinforcement of pain by the gabapentin unconditioned stimulus was great enough to 
overcome any positive associations made to the grey chamber as evidenced by a 
significant difference score between saline and gabapentin and no differences between 
saline and grey or gabapentin and grey. If anything, part of the gabapentin reward is 
masked by the slight increase in grey chamber times indicating that we are 
underestimating the magnitude of the effects on motivation to seek pain relief. Another 
perspective is that since animals were never placed into the grey chamber after i.p. 
injection, this area was less aversive than the white or black chambers, which were 
paired with three i.p. injections each during conditioning. A third explanation is that after 
three days of conditioning in only the white and black chambers novelty of the grey 
chamber was reintroduced during postconditioning. A recent report indicates that 
injection of i.p. saline during habituation or preconditioning does not alter production of 
CPP and may even increase avoidance of the grey chamber after conditioning (Zhang et 
al, 2014). The use of a two chamber apparatus may also overcome this limitation, but 
also introduces additional methodological considerations beyond the scope of this 
discussion.  
 
2.6.2.4  Expression of CPP after systemic drug administration 
 The technical challenge to expression of CPP is that the desired effect of the 
analgesic drug (i.e. unconditioned stimulus) needs to be rapid so that the animals 
associate analgesia with chamber contextual cues (i.e. conditioned stimulus). 
Furthermore, differential effects of drugs on evoked versus ongoing pain may contribute 
to the failure of injured animals from exhibiting CPP. A negative result (i.e. no expression 
of CPP to analgesic drug pairing) indicates that the experiment should be repeated in 
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the presence of a positive control (e.g. morphine production of CPP in naïve animals, 
clonidine in SNI animals, others).  
 
2.6.3  Conclusions when experiments fail to produce CPP 
 Several recent studies highlight the differences of analgesic drugs on evoked and 
spontaneous pain as assessed by CPP testing. Wei et al (2013) found that the TRPA1 
antagonist Chembridge-5861528 alleviates mechanical hypersensitivity but does not 
produce CPP in streptozotocin (STZ) treated rats, a model of diabetic neuropathy. 
However, the authors were able to produce CPP in SNI animals with intrathecal 
clonidine indicating that the CPP method was appropriate. The authors suggest that 15 
min of conditioning may not be enough time for drug effects on spontaneous pain (Wei 
et al, 2013). In another STZ study, systemic administration of the gabapentin analog 
pregabalin alleviated evoked mechanical hypersensitivity but not spontaneous pain as 
evidenced by the lack of expression of CPP (Rutten et al, 2011). The authors suggested 
that CPP is not suitable for measurement of spontaneous pain in the STZ model. 
However, due to the lack of a positive control for the CPP assay, an alternative 
explanation is that CPP was not expressed due to methodological concerns, or that STZ 
does not invoke a state of ongoing aversiveness in rodents.  
 Our results suggest that CPP is indeed a predictive tool of the clinical efficacy of 
analgesic drugs such as gabapentin for the treatment of spontaneous neuropathic pain. 
However, enthusiasm may be diminished by the notion that normal ambulatory behavior 
produces a pain-like stimulus evoked by the tactile environment (Bennett, 2012). In other 
words, exploratory behavior in the CPP apparatus induces an evoked pain-like state. 
This concern is mitigated by the findings of Qu et al, who found that analgesic drugs 
produced CPP in axotomized, but not sham, animals. The authors conclude that “these 
observations in animals with complete denervation of the hind paw also provide an 
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important control, eliminating concerns for pain resulting from tactile stimulation 
potentially arising from ambulation within the testing apparatus” (Qu et al, 2011). In 
addition, it is unlikely that the low threshold, innocuous stimulation of normal ambulatory, 
exploratory movement in the CPP chamber is sufficient to produce ongoing affective 
pain.  
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CHAPTER 3:  Pioglitazone rapidly reduces neuropathic pain through astrocyte 
and non-genomic PPARγ mechanisms 
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3.1  Abstract 
 Repeated administration of peroxisome proliferator-activated receptor gamma 
(PPARγ) agonists reduces neuropathic pain-like behavior and associated changes in 
glial activation in the spinal cord dorsal horn. As PPARγ is a nuclear receptor, sustained 
changes in gene expression are widely believed to be the mechanism of pain reduction. 
However, we recently reported that a single intrathecal injection of pioglitazone, a 
PPARγ agonist, reduced hyperalgesia within 30 minutes, a time frame that is typically 
less than that required for genomic mechanisms. To determine the very rapid anti-
hyperalgesic actions of PPARγ activation we administered pioglitazone to rats with 
spared nerve injury (SNI) and evaluated hyperalgesia. Pioglitazone inhibited 
hyperalgesia within 5 min of injection, consistent with a non-genomic mechanism. 
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Systemic or intrathecal administration of GW9662, a PPARγ antagonist, inhibited the 
anti-hyperalgesic actions of intraperitoneal or intrathecal pioglitazone, suggesting a 
spinal PPARγ-dependent mechanism. To further address the contribution of non-
genomic mechanisms, we blocked new protein synthesis in the spinal cord with 
anisomycin. When co-administered intrathecally, anisomycin did not change pioglitazone 
anti-hyperalgesia at an early 7.5 min timepoint, further supporting a rapid non-genomic 
mechanism. At later timepoints anisomycin reduced pioglitazone anti-hyperalgesia, 
suggesting a delayed recruitment of genomic mechanisms. Pioglitazone reduction of 
SNI-induced increases in GFAP expression occurred more rapidly than expected, within 
60 min. We are the first to show that activation of spinal PPARγ rapidly reduces 
neuropathic pain independent from canonical genomic activity. We conclude that acute 
pioglitazone inhibits neuropathic pain in part by reducing astrocyte activation, and via 
both genomic and non-genomic PPARγ mechanisms. 
 
3.2  Introduction  
Peroxisome proliferator-activated receptor gamma (PPARγ) is activated by 
thiazolidinedione (TZD) drugs such as pioglitazone (Saltiel and Olefsky, 1996) that cross 
the blood brain barrier (Maeshiba et al, 1997). TZDs reduce molecular and behavioral 
sequelae of many neurological diseases [see (Feinstein, 2003; Kapadia et al, 2008; 
Maeda and Kishioka, 2009; Yonutas and Sullivan, 2013)]. It is widely assumed that 
genomic PPARγ activity mediates reduction of inflammatory (Oliveira et al, 2007; 
Morgenweck et al, 2010) and neuropathic (Maeda et al, 2008; Morgenweck et al, 2013) 
pain after repeated TZD dosing. However, agonists for PPARγ and other nuclear 
receptors (e.g. estrogen, glucocorticoid, PPARα) can modulate neuronal excitability 
(Filardo et al, 2002; Levin, 2008; Joels et al, 2012) and pain (LoVerme et al, 2006; Churi 
et al, 2008; Fehrenbacher et al, 2009; Zhang et al, 2012) within minutes. Thus, the anti-
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hyperalgesic effects of nuclear receptor agonists may occur through multiple 
mechanisms including: 1) genomic, receptor-dependent transcription/translation, 2) non-
genomic, receptor-dependent activation of membrane-bound receptors (Luconi et al, 
2010; Rowan et al, 2010; Joels et al, 2012), 3) receptor-independent “off-target” effects 
at GPCRs (Maggiolini and Picard, 2010; Nakamoto et al, 2012; Nakamoto et al, 2013).  
Traumatic nerve injury produces changes in the spinal cord such as astrocyte 
activation (Zhang and De Koninck, 2006; Vega-Avelaira et al, 2007), increased post-
synaptic responses to glutamate (Wei et al, 2008), and long-term potentiation (Gruber-
Schoffnegger et al, 2013) resulting in central sensitization (Scholz and Woolf, 2007). 
During chronic pain states, activated spinal astrocytes release pro-nociceptive mediators 
(Watkins et al, 2001; Ohtori et al, 2004) such as TNFα that facilitate pain sensitization 
[for review see (Grace et al, 2014)]; therefore, pharmacotherapeutic approaches that 
decrease astrocyte activation may reduce chronic pain. TZDs agonize PPARγ 
expressed in spinal cord (Moreno et al, 2004) and brain (Cristiano et al, 2001) astrocytes 
to reduce activation (Bernardo and Minghetti, 2008) and GFAP upregulation (Heneka et 
al, 2005). Dosing over several weeks produced anti-hyperalgesia that was associated 
with reductions in spinal GFAP (Maeda et al, 2008; Jia et al, 2013; Morgenweck et al, 
2013), injury-induced pro-inflammatory cytokine expression (Jia et al, 2010), and in vitro 
astrocyte TNFα release (Storer et al, 2005; Gurley et al, 2008). A single injection of 
PPARγ agonist reduces neuropathic pain (Churi et al, 2008); however, an important gap 
is whether there are acute effects on spinal astrocytes. 
Here, we characterized the effects of PPARγ activation in neuropathic (spared nerve 
injury; SNI) and acute nociceptive (capsaicin) conditions after acute drug administration. 
We hypothesized that rapid inhibition of pain by PPARγ agonists is mediated by 
receptor-dependent, spinal mechanisms and is independent of translation (i.e. non-
genomic). We used systemic and spinal agonist/antagonist administration to determine 
56 
the site of PPARγ anti-hyperalgesia. We investigated pain-like hypersensitivity as early 
as 5 min after intrathecal injection of pioglitazone in the presence or absence of 
anisomycin, an inhibitor of protein synthesis (Grollman and Walsh, 1967; Frey et al, 
1988; Schafe and LeDoux, 2000). Finally, we tested whether a single pioglitazone 
injection, as opposed to repeated administration (Morgenweck et al, 2013), would 
reduce astrocyte activation in the form of GFAP overexpression after SNI.  
 
3.3  Materials & Methods 
3.3.1  Animals 
Male Sprague-Dawley rats (CD-IGS, Charles River Laboratories, Inc., Wilmington, MA) 
weighing 300-450g at the time of behavioral procedures were housed 2 per cage on a 
12-hour light/dark cycle (7am lights on / 7pm lights off) in a temperature (68-72 ºF) and 
humidity controlled room with food and water provided ad libitum. All efforts were made 
to minimize animal suffering, to reduce the number of animals used, and to utilize 
alternatives to in vivo techniques, in accordance with the International Association for the 
Study of Pain and the National Institutes of Health Office of Laboratory Animal Welfare 
Guide for the Care and Use of Laboratory Animals. All behavioral procedures were 
performed between 8am-6pm (lights on) and approved by an Institutional Animal Care 
and Use Committee (IACUC) protocol. Behavioral measurements and 
immunohistochemistry quantification were performed by an observer blinded to 
experimental treatments (e.g. injury and/or drug). 
 
3.3.2  Spared Nerve Injury (SNI) surgery 
Surgical anesthesia was achieved with isoflurane (5% induction and 1.5% 
maintenance diluted in oxygen). As previously described (Decosterd and Woolf, 2000; 
Taylor et al, 2007), the skin was incised on the left hindlimb over the sciatic nerve 
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trifurcation. The overlying muscles were retracted to expose the common peroneal, 
tibial, and sural nerves. The common peroneal and tibial nerves were ligated with 6-0 
silk (Ethicon, Somerville, NJ) and transected 1mm proximal and 1mm distal to the 
ligation. The ligation knot and adjacent nerve were removed. Sural nerve perturbations 
were avoided. The muscle and skin were closed with loosely tied 5-0 absorbable sutures 
(Ethicon) and 9mm stainless steel wound clips, respectively. During sham surgeries, all 
steps were performed except ligation and transection of the common peroneal and tibial 
nerves. SNI or sham surgery day is referred to as day 0. 
 
3.3.3  Pain-like behavior.  
 Animals were acclimated in individual Plexiglas boxes (4” x 8” x 4”) on top of a raised 
stainless steel mesh grid (mechanical and cold) or Plexiglas floor (Hargreaves) for 1 h. 
Fluctuations in noise, vibrations, temperature, and other distractors in the behavioral 
testing room were avoided to optimize reliable measurements between cohorts of 
animals tested on different days. 
 Mechanical hypersensitivity was assessed using von Frey filaments (Stoelting, Inc., 
Wooddale, IL). The lateral aspect of the hindpaw plantar surface (sural receptive field) 
was stimulated with an incremental series of 8 monofilaments of logarithmic stiffness 
using a modified up-down method (Dixon, 1980; Chaplan et al, 1994). Each filament was 
applied to the sural receptive field three times at proximal, intermediate, and distal 
locations with respect to the heel. Testing began by applying an intermediate von Frey 
monofilament (number 4.31, exerts 2.0 g of force) perpendicular to the glabrous skin, 
causing a slight bending. In the case of a positive response (withdraw of the paw) a 
filament exerting less force was applied. In the case of a negative response, a filament 
exerting greater force was applied. The calculated 50% withdraw threshold is reported. 
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 Cold hypersensitivity was assessed after application of a drop of acetone to the sural 
receptive field. We used a 3 mL syringe attached to an 8 cm length of PE-10 tubing 
flared to a diameter of 3.5 mm at the distal end. Surface tension maintained the volume 
of the drop to 10-12 μl. The amount of time the animal lifted, shook, or licked the affected 
hindpaw was recorded with a cutoff of 30 s after each acetone application. The average 
of three trials per subject at each timepoint is reported.  
 Heat hypersensitivity was assessed by recording paw withdraw latencies using the 
Hargreaves method and apparatus (Hargreaves et al, 1988). An adjustable infrared heat 
source (8 V, 50 W lamp, Ugo Basile, Italy) was positioned under the Plexiglas floor 
directly beneath the uninjured hindpaw. Prior to each behavioral testing session, 
intensity was adjusted so that the average latency to paw withdraw was 9 ± 2 s. If an 
animal did not respond within 20 s, the radiant beam was shut off to avoid tissue 
damage. The average of three trials per subject at each timepoint is reported.  
 
3.3.4  Motor coordination.  
 Motor coordination was assessed by placing the animals on an accelerating rotarod 
(Stoelting, Wood Dale, IL). Beginning at 2 revolutions per minute (rpm), the rotarod 
machine was programed to accelerate 0.5 rpm every 5 s until reaching 60 rpm. Animals 
were acclimated to the rotarod and subjected to one training session per d for 2 
consecutive d prior to drug administration. During training and testing, the rats were 
placed on the rotating bar at 2 rpm, the acceleration program was started, and the time 
spent on the rotarod prior to fall was recorded. During the first training session, the 
animals were repeatedly placed on the rotarod until they performed 3 consecutive trials 
≥ 150 s or reached a predetermined cutoff of 20 trials, whichever occurred first. By the 
second day of training, all rats successfully completed 3 consecutive trials ≥ 150 s prior 
to reaching 20 trials. Baseline measurement of time spent on the rotarod was recorded 7 
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d after SNI followed by reassessment at 1, 2, and 3 h after i.p. or i.t. drug administration. 
Three trials per timepoint were averaged. 
 
3.3.5  Intracerebroventricular cannulation.  
 Surgery was performed one week before injury to allow for 5 μl of drug or vehicle 
injection directly into the ventricle. Surgical anesthesia was achieved with isoflurane (5% 
for induction, 1.5% for maintenance in oxygen). Rats were placed in a stereotaxic 
apparatus fitted with blunt ear bars (Stoelting, Kiel, WI). After an incision to expose the 
cranium, the dorsal surface of the skull was leveled by zeroing the dorsoventral 
coordinate at lambda and bregma. A 26Ga stainless steel guide cannula (Plastics One, 
Roanoke, VA) was lowered to the right lateral brain ventricle using the following 
stereotaxic coordinates: 0.7 mm posterior to bregma, 1.5 mm lateral from midline and 
3.3-4.0 mm below the skull surface (Paxinos and Watson, 1997). Correct placement was 
indicated by the observation of the movement of 1µl sterile saline from a piece of PE-10 
tubing attached to the cannula into the ventricle (Taylor et al, 1994). The cannula was 
fixed to the skull with 3 small screws and dental cement and after suturing the incision a 
30 Ga stylet (Plastics One) was secured within the guide cannula. 
 
3.3.6  Drugs 
 Pioglitazone potassium salt (10028, Cayman Chemical, Ann Arbor, MI) was 
dissolved in a 0.9 % saline slurry. GW9662 (70785, Cayman Chemical) was dissolved in 
a mixture of ethanol, ethoxylated castor oil, and saline (2:2:6) for i.t. administration and 
50% DMSO in saline for i.p. administration. Neither vehicle solution altered pain-like 
behavior (see Fig 2). Anisomycin (A9789, Sigma-Aldrich, St. Louis, MO) was first 
dissolved in a small volume of 1 M HCl and then an equal volume of 0.9% saline was 
added. Next, the solution was titrated with NaOH to obtain a physiological pH of 7.0-7.4. 
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Finally, the anisomycin solution was further diluted in saline to a final concentration of 20 
mg/ml. Capsaicin (M2028, Sigma-Aldrich) was first dissolved in 100% ethanol (5% final 
v/v) followed by addition of a Tween 80 (P1754, Sigma-Aldrich) in saline (8% v/v) 
solution to a final capsaicin concentration of 50 mg/ml (w/v). Capsaicin (50 μl) was 
injected into the subdermal space between the 2nd and 3rd digits on the ventral plantar 
surface using a 30 Ga ½” needle. 
 
3.3.7  Drug Injections 
 Rats were anesthetized with isoflurane. Vehicle or drug solution (10-20 μl) was 
injected into the subarachnoid space using a 27 Ga 1” needle inserted into a stretch of 
PE-20 tubing and attached to a Hamilton micro syringe (Mestre et al, 1994). We 
confirmed needle placement by both visualization of cerebrospinal fluid aspiration within 
the tubing and/or a reflexive tail/hindpaw flick. For systemic pioglitazone studies, i.p. (2 
or 10 mg/kg) or i.t. GW9662 (300 µg) was administered 15 min prior to pioglitazone. For 
intrathecal pioglitazone studies, GW9662 (300 µg) or anisomycin (0-200 μg) was co-
administered with pioglitazone to avoid multiple i.t. injections.  
 
3.3.8  Capsaicin-induced nociception.  
 Intrathecal vehicle (saline), pioglitazone (0-300 μg), or anisomycin (0-200 μg) were 
injected 20 min before intraplantar (i.pl.) capsaicin (50 μg in 50 μl). Behavior was 
recorded for 0-2 min following i.pl. capsaicin. The number of flinches and the time spent 
licking or lifting (s) the affected hindpaw were combined and reported as the number of 
nociceptive responses, where 1 s of licking/lifting is equal to one flinch response 
(Seabrook et al, 2002; Lu et al, 2009; Andersson et al, 2013). Sham injections consisted 
of capsaicin vehicle as a control. Rats were perfused 60 min following i.pl. capsaicin for 
Fos immunohistochemistry.  
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3.3.9  Immunohistochemical quantification of Fos and GFAP in the dorsal horn.  
 Rats were anesthetized with pentobarbital (Fatal Plus, Med-Vet International, 
Mettawa, IL) and perfused through the left ventricle with 250 ml of room temperature 0.1 
M phosphate buffered saline (PBS) with heparin (10,000 USP units/L) followed by 250 
ml of ice-cold fixative (10% phosphate buffered formalin). The lumbar spinal cord was 
removed and post-fixed overnight in 10% phosphate buffered formalin and then 
cryoprotected in 30% sucrose in 0.1 M PBS for several days. Transverse sections (30 
μm) from L4-L5 were cut on a freezing microtome and collected in 0.1 M PBS. The 
sections were washed three times in 0.1 M PBS and then pretreated with blocking 
solution (3% normal goat serum and 0.3% Triton X-100 in 0.1 M PBS) for 1 h. Sections 
were incubated overnight at room temperature in blocking solution containing either 
rabbit anti-Fos (1:500, SC-52, Santa Cruz Biotechnology, Santa Cruz, CA) for capsaicin 
studies or anti-GFAP (1:1000, ab7779, Abcam, Cambridge, MA) for SNI studies. The 
slices were washed three times in 0.1 M PBS, incubated in goat anti-rabbit (1:800, Alexa 
488 or 568, Molecular Probes, Grand Island, NY) for 90 min, washed in 0.1 M PBS then 
0.01 M PB, mounted onto Superfrost Plus slides, air dried, and cover-slipped using 
Prolong Gold with DAPI mounting medium (Molecular Probes, Grand Island, NY). 
 All images were captured and analyzed on a Nikon Eclipse TE2000-E microscope 
using 4x or 10x objectives using NIS-Elements Advanced Research software. In 
capsaicin studies we quantified the number of Fos+ cell profiles in lamina I-V of the 
dorsal horn. In SNI studies the dorsal horn was separated into lamina I-II, lamina III-IV, 
and lamina V as well as medial, central, and lateral regions of interest (ROI).  Medial-
lateral ROI correspond to afferent input from the tibial (medial), common peroneal 
(central), and sural (lateral) receptive fields as previously described (Corder et al, 2010). 
Each of the six ROI were quantified and analyzed separately. For GFAP, pixel intensity 
values were summed, normalized to ROI area, and background subtracted. Background 
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intensity was determined by selecting a ROI in the devoid of GFAP+ cells. This method 
accounts for changes in both the number and the fluorescence intensity of GFAP+ cells. 
Slices were analyzed by an observer blinded to treatment. Quantification of 4-6 slices 
per subject was averaged for each ROI and n=3-4 rats per group are reported.  
 
3.3.10  Western blotting of lumbar spinal GFAP.  
 Western blot analyses were performed on lumbar spinal cord quadrants that were 
sonicated on ice in 50 mM Tris buffer containing 100 mM 6-amino-n-caproic acid, 1 mM 
EDTA, 5 mM benzamidine, 0.2 mM phenylmethyl sulfonyl fluoride (in 100% ethanol), 
and protease inhibitors. After extraction, proteins were subjected to NuPAGE Bis–Tris 
(4-12%) gel electrophoresis under reducing conditions (Invitrogen, Carlsbad, CA) and 
then transferred to nitrocellulose membranes electrophoretically (Invitrogen, Carlsbad, 
CA). Nonspecific binding sites on the membrane were blocked with Odyssey Blocking 
Buffer (50%; LI-COR Biosciences, Lincoln, NE) in TBS containing 0.1% Tween-20, 
0.05% Tris-Chloride, and 0.03% 5 M NaCl for 1 h at 22-24°C. Membranes were 
subsequently incubated with primary antibodies in Odyssey Blocking buffer containing 
0.1% Tween-20 overnight at 4°C. The membranes were then washed with PBS 
containing 0.1% Tween-20, and probed with appropriate IRDye secondary antibodies 
(LI-COR Biosciences) in Odyssey Blocking buffer containing 0.1% Tween-20 for 1 h at 
22-24°C, protected from light. Following washing with PBS containing 0.1% Tween-20, 
membranes were scanned on an Odyssey Infrared Imaging System (LI-COR 
Biosciences, Lincoln, NE). Primary antibodies and dilution ratios used were rabbit GFAP 
(1:1000, z0334, Dako, Carpinteria, CA), and mouse β actin (1:100,000, A5316, Sigma-
Aldrich, St. Loius, MO). Secondary antibodies used were goat anti-mouse IRDye 680RD 
(1:15,000, LI-COR Biosciences), goat anti-rabbit IRDye 800CW (1:15,000, LI-COR 
Biosciences). Bands were quantified using Image Studio (LI-COR Biosciences).  
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3.3.11  Statistical analysis. 
 For analysis of behavioral data and westerns, multiple groups were compared for 
significant differences over time using repeated measures two-way ANOVA or between 
groups using a standard two-way ANOVA followed by Holm-Sidak multiple comparison 
correction. Area-under-the-curve (AUC) was calculated using the trapezoidal method 
and analyzed using a one-way ANOVA with Holm-Sidak multiple comparison correction 
or an unpaired, two-tailed t-test. Ipsilateral versus contralateral (paired) or pioglitazone 
versus saline (unpaired) comparisons of GFAP immunohistochemistry ROIs (6 total 
analyses) or GFAP western quadrants were analyzed using a two-tailed t-test. An alpha 
value of α=0.05 was used to determine statistical significance. All data were analyzed 
and graphed using Prism 6.0 (GraphPad, La Jolla, CA) and are presented as mean ± 
SEM. 
 
3.4  Results 
3.4.1  Systemic pioglitazone reduces mechanical and cold hypersensitivity 
 To determine whether PPARγ activation reduces hyperalgesia, we evaluated 
behavioral indices of neuropathic pain after a single i.p. injection of pioglitazone. Spared 
nerve injury (SNI) decreased mechanical [time; F (1, 37) = 1453; P < 0.0001] and cold 
[time; F (1, 37) = 86; P < 0.0001] sensitivities at 14 d after injury. As illustrated in Fig 1A-
B, systemic pioglitazone attenuated mechanical [dose x time; F (21, 259) = 5.756; P < 
0.0001] and cold hypersensitivity [F (21, 259) = 3.485; P < 0.0001]. Area under the curve 
(AUC) analyses in Fig 1C-D indicate that pioglitazone dose-dependently attenuated 
mechanical [dose; F (3, 37) = 6.747; P = 0.001] and cold hypersensitivity [F (3, 37) = 
3.575; P = 0.023]. 
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3.4.2  PPARγ in the spinal cord mediates the anti-hyperalgesic actions of systemic 
pioglitazone  
 Churi et al. reported that a single intrathecal injection of the PPARγ agonist 
rosiglitazone produced anti-hyperalgesia within one hour (Churi et al, 2008). However, 
the authors did not test for PPARγ-dependency. To address this gap and test the 
hypothesis that PPARγ mediates the acute anti-hyperalgesic effects of i.p. pioglitazone, 
we pretreated SNI rats with GW9662, an irreversible PPARγ antagonist (Leesnitzer et al, 
2002; Chen et al, 2004). As illustrated in Fig 2A-D, systemic GW9662 (i.p.) prevented 
pioglitazone reductions in mechanical [AUC; F (2, 25) = 13.14; P = 0.0001] and cold 
[AUC; F (2, 27) = 3.992; P = 0.03] hypersensitivity. 
 Next we sought to determine whether the anti-hyperalgesic effects of systemic 
pioglitazone are mediated through activation of spinal PPARγ. As illustrated in Fig 2E-H, 
intrathecal (i.t.) GW9662 attenuated pioglitazone reduction of mechanical [AUC; F (3, 
23) = 18.55; P < 0.0001] and cold [AUC; F (3, 23) =12.85; P < 0.0001] hypersensitivity. 
Both systemic and spinal administration of GW9226 attenuated the reduction of 
mechanical and cold hypersensitivity by administration of systemic pioglitazone. 
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Figure 3-1. A single systemic injection of pioglitazone (Pio) dose-dependently 
reduced behavioral signs of neuropathic pain. 
Spared nerve injury (SNI, arrow) resulted in pain-like hypersensitivity. 
Intraperitoneal (i.p.) pioglitazone dose-dependently reversed (A) mechanical and (B) 
cold hypersensitivity 14d after SNI. Pain-related behavioral responses to plantar 
application of von Frey and acetone stimuli were measured before (0d) and after 
(14d) SNI and at 15, 30, 60, 90, 120, 180, and 240 min after intraperitoneal (i.p.) 
injection of pioglitazone (0, 10, 30, 100 mg/kg) in saline vehicle. Area under the 
curve (AUC) is shown for (C) von Frey and (D) acetone pain-related behaviors.  
“i.p. Pio 100 mg/kg” significantly different from “i.p. Saline”. † “i.p. Pio 30 mg/kg” and 
“i.p. Pio 100 mg/kg” significantly different from “i.p. Saline”. “n” are shown in 
parentheses. 
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Figure 3-2. Anti-hyperalgesic actions of systemic pioglitazone are mediated by 
spinal PPARγ.  
Systemic GW9662 (GW), a PPARγ antagonist, blocked pioglitazone (Pio) reduction 
of (A-B) mechanical and (C-D) cold hypersensitivity 14d after SNI. (E-F) Spinal GW 
completely abolished pioglitazone reduction of mechanical hyperalgesia and (G-H) 
partially blocked pioglitazone alleviation of cold hypersensitivity. GW was 
administered i.p. or i.t. 15 min prior to i.p. pioglitazone.  significantly different from 
“i.p. GW 10 mg/kg” or “i.p. Pio 100 mg/kg + i.t. GW 300μg”. † significantly different 
from “i.p. GW 2 mg/kg” and “i.p. GW 10 mg/kg”. # significantly different from “i.p. 
Saline + i.t. Vehicle”. ‘n’ are shown in parentheses.  
 
3.4.3  PPARγ in the spinal cord mediates the anti-hyperalgesic actions of intrathecal 
pioglitazone 
 To support the PPARγ antagonist experiment above in identifying the spinal cord as 
a key site of PPARγ anti-hyperalgesic action, we administered pioglitazone and/or 
GW9662 by the intrathecal or intracerebroventricular route. Fig 3A demonstrates that i.t. 
pioglitazone attenuated mechanical hyperalgesia [dose x time; F (18, 162) = 2.951; P = 
0.0001] as rapid as 30 min after injection in a dose-dependent manner. To account for 
possible supraspinal activation of PPARγ after i.t. pioglitazone via the cerebrospinal fluid 
circulation, we injected the same doses via the intracerebroventricular (i.c.v.) route. We 
found no anti-hyperalgesic effect of pioglitazone at these doses [F (3, 21) = 1.959; P = 
0.15]. Fig 3B illustrates that co-administration of the PPARγ antagonist GW9662 
completely blocked the anti-hyperalgesic actions of i.t. pioglitazone [drug x time; F (18, 
198) = 16.26; P < 0.0001]. 
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Figure 3-3. Spinal PPARγ mediates pioglitazone anti-hyperalgesia.  
(A) Intrathecal (i.t.) pioglitazone (Pio) dose-dependently reduced mechanical 
hyperalgesia at doses that have no effect when administered by the 
intracerebroventricular (i.c.v.) route. (B) Intrathecal co-administration of the PPARγ 
antagonist GW9662 (GW) completely reversed pioglitazone anti-hyperalgesia. † 
high and medium ‡ high, medium, low dose Pio significantly different from “i.t. 
Saline”.  significantly different from “i.t. Saline + i.t. Vehicle”. ‘n’ are shown in 
parentheses. 
 
3.4.4  PPARγ activation does not produce motor deficits or analgesia   
 We determined whether the anti-hyperalgesic actions of pioglitazone might be 
confounded by off-target effects on motor systems or transient reflexive pain (Taylor, 
2001). Fig 4A-B illustrates that a relatively high dose of pioglitazone did not change 
rotarod performance after i.p. [p = 0.81] or i.t. [p = 0.35] injection. Because von Frey 
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mechanical withdraw thresholds are maximal in uninjured rats (e.g. 15 g), we assessed 
response latencies to noxious heat to determine if pioglitazone altered acute nociception 
in sham rats. Intrathecal pioglitazone did not change heat response latencies [p = 0.5] 
suggesting that the effects of PPARγ activation are not analgesic. Together with our 
previous reports (Churi et al, 2008; Morgenweck et al, 2010; Morgenweck et al, 2013), 
we conclude that reduction of mechanical hyperalgesia by PPARγ agonists is not 
secondary to adverse effects on motor coordination or normal sensory thresholds.  
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Figure 3-4. Pioglitazone did not produce ataxia or changes in transient 
nociception.  
Motor coordination was assessed on an accelerating rotarod before and at 1, 2, and 
3 h after high dose pioglitazone (Pio) administration by (A) systemic (i.p. 100 mg/kg) 
or (B) spinal (i.t. 1000 μg) routes. Pioglitazone did not change time spent on the 
accelerating rotarod. (C) The analgesic effects of pioglitazone were tested using the 
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Hargreaves assay before and after intrathecal saline or pioglitazone administration 
in sham rats. Pioglitazone did not change paw withdraw latencies to noxious heat. n 
= 8-10 per group. 
 
3.4.5  PPARγ agonists rapidly reduce nociceptive and neuropathic pain-like behavior  
 The above studies illustrate that i.t. administration of pioglitazone reduces tactile 
hypersensitivity within 30 min of administration in SNI rats. Consistent with this finding, 
intrathecal pioglitazone, compared to saline, reduced nociceptive behavior when given 
20 min prior to intraplantar capsaicin (nociceptive responses; 16.3 ± 2.3 vs. 62.2 ± 16.1; 
n = 5-6) [p = 0.013]. To test the hypothesis that PPARγ anti-hyperalgesic mechanisms 
occur rapidly after traumatic nerve injury, we extended our temporal analysis of pain-like 
behavior in the SNI model to earlier time points. Fig 5A-B demonstrates that the PPARγ 
agonists rosiglitazone [F (1, 9) = 5.942; P = 0.0375] and pioglitazone [F (1, 8) = 28.24; P 
= 0.0007] attenuated SNI-associated mechanical hypersensitivity within 5 min of 
injection. We repeated the study with 7.5 min as the first behavioral timepoint to allow full 
recovery from isoflurane anesthesia, as evidenced by the slight increase in von Frey 
thresholds in the saline control group in Fig 5B. Fig 5C illustrates a robust anti-
hyperalgesic effect of pioglitazone [F (1, 14) =26.62; P = 0.0001] and at the 7.5 minute 
timepoint [p < 0.0001] in the absence of a residual anesthetic effect [p = 0.9998]. Our 
findings that rosiglitazone and pioglitazone produce anti-hyperalgesia and anti-
nociception within 5-20 min of administration suggest that non-genomic PPARγ 
mechanisms mediate rapid reduction of pain-like behavior. 
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Figure 3-5. PPARγ agonists rapidly reduce mechanical hyperalgesia.  
Intrathecal injection of the PPARγ ligands (A) rosiglitazone (Rosi) or (B) pioglitazone 
(Pio) rapidly (within 5 min) reduced mechanical hypersensitivity 14d after SNI. 
Intrathecal injections were performed under isoflurane anesthesia, which resulted in 
a small anti-hyperalgesic effect at 5 min. Therefore, we repeated the experiment 
with 7.5 min the earliest timepoint tested. (C) Pioglitazone rapidly attenuated 
mechanical hypersensitivity that lasted from 7.5 to 90 min with no anesthesia effect 
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in the saline group.  significantly different from “i.t. Saline”. ‘n’ are shown in 
parentheses. 
 
3.4.6  In vivo blockade of protein translation in the dorsal horn by intrathecal anisomycin 
 To examine whether a translation-independent (i.e. non-genomic) mechanism 
mediates the rapid anti-hyperalgesic effects of PPARγ, we administered intrathecal 
anisomycin to block protein synthesis in the dorsal horn in vivo at a dose that did not 
produce confounding alterations in nociception (Kim et al, 1998). To achieve this, we 
evaluated the effect of multiple doses of anisomycin, based on previously used doses of 
25 to 125 µg (Schafe and LeDoux, 2000; Parsons et al, 2006; Asiedu et al, 2011; Bonin 
and De Koninck, 2014), on capsaicin-induced protein (i.e. Fos) expression. Capsaicin 
activates TRPV1-positive primary afferent nociceptors (Brederson et al, 2013) resulting 
in spontaneous, dose-dependent pain in humans (Simone et al, 1989). Intraplantar 
injection of capsaicin in rodents elicits spontaneous nociceptive behavior (Simone et al, 
1987) and induces Fos expression in the superficial dorsal horn within 30 to 90 min 
(Hossaini et al, 2010; Beaudry et al, 2011), providing a suitable tool for evaluating effects 
of anisomycin on new protein synthesis.  
 As depicted in Fig 6A, we administered intrathecal pioglitazone and/or anisomycin 
twenty minutes prior to evaluation of capsaicin-evoked nociceptive behavior. Sixty 
minutes after capsaicin injection, we euthanized animals for quantification of Fos 
expression in the L4-L5 dorsal horn. As illustrated in Fig 6B, combinations of capsaicin, 
pioglitazone, and anisomycin administration significantly altered Fos expression in 
laminae I-V [group; F (7, 17) = 9.38; P < 0.0001]. Compared to vehicle injection, 
intraplantar capsaicin increased Fos expression [p = 0.007], an effect that was dose-
dependently inhibited by pretreatment with 100-200 μg doses of anisomycin [p < 0.05] 
but not 50 μg [p = 0.064]. Anisomycin (200 µg) also reduced Fos expression when co-
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administered with pioglitazone [p = 0.0006]. Pioglitazone did not alter capsaicin-evoked 
Fos [p = 0.74] when administered alone.  
 We offer two explanations for the lack of effect of pioglitazone on spinal Fos 
expression even though nociceptive behavior was reduced after intraplantar capsaicin 
injection. First, Fos and behavior do not always positively correlate: drug-induced 
reduction of pain-like behavior can occur in the absence of (Harris, 1998; Coggeshall, 
2005; Gao and Ji, 2009) or with increases in (Orii et al, 2002) Fos expression. Second, 
the target of pioglitazone, PPARγ, directly activates c-fos transcription (Rogue et al, 
2010). If pioglitazone directly increases Fos expression in inhibitory interneurons, which 
can account for a significant population of total cells expressing Fos (Todd et al, 1994), 
then this would confound the ability of our Fos method to reflect noxious stimulus-
evoked spinal neuron activation.  
 
3.4.7  Anisomycin does not alter the anti-nociceptive effects of intrathecal pioglitazone 
 Having validated that anisomycin reduces protein translation (i.e. Fos) in the dorsal 
horn, we used this method to explore the anti-nociceptive and translation-independent 
actions of PPARγ activation in the capsaicin model. As illustrated in Fig 6C, 
combinations of capsaicin, pioglitazone, and anisomycin administration significantly 
altered nociceptive behavior [group; F (7, 35) = 5.476; P = 0.0003]. Intraplantar 
capsaicin markedly increased nociceptive behavior when compared to vehicle injection 
[p = 0.0055]. Anisomycin alone (50-200 μg) did not alter capsaicin-evoked nociceptive 
behavior [p > 0.05]. Pioglitazone reduced nociceptive behavior when administered alone 
[p = 0.0029] or in combination with the 200 µg dose of anisomycin [p = 0.0029]. These 
results indicate that anisomycin blocks genomic activity (i.e. Fos expression) in the 
dorsal horn without altering nociceptive behavior or pioglitazone anti-nociception, 
providing proof of principle for this method. 
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Figure 3-6. Anisomycin reduces translation of capsaicin-evoked Fos without 
blocking the rapid anti-nociceptive actions of pioglitazone.  
(A) Experimental timeline to test the hypothesis that capsaicin evoked Fos 
translation is inhibited by intrathecal anisomycin pretreatment. (B) Vehicle (0μg 
Cap), pioglitazone (Pio), and/or anisomycin (Ani) were co-administered i.t. 20 min 
prior to i.pl. capsaicin (50μg). Capsaicin-induced spontaneous licking, lifting, and 
flinching nociceptive responses from 0-2 min after injection were almost completely 
abolished by pioglitazone (300μg) alone or in combination with anisomycin (200μg) 
pretreatment. Anisomycin (50-200μg) alone did not alter capsaicin nociception. (C) 
Capsaicin-evoked Fos expression was dose-dependently inhibited by anisomycin 
and unaltered by pioglitazone. (D) Sham injection of vehicle produced moderate Fos 
expression when compared to (E) i.t. vehicle injections followed by i.pl. capsaicin. 
(F) 50μg, (G) 100μg, (H) 150μg, and (I) 200μg anisomycin dose-dependently 
reduced Fos. (J) Pioglitazone alone had no effect on Fos expression while (K) 
anisomycin completely abolished Fos when co-administered with pioglitazone.  
significantly different from capsaicin only (black bars). n = 3-9 for behavioral and n = 
3-4 for Fos analyses.  
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3.4.8  Spinal anisomycin does not change the rapid anti-hyperalgesic effects of 
pioglitazone 
 Next we extended spinal anisomycin blockade of translation in the dorsal horn to the 
SNI model of neuropathic pain. We began with a dose of anisomycin that, when 
administered into the brain, inhibits conditioned taste aversion (Rosenblum et al, 1993), 
auditory fear conditioning (Schafe and LeDoux, 2000; Parsons et al, 2006; Parsons et al, 
2006), and incorporation of radioactive methionine into nascent proteins (Rosenblum et 
al, 1993; Parsons et al, 2006). We found that the 200 µg dose of anisomycin abolished 
capsaicin-evoked Fos, but also produced a confounding attenuation of SNI-induced 
mechanical hypersensitivity. By lowering the anisomycin dose to 100 µg, we obtained a 
significant reduction in Fos without altering SNI-induced hypersensitivity. As illustrated in 
Fig 7A, combinations of intrathecal vehicle, pioglitazone, or anisomycin changed 
mechanical sensitivity in SNI rats when analyzed across the entire 240 min time course 
[drug x time; F (24, 168) = 3.416; P < 0.0001]. Further analysis of the 7.5 - 120 min 
timepoints revealed that pioglitazone attenuated mechanical hypersensitivity when 
injected alone [vs. Vehicle + Saline; F (1, 9) = 29.41; P = 0.004] or with 100 µg 
anisomycin [vs. Vehicle + Saline; F (1, 11) = 5.098; P = 0.045]. At this dose, anisomycin 
alone did not inhibit mechanical hypersensitivity [p = 0.54]. To compare the effect of 
anisomycin on pioglitazone anti-hyperalgesia at early versus delayed timepoints, we 
analyzed the data at each of four timepoints (Fig 7B): before intrathecal injections (pre-
drug), during early pioglitazone anti-hyperalgesia (7.5 min), during late pioglitazone anti-
hyperalgesia (60 min), and after anti-hyperalgesia resolved (180 min). Compared to 
intrathecal vehicle, pioglitazone [p = 0.013] and pioglitazone plus anisomycin [p = 0.026] 
attenuated hypersensitivity at 7.5 min when compared to intrathecal vehicle only [drug; F 
(3, 20) = 5.173; P = 0.008]. By contrast, the delayed anti-hyperalgesic actions of 
77 
pioglitazone at 60 min [p = 0.003 vs. Vehicle + Saline] were significantly reduced by 
anisomycin [p = 0.021 vs. Vehicle + Pio]. 
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Figure 3-7. Early but not late pioglitazone anti-hyperalgesia is independent of 
translation. 
To test whether immediate PPARγ anti-hyperalgesia is dependent on canonical 
genomic activity, we co-administered pioglitazone with an anisomycin dose that 
blocks translation but not nociception (100μg; see discussion for details). (A) 
Timecourse of mechanical thresholds after i.t. injection of pioglitazone (Pio) or 
anisomycin (Ani). (B) Analysis of mechanical thresholds at 7.5, 60 and 180 min 
timepoints. Anisomycin did not change the anti-hyperalgesic effects of pioglitazone 
at the early 7.5 min period, but reduced pioglitazone anti-hyperalgesia at 60 min. 
These results suggest that pioglitazone produces its anti-hyperalgesic effects by 
both translation-independent (7.5 min) and translational-dependent (60 min) 
mechanisms.  significantly different. ‘n’ are shown in parentheses. 
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3.4.9  Acute pioglitazone reduces expression of GFAP after nerve injury 
 Neuropathic pain is associated with astrocyte activation after nerve injury (Zhang and 
De Koninck, 2006). We previously reported that repeated administration of pioglitazone 
reduced not only established neuropathic pain, but also astrocyte activation in the dorsal 
horn of SNI rats (Morgenweck et al, 2013). To determine whether a single administration 
of pioglitazone also reduces astrocyte activation after SNI, we evaluated the protein 
expression of GFAP in the lumbar dorsal horn using both immunohistochemistry and 
western blot as soon as 60 min.  
 Similar to previous reports (Zhang and De Koninck, 2006), Fig 8A-B illustrates that 
SNI produced a unilateral increase in GFAP expression in the ipsilateral dorsal horn 14d 
after injury [ipsi vs. contra; F (1, 12) = 8.55; P = 0.0127]. This occurred in both injured 
(tibial and common peroneal) and uninjured (sural) innervation territories [t-test; p < 
0.05]. Fig 8C-D illustrates that pioglitazone reduced GFAP expression in the 
contralateral and ipsilateral dorsal horn within 60 min of injection [drug; F (1, 8) = 74.93; 
P < 0.0001]. 
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Figure 3-8. Acute PPARγ activation reduces GFAP expression.  
(A) Spared nerve injury produced an increase in GFAP expression on the injured 
(ipsilateral) side when compared to the uninjured (contralateral) side of the lumbar 
dorsal horn. (B) SNI-induced a GFAP increase in injured (tibial and common 
peroneal) and uninjured (sural) innervation territories. (C-D) Pioglitazone (100 mg/kg 
i.p.; 1 h prior to perfusion) reduced GFAP expression on both the contralateral and 
ipsilateral dorsal horn. Each region of interest was analyzed separately using a two-
tailed t-test. # significantly different from “contralateral” in the “Saline” group 
(paired).  significantly different from “Saline” (unpaired). n = 3 per group. 
 
 To confirm that the acute reduction of GFAP expression elicited by pioglitazone (Fig 
8) did not result from structural changes that mask the GFAP antibody epitope in fixed 
tissue, we performed denaturing western blots. At 14 d after sham or SNI surgery, we 
administered i.p. pioglitazone, measured behavioral anti-hyperalgesia, and harvested 
L4-5 spinal cord quadrants 90 min later. As illustrated in Fig 9A, pioglitazone but not 
saline reduced mechanical hyperalgesia in SNI animals [drug; F (1, 10) = 11.17; P = 
0.0075] at 60 [p = 0.023] and 90 [p < 0.0001] min after administration. Western blot 
analysis of the four lumbar quadrants is reported in Fig 9B (dorsal) and Fig 9C (ventral). 
Neither injury [p = 0.58] nor drug [p = 0.33] treatment changed GFAP expression in the 
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contralateral dorsal horn. By contrast, we found a significant injury x drug interaction in 
the ipsilateral dorsal horn [F (1, 20) = 11.39; P = 0.003]. Post-hoc tests revealed that SNI 
increased GFAP expression when compared to sham animals treated with saline [p = 
0.0014]. This increase was reduced by pioglitazone in the ipsilateral [p = 0.0026] but not 
contralateral [p = 0.54] dorsal horn of SNI animals (Fig 9B). In the contralateral ventral 
horn, neither injury [p = 0.14] nor pioglitazone [p = 0.40] changed GFAP expression. 
Injury [p = 0.41] or pioglitazone [p = 0.84] did not change GFAP expression in the 
ipsilateral ventral horn.  
 
 
Figure 3-9. SNI is required for pioglitazone reduction of pain and astrocyte 
activation. 
To determine whether pioglitazone is toxic to astrocytes and to rule out 
conformational changes in the GFAP antibody epitope during immunohistochemical 
analysis we performed a denaturing western blot. Spinal cord quadrants (L4-5) were 
harvested 90 min after i.p. pioglitazone administration at d14 after sham or spared 
nerve injury (SNI) surgery. (A) Pioglitazone attenuated mechanical hypersensitivity 
in SNI, but not sham, animals. (B) Dorsal and (C) Ventral integrated densities 
normalized to Sham + Saline are shown. There was no effect of injury or drug 
treatment in the ventral horn or in the contralateral dorsal horn segments. GFAP 
expression was increased in the ipsilateral dorsal horn of SNI + Saline animals 
when compared to all other groups. Pioglitazone significantly reduced ipsilateral 
dorsal horn GFAP expression in SNI, but not sham, animals. This suggests that the 
anti-hyperalgesic effects of pioglitazone are associated with decreased astrocyte 
activation after nerve injury.  significantly different from “SNI + Saline”. n=6-7 per 
group.  
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3.5  Discussion 
3.5.1  Anisomycin to assess translation-independent activity of nuclear receptors in the 
spinal cord 
 Here we used in vivo administration of anisomycin to dissect genomic versus non-
genomic mechanisms of a nuclear receptor in the spinal cord. Previous studies using 
anisomycin suggested that protein translation is necessary for late phase LTP in the 
brain (Krug et al, 1984; Frey et al, 1988), hyperalgesic priming in the peripheral nervous 
system (Asiedu et al, 2011), ongoing pain transmission in the spinal cord (Kim et al, 
1998), and reduction of established hyperalgesia during pain memory reconsolidation in 
the spinal cord (Bonin and De Koninck, 2014). As these studies did not confirm inhibition 
of translation, we found it important to demonstrate that intrathecal anisomycin inhibits 
spinal protein expression. We found that anisomycin, at a dose of 100 µg, decreased 
expression of capsaicin-evoked Fos without changing SNI-induced hyperalgesia. This 
provides proof of principle for using this approach to determine the contribution of non-
genomic PPARγ mechanisms to the rapid and delayed phases of pioglitazone anti-
hyperalgesia. 
 
3.5.2  Non-genomic PPARγ activity mediates the early anti-hyperalgesic effect of 
pioglitazone 
 Based on our finding that the anti-hyperalgesic effect of pioglitazone occurred very 
rapidly (7.5 min) and this was maintained in the presence of 100 μg anisomycin, we 
suggest the involvement of a non-genomic PPARγ mechanism. Non-genomic 
mechanisms in the dorsal horn might also explain the rapid anti-hyperalgesic effects 
observed after interruption of other nuclear receptors including estrogen and PPARα 
receptors. For example, in vivo administration of 17β-estradiol rapidly (within 15 min) 
enhanced bradykinin-induced hyperalgesia (Rowan et al, 2010) and inhibited opioid 
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receptor-like 1 anti-nociception (Small et al, 2013): these were unaffected by 
pretreatment with anisomycin or conjugation of 17β-estradiol to membrane-impermeable 
BSA (Rowan et al, 2010; Small et al, 2013) suggesting that membrane estrogen 
receptors contribute to rapid pain modulation. Also, the inhibition of neuropathic pain 
(within 30 min) by the PPARα agonists PEA and GW7647 (Costa et al, 2008) was 
abrogated in PPARα knockout mice or by pharmacological blockade of calcium-activated 
potassium channels (Lo Verme et al, 2005; LoVerme et al, 2006; Costa et al, 2008) 
suggesting both rapid and PPARα-dependent analgesic actions. We speculate that, in a 
similar manner, the rapid anti-hyperalgesic effect of pioglitazone is mediated by 
membrane PPARγ that is linked to ion channel activity, neuronal excitability, and/or 
central sensitization mechanisms. 
 
3.5.3  Genomic PPARγ activity mediates the late anti-hyperalgesic effects of 
pioglitazone 
 We found that anisomycin significantly reduced the anti-hyperalgesic effects of 
pioglitazone at later time points (60 minutes), supporting a contribution of classical 
genomic mechanisms involving transcription and translation. This is consistent with 
several reports indicating that repeated pioglitazone administration produced sustained 
anti-hyperalgesic actions persisting for days to weeks after cessation of drug 
administration (Takahashi et al, 2011; Morgenweck et al, 2013), beyond the time 
necessary for drug clearance (Maeshiba et al, 1997). Similarly, our current results and 
previous studies (Park et al, 2007; Churi et al, 2008; Morgenweck et al, 2010) indicate 
that a single TZD injection produces anti-hyperalgesia lasting for several hours, much 
longer than the half-life of pioglitazone (Maeshiba et al, 1997). In summary, our results 
suggest pioglitazone anti-hyperalgesia transitions from a rapid, anisomycin–resistant 
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mechanism to a delayed, anisomycin-sensitive mechanism within approximately 60 
minutes.  
 
3.5.4  The anti-hyperalgesic effect of pioglitazone is mediated by spinal PPARγ  
 PPARγ agonists reduce tactile hypersensitivity after nerve injury, but the site(s) of 
action and selectivity of these agents remain elusive. Here, systemic or spinal 
pioglitazone decreased nerve injury-induced tactile hypersensitivity, and this effect was 
lost when given in the presence of intrathecal GW9662. We conclude that PPARγ in the 
dorsal horn of the spinal cord contributes to the anti-hyperalgesic effects of pioglitazone. 
This is consistent with previous studies showing that: 1) PPARγ is expressed in the 
lumbar spinal cord (Churi et al, 2008; Maeda et al, 2008); 2) hyperalgesia after SNI was 
exacerbated by intrathecal administration of the PPARγ antagonist BADGE 
(Fehrenbacher et al, 2009); and 3) intrathecal GW9662 inhibited the anti-hyperalgesic 
effect of both repeated systemic or single intrathecal administration of rosiglitazone or 
15d-PGJ2 (Churi et al, 2008; Morgenweck et al, 2013). It is unlikely that brain PPARγ 
mediates anti-hyperalgesia after intrathecal pioglitazone, because i.c.v. administration of 
comparable doses had no effect; this is consistent with previous results showing that low 
i.c.v. doses of rosiglitazone or 15d-PGJ2 (Churi et al, 2008) did not change tactile 
hypersensitivity.  
 Our studies do not rule out “off-target” effects that might contribute to rapid 
pioglitazone anti-hyperalgesia. Gras et al (2009) reported that rosiglitazone-stimulated 
calcium mobilization was lost after GPR40 siRNA knockdown, suggesting that TZDs (i.e. 
PPARγ agonists) may activate GPR40 (Gras et al, 2009). Activation of GPR40, which is 
expressed in brain (Ma et al, 2007; Ma et al, 2008) and spinal cord neurons (Nakamoto 
et al, 2012), by endogenous (DHA) and exogenous (GW9508) ligands reduced 
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inflammatory pain (Nakamoto et al, 2012; Nakamoto et al, 2013). Thus GPR40 is an 
intriguing target for future studies.  
 
3.5.5  Pioglitazone acutely inhibits astrocyte activation 
 We previously reported that repeated pioglitazone administration spanning several 
weeks reduced GFAP in the dorsal horn (Morgenweck et al, 2013). Here we observed 
the same result in a timeframe of just 60 minutes following a single dose of pioglitazone, 
leading us to speculate that astrocytes contribute to rapid anti-hyperalgesia 
mechanisms. This might be PPARγ-dependent, since markers of astrocyte activation are 
reduced by other PPARγ agonists (Storer et al, 2005; Gurley et al, 2008).  
 Our results are not the first to describe that an acute intervention (i.e. pioglitazone) 
can alter astrocyte function. For example, increases in GFAP expression occur as soon 
as 30 min after electrical stimulation of primary afferents (Wang et al, 2010) or 
intraplantar injection of CFA (Wang et al, 2010) or snake venom toxin sPLA2-Asp49 
(Chacur et al, 2004). Second, the astrocyte toxins l-α-aminoadipate and fluorocitrate 
reduced neuropathic pain and GFAP expression within 30 to 60 min of administration 
(Zhuang et al, 2006; Wei et al, 2008). Third, fluorocitrate prevented the early phase of 
TNFα-induced long term potentiation (LTP) in the ex vivo spinal cord (Gruber-
Schoffnegger et al, 2013). Therefore, based on the current finding that pioglitazone 
reduced GFAP in the dorsal horn, we propose that pioglitazone inhibits the astrocytic 
release of neuron-sensitizing molecules that contribute to LTP and, ultimately, the 
maintenance of chronic neuropathic pain. Indeed, pioglitazone reduced the release of 
TNFα from astrocytes in culture (Storer et al, 2005). 
 Our results do not rule out a supraspinal component to the anti-hyperalgesic actions 
of systemically-administered pioglitazone. This hypothesis is suggested by the findings 
that: 1) in models of CNS injury, pioglitazone reduced mitochondrial dysfunction (Hunter 
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and Bing, 2007; Hunter et al, 2008; Sauerbeck et al, 2011; Yonutas and Sullivan, 2013) 
and promoted glucose metabolism in astrocytes (Dello Russo et al, 2003; Pancani et al, 
2011); 2) pioglitazone reduced Aβ-induced astrocyte activation in the hippocampus 
(Heneka et al, 2005); 3) PPARγ is expressed in cortical astrocytes (Cristiano et al, 2001; 
Moreno et al, 2004); 4) astrocytes in the anterior cingulate cortex facilitate pain 
sensitization and inhibition (Chen et al, 2012; Ikeda et al, 2013; Grace et al, 2014; 
Yamashita et al, 2014). This provides for the possibility that systemic pioglitazone 
administration produces anti-hyperalgesia through cortical, in addition to spinal, 
astrocytic mechanisms. 
 Investigations of nerve injury-induced activation of astrocytes in areas of the dorsal 
horn innervated by injured versus uninjured afferents are sparse (Zhang and De 
Koninck, 2006; Beggs and Salter, 2007; Corder et al, 2010). Here, our 
immunohistochemical quantification method (Corder et al, 2010) revealed that nerve 
injury increased GFAP expression in regions of the ipsilateral dorsal horn innervated by 
both injured tibial afferents (medial) and uninjured sural afferents (lateral). This is 
consistent with qualitative studies showing that astrocyte activation extends beyond 
injured territories (Beggs and Salter, 2007), and suggests that astrocytes induce 
hyperalgesia by sensitizing intact nociceptive pathways. 
 Validation of immunohistochemical results with a complementary approach is 
essential because IHC assays can be misinterpreted due to drug or injury-induced 
cytotoxic changes in the conformation and/or the formalin sensitivity of the GFAP 
epitope (i.e. epitope masking) (Bell et al, 1987; Eng et al, 2000). We chose an approach 
involving a denaturing western blot, and the results indicate that pioglitazone does not 
change GFAP expression in sham animals, nor on the contralateral side in SNI animals, 
nor in the ventral horn in sham or SNI animals. This not only suggests that astrocyte 
viability is preserved after pioglitazone injection, but also that epitope masking does not 
86 
confound our conclusion that a single injection of pioglitazone exerts anti-hyperalgesic 
actions in part by reducing astrocyte activation.  
   
3.5.6  Conclusions 
 Our results indicate that pioglitazone acts at spinal PPARγ to inhibit astrocyte 
activation and to produce fast-acting, dose-dependent, and translation-independent 
inhibition of pain-like hypersensitivity after traumatic nerve injury. The specific 
mechanisms of rapid pain reduction by PPARγ and the involvement of astrocytes 
warrant further investigation. Our studies do not rule out actions of PPARγ agonists in 
the peripheral nervous system (Maeda et al, 2008; Takahashi et al, 2011) that would 
reduce spinal sensitization, but do illustrate an important behavioral and neurobiological 
role for non-genomic inhibition of pain in the spinal cord by a nuclear receptor. 
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CHAPTER 4:  Pioglitazone inhibits the development of hyperalgesia and 
sensitization of spinal nociresponsive neurons in type 2 diabetes 
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4.1  Abstract 
 Thiazolidinedione drugs (TZDs) such as pioglitazone are FDA-approved for the 
treatment of insulin resistance in type 2 diabetes. However, whether TZDs reduce 
painful diabetic neuropathy (PDN) remains unknown. Therefore we tested the 
hypothesis that chronic administration of pioglitazone would reduce PDN in Zucker 
Diabetic Fatty (ZDFfa/fa) rats. Compared to Zucker Lean (ZLfa/+) controls, ZDF developed: 
(1) elevated blood glucose, HbA1c, methylglyoxal and insulin; (2) mechanical and 
thermal hyperalgesia at the hindpaw; (3) increased avoidance of noxious mechanical 
probes in a mechanical conflict avoidance behavioral assay, the first report of a measure 
of affective-motivational pain-like behavior in ZDF; and (4) exaggerated lumbar dorsal 
horn immunohistochemical expression of pressure-evoked phosphorylated extracellular 
signal-regulated kinase (pERK). Seven weeks of pioglitazone (30 mg · kg-1 · d-1 in food) 
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reduced blood glucose, HbA1c, hyperalgesia, and pERK in ZDF. This is the first report to 
reveal hyperalgesia and spinal sensitization in the same ZDF animals, both evoked by a 
noxious mechanical stimulus that reflects pressure pain frequently associated with 
clinical PDN. As pioglitazone provides the combined benefit of reducing hyperglycemia, 
hyperalgesia, and central sensitization, we suggest that TZDs represent an attractive 
pharmacotherapy in patients with type 2 diabetes-associated pain. 
 
4.2  Introduction 
 Approximately one-third of patients with diabetes experience pain (Davies et al, 
2006; Abbott et al, 2011; Lee-Kubli et al, 2014), commonly referred to as painful diabetic 
neuropathy (PDN) (Vincent et al, 2011).  A majority of preclinical PDN studies focus on 
the streptozotocin (STZ) model of type 1 diabetes (Calcutt et al, 2009). However, 90% of 
diabetic patients are type 2 (World Health Organization), the prevalence of PDN is 
greater in patients with type 2 (Van Acker et al, 2009; Abbott et al, 2011), and pain 
mechanisms in type 1 versus type 2 likely differ (Schmidt et al, 2003; Schmidt et al, 
2004; Kamiya et al, 2005; Schuelert et al, 2015). Therefore we chose to study a genetic 
model of type 2 PDN, the Zucker Diabetic Fatty (ZDFfa/fa) rat (Clark et al, 1983). 
 Hyperglycemia develops within 6-10 wks of age (Clark et al, 1983; Li et al, 2006; 
Brussee et al, 2008; Sugimoto et al, 2008) in ZDF but not Zucker Lean (ZLfa/+) controls, 
and is followed by behavioral correlates of PDN, including hypersensitivity to mechanical 
(Roane and Porter, 1986; Zhuang et al, 1997; Brussee et al, 2008; Sugimoto et al, 2008; 
Otto et al, 2011; Vera et al, 2012; Galloway and Chattopadhyay, 2013) and thermal 
(Roane and Porter, 1986; Li et al, 2006; Rong and Ma, 2011; Galloway and 
Chattopadhyay, 2013) somatosensory stimulation. However, conflicting studies report 
either hypoalgesia (Sugimoto et al, 2008; Shevalye et al, 2012) or hyperalgesia (Roane 
and Porter, 1986; Zhuang et al, 1997) in similarly aged ZDF. This raises concerns 
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regarding examination of sensory thresholds at just a single age without regard to the 
developmental stage of diabetes (Roane and Porter, 1986; Zhuang et al, 1997; Li et al, 
2006; Brussee et al, 2008; Shevalye et al, 2012), or omission of ZL controls when 
multiple ages are assessed (Otto et al, 2011). These deficiencies in the literature led us 
to rigorously evaluate multiple pain-like behaviors in ZDF and ZL at various ages in a 
well-controlled study. 
 We hypothesized that spinal cord plasticity contributes to pain in type 2 diabetes 
because: (1) hyperalgesic db/db mice exhibit dorsal horn increases in both 
phosphorylated extracellular signal-regulated kinase (pERK) (Dauch et al, 2012; Xu et 
al, 2014), a marker of nociresponsive neuron activation (Gao and Ji, 2009) in the spinal 
dorsal horn (Ji et al, 1999; Zhuang et al, 2005; Morgenweck et al, 2013), and the 
astrocyte activation marker GFAP (Liao et al, 2011; Dauch et al, 2012; Ren et al, 2012; 
Xu et al, 2014); (2) intrathecal injection of either the ERK phosphorylation inhibitor 
U0216 (Xu et al, 2014) or the astrocyte toxin L-α-aminoadipate (Liao et al, 2011) 
reverses hyperalgesia; and (3) augmented NMDA and AMPA receptor expression and 
function in the spinal cord (Li et al, 1999) may contribute to hyperalgesia in ob/ob mice 
(Latham et al, 2009). A recent report indicated that spinal neurons in ZDF exhibit central 
sensitization in response to non-noxious hindpaw stimulation (Schuelert et al, 2015). 
However, concurrent evaluation of pain-like behavior was not performed. We go beyond 
these studies by evaluating spinal plasticity in PDN using a clinically relevant noxious 
pressure stimulus to evoke not only pERK in the spinal dorsal horn but also behavioral 
hyperalgesia in the same subjects.   
 Thiazolidinedione drugs (TZDs) such as pioglitazone (Actos®) are approved by the 
U.S. Food and Drug Administration for the treatment of type 2 diabetes. TZDs also 
reduce the molecular and behavioral sequelae of neurological disease (Feinstein, 2003; 
Kapadia et al, 2008), as well as neuropathic pain associated with brain (Sauerbeck et al, 
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2011; Yonutas and Sullivan, 2013), spinal cord (Park et al, 2007; McTigue, 2008) or 
nerve (Churi et al, 2008; Maeda et al, 2008; Takahashi et al, 2011; Morgenweck et al, 
2013; Griggs et al, 2015) injury. For example, we recently reported that pioglitazone 
reduced hypersensitivity to non-noxious mechanical stimulation in rats with traumatic 
nerve injury (Morgenweck et al, 2013). However, it still remains unclear whether TZDs 
reduce the neuropathic pain associated with type 2 diabetes (Taylor, 2015). In addition, 
behavioral signs of PDN in rodents are more frequently associated with hypersensitivity 
to noxious, rather than non-noxious stimulation. To address these gaps, we tested the 
hypothesis that chronic administration of Actos® would prevent the development of 
noxious pressure-evoked hyperalgesia and spinal central sensitization in ZDF rats.  
 
4.3  Materials and Methods 
4.3.1  Subjects 
 Experiments were carried out in accordance with the Institutional Animal Care and 
Use Committee at the University of Kentucky (Approved Protocol # 2009-0429). All 
efforts were made to minimize animal suffering, to reduce the number of animals used, 
and to utilize alternatives to in vivo techniques, in accordance with the International 
Association for the Study of Pain (Zimmermann, 1983) and the National Institutes of 
Health Office of Laboratory Animal Welfare Guide for the Care and Use of Laboratory 
Animals.  
 Male ZL and ZDF rats (http://www.criver.com/products-services/basic-research/find-
a-model/zucker-diabetic-fatty-(zdf)-rat, Charles River, Wilmington, MA) aged 4-19 weeks 
were used for all experiments. “Obese” ZDF rats are homozygous for the loss-of-function 
“fatty” mutation in the leptin receptor (fa/fa) that results in the development of type 2 
diabetes (Clark et al, 1983). “Lean” ZL rats are heterozygous (fa/+), do not develop a 
diabetic phenotype, and are genetic controls for ZDF. All rats were housed in a 
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temperature- and humidity-controlled room on a 12 hour light – 12 hour dark cycle with 
lights on from 7:00am to 7:00pm. Prior to any behavioral or dietary manipulations, all 
rats were provided water and Formulab 5008 (TestDiets, Purina Mills, Richmond, IN) 
chow ad libitum. Formulab 5008 (formerly Purina 5008) food yields reliable diabetic 
symptoms including hyperglycemia, hyperlipidemia, impaired glucose tolerance and 
insulin insensitivity as reported by Charles River.  
 
4.3.2  Measurement of Blood Glucose & HbA1c 
 Blood was collected at sacrifice for the measurement of MG-AGE and insulin at 19 
wks of age in the Characterization of PDN study, and for the measurement HbA1c both 
before (12 wks) and after (19 wks) drug treatment in the Pioglitazone Administration 
study. Blood glucose was measured at weekly intervals in both studies. The 
experimental designs for these studies are described below.  
 Rats were lightly restrained in a towel and the distal tail wiped with an alcohol swab. 
A small nick was made at the distal tip of the tail using a #11 scalpel blade. Initial 
bleeding was wiped clean with gauze and subsequent drops of blood were either loaded 
into a room temperature HbA1c cartridge and analyzed using a DCA Vantage Analyzer 
(Siemens, Munich, Germany), or placed on a glucose test strip in triplicate and inserted 
into a glucose monitor (TrueTrack, Walgreens, Deerfield, IL). To avoid perturbations in 
pain-like behavior elicited by fasting or exogenous glucose administration in a tolerance 
test (Dobretsov et al, 2001; Dobretsov et al, 2003), non-fasted blood glucose was 
measured. A random blood glucose level greater than 200 mg/dL (11.1 mmol/L) was 
defined as hyperglycemia (Sacks, 2011). We measured blood glucose at the same time 
each week to minimize circadian-induced fluctuations.  
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4.3.3  Pain-Like Behavior: Stimulus-Evoked 
 Fluctuations in noise, vibrations, temperature, and other distractors in the behavioral 
testing room were minimized to optimize reliable measurements between cohorts of 
animals tested during different behavioral sessions. To further reduce variability and 
acclimate animals to the different testing apparatuses, two weeks of training were 
performed prior to behavioral measures reported at 8 weeks of age. 
 Heat hyperalgesia was assessed by placing the animals on a heated surface (52.5 ± 
1 °C) within an acrylic enclosure (Hotplate; Columbus Instruments, Columbus, OH). The 
time until a hindpaw withdraw response (e.g. jumping, licking, flicking) occurred was 
recorded. The animal was immediately removed after the withdraw response or at a 
cutoff of 30 s to avoid tissue injury. Three trials, with an inter-trial interval of at least 5 
min, were averaged for each time point. 
 Mechanical hyperalgesia was measured using the Randall Selitto method (Randall et 
al, 1957) with slight modification to accommodate an electronic device with a force 
transducer (IITC Life Science Inc., Woodland Hills, CA). The thoracic body and head 
were lightly restrained in a towel with both hindpaws exposed. To start, one hindpaw 
was placed into the calipers with the blunted-point of the force transducer placed on the 
plantar surface between the 2nd and 3rd digits. The force exerted on the surface of the 
hindpaw by the blunted-point was gradually and uniformly increased until a withdraw 
reflex occurred. Animals were not required to vocalize. The gram force required to elicit 
a withdraw response was recorded. Because patients report increased responsiveness 
to repeated mechanical stimuli (Otto et al, 2003), we used multiple trials per time point to 
assess pressure hyperalgesia. The force until paw withdraw was measured three times 
for each hindpaw and then averaged together, as there was no significant difference in 
left versus right withdraw thresholds. The combined average of hindpaw withdraw 
thresholds is reported at each timepoint. 
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 Cold hyperalgesia was assessed by placing the animal on a cooled surface (4ºC ± 
0.5ºC) within an acrylic enclosure (Coldplate; IITC Life Science Inc., Woodland Hills, CA) 
for five minutes. The combined number of nociceptive responses (e.g. jumping, licking, 
flicking) for both hindpaws during the 5 min period is reported (Jasmin et al, 1998). 
 
4.3.4  Pain-Like Behavior: Affective-Motivational 
 To assess the affective-motivational component of pain, we utilized a novel 
Mechanical Conflict Avoidance System (MCS) (Lau et al, 2012). MCS gives animals the 
option to remain in a start chamber containing an aversive light stimulus or choose to 
cross a chamber containing an aversive mechanical stimulus in the form of height-
adjustable, blunted probes. If animals chose to leave the light chamber and cross the 
probes in the stimulus chamber, they then had the option to enter a darkened reward 
chamber. MCS behavioral testing began at 17 wks of age and consisted of three stages: 
familiarization, training, and testing. The latency to exit the light chamber was used as a 
measure of avoidance of the mechanical stimulus, and therefore a measure of affective-
motivational pain-like behavior. 
 Familiarization – 1 day. Animals were placed in the light chamber with the light off; 
access to the stimulus chamber was restricted by a closed guillotine door. After 15 s of 
darkness, the light was turned on. After 20 s of light exposure, the guillotine door was 
raised and the animal was free to explore the entire apparatus, including the dark 
chamber, for 5 min. The animal was then returned to the homecage. 
 Training – 4 days. Animals were trained to move from the light chamber, through the 
stimulus chamber at a probe height of 0 mm (i.e. no probes), and into the dark chamber. 
Animals were placed in the light chamber with the light off; access to the stimulus 
chamber was restricted by a closed guillotine door. After 15 s of darkness, the light was 
turned on. After 20 s of light exposure, the guillotine door was raised and a timer started 
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to measure the latency to exit the light chamber. If the animal did not exit the light 
chamber within 30 s, the guillotine door was closed and the animal was returned to its 
homecage. Upon entering the dark chamber, a second guillotine door was closed to 
restrict the animal to the dark chamber. Animals remained in the dark chamber for 45 s 
to reinforce the crossing of the stimulus chamber and then were returned to the 
homecage. Each animal underwent four training trials on each of the four training days.  
 Testing – 3 days. Assessment of the latency to exit in the presence of varying 
degrees of mechanical stimulus (1, 3, 4 mm) was initiated at 18 wks of age. Each testing 
day began with 1 trial in the absence of a stimulus (0 mm) followed by 3 trials with the 
probes raised to a predetermined height: 1 mm (d 1), 3 mm (d 2), 4 mm (d 3). The 
training procedure described above was also used for testing in either the absence (trial 
1) or presence (trials 2-4) of mechanical probes in the stimulus chamber. Only one probe 
height was tested per day. Assessment at the 0 mm probe height was used to confirm 
that animals were still trained to cross the stimulus chamber. 
 Animals remained in their home cage for at least 10 min between training and testing 
trials. All four paws were required to leave the light chamber to determine the latency to 
exit. The average of 4 trials for each training day or 3 trials for each testing probe height 
is reported for each animal. 
 
4.3.5  pERK Quantification via Immunohistochemistry 
 Upon general anesthesia with isoflurane (5% induction, 1.5% maintenance), the 
plantar surface between the 2nd and 3rd digits of the left hindpaw was stimulated with 110 
g of constant force for 30 s per minute over a 5 min period. These stimulus parameters 
were chosen to mimic those used to elicit withdraw responses to noxious pressure as 
described above for mechanical hyperalgesia testing. Ten minutes after initiating 
pressure stimulation, animals were perfused through the left ventricle with 250 ml of 
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room temperature 0.1 M phosphate buffered saline (PBS) with heparin (10,000 USP 
units/L) followed by 250 ml of ice-cold fixative (10% phosphate buffered formalin). The 
lumbar spinal cord was removed and post-fixed overnight in 10% phosphate buffered 
formalin and then cryoprotected in 30% sucrose in 0.1 M PBS for several days. 
Transverse sections (30 μm) from L4-L5 were cut on a freezing microtome and collected 
in 0.1 M PBS. The sections were washed three times in 0.1 M PBS and then pretreated 
with blocking solution (3% normal goat serum and 0.3% Triton X-100 in 0.1 M PBS) for 1 
h. Sections were then incubated in blocking solution containing the primary antibodies 
rabbit anti-pERK (1:250, #4370, Cell Signaling Technology, Danvers, MA) and Alexa 
Fluor 488 conjugated mouse anti-NeuN (1:200, MAB377X, EMD Millipore, Billerica, MA) 
overnight at room temperature on a slow rocker in the dark. The sections were washed 
three times in 0.1M PBS, and incubated in goat anti-rabbit secondary antibody (1:800, 
Alexa 568, Molecular Probes, Grand Island, NY) for 90 min, washed in 0.1M PBS, 0.01M 
PBS, then 0.01M PB, and non-sequentially mounted onto Superfrost Plus slides, air 
dried, and cover-slipped with Prolong Gold with DAPI mounting medium (Molecular 
Probes). 4-6 high quality sections were randomly selected for quantification. 
 All images were captured on a Nikon Eclipse TE2000-E microscope using a 10x 
objective and analyzed using NIS-Elements Advanced Research software. We focused 
our quantification of the number of pERK immunopositive cell profiles within lamina I-II, 
where the majority of C-fibers and nociceptive peripheral afferents terminate within the 
dorsal horn (Basbaum et al, 2009; Corder et al, 2010). Colabeling of pERK with NeuN is 
expressed as the percentage of the total number of pERK profiles in laminae I-II also 
expressing NeuN. Each spinal cord slice was analyzed by an observer blinded to 
treatment. The average of n=5-6 animals per group is reported.  
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4.3.6  Quantification of Methylglyoxal-Derived Advanced Glycation End-Products (MG-
AGEs)  
 MG-AGEs were quantified using a competitive ELISA according to the 
manufacturer’s instructions (STA-811, Cell BioLabs, San Diego, CA). This ELISA uses a 
primary antibody that recognizes the hydroimidazolone (H1) moiety created by the 
modification of protein residues by methylglyoxal (Ahmed, 2003). Whole blood taken 
from the left ventricle prior to transcardial perfusions was collected in serum separator 
tubes (SST™, BD Biosciences, Franklin Lakes, NJ) and allowed to clot for 30 min. 
Clotted blood in SSTs was centrifuged at 5000 x g for 10 min at 4ºC and the serum was 
transferred to fresh microcentrifuge tubes and stored at -80ºC until MG-H1 ELISA 
analysis. Serum samples were diluted 1:2 in 0.1 M PBS to obtain concentrations in the 
span of the standard curve.  
  
4.3.7  Insulin Quantification via ELISA 
Non-fasted insulin levels were quantified by ELISA according to the manufacturer’s 
recommendations (EMD Millipore; EZRMI-13K; Darmstadt, Germany) from serum 
obtained as described above in serum separator tubes (SST™, BD Biosciences) at time 
of sacrifice. 
 
4.3.8  Pioglitazone Incorporation into Food 
 Actos® (pioglitazone hydrochloride; Takeda Pharmaceuticals U.S.A., Inc., Deerfield, 
IL) was obtained from the University of Kentucky pharmacy in 30 mg tablets of 25% 
purity, and was incorporated into Formulab 5008 rat chow (TestDiets, Purina Mills, 
Richmond, IN). Average body weight and food consumption (Saitoh et al, 2007) were 
used to determine the concentration of Actos in chow required to achieve a dosing of 30 
mg pioglitazone / kg body weight / day. For ZDFs the concentration of Actos in chow 
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was 0.16% (catalog no. 5W01) and for ZLs the concentration was 0.207% (catalog no. 
5W02). Food was provided ab libitum and consumption and body weights were 
monitored in order to calculate actual dosing.  
 
4.3.9  Experimental Design: Characterization of PDN  
 To determine the time course of development of pain-like behavior, we monitored ZL 
and ZDF rats weekly from 4 to 18 weeks of age with n=12 per group. Weekly 
measurement of pain-like behaviors occurred on Monday thru Friday in the following 
order: coldplate, pressure, hotplate. Assessment of pain-like behaviors occurred prior to 
determination of blood glucose and mass at 2-4pm on Fridays. Animals were not fasted 
in order to minimize the potential effects of fasting on pain-like behavior. At least one day 
separated coldplate and hotplate determinations to avoid cross-modality sensitization. 
After behavioral and metabolic outcomes were assessed at 18 wks, the left hind paws of 
control and diabetic rats were stimulated, using the same pressure device used to 
determine behavioral hyperalgesia, in order to evoke pERK. Next, cardiac blood was 
taken prior to transcardial perfusion and fixation, and then tissues were harvested for 
subsequent assays. 
 
4.3.10  Experimental Design: Pioglitazone Administration 
  Rats were divided into the following treatment groups using a 2x2 experimental 
design: ZL Vehicle (n=10), ZL Pioglitazone (n=10), ZDF Vehicle (n=10), ZDF 
Pioglitazone (n=9). Vehicle food was defined as unaltered Formulab 5008 chow.  
 Pain-like behaviors, blood glucose, and weight were measured weekly from 10 to 19 
wks of age. HbA1c was measured at 12 and 19 wks. Vehicle or pioglitazone food 
treatment began after assessment of behavioral and metabolic outcomes at 12 wks and 
all further testing was performed by an observer blinded to drug treatment group. Food 
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consumption was measured 3 times per week by calculating the mass difference 
between food added to the cage and food remaining in the cage then dividing by 2, as 
rats were housed in pairs, and the number of days that had lapsed between food 
additions. After outcome measurements were obtained during week 19, animals were 
pressure-stimulated to evoke pERK, perfused and fixed with buffered formalin for 
immunohistochemical analyses of spinal cords. 
 One rat from the ZDF Pioglitazone group was removed from all analyses prior to 
beginning pioglitazone administration due to an abnormally high baseline blood glucose 
level of 514 mg/dL (more than double all other animals). Because the phenotype for 
coldplate responses in ZDF was modest, we did not assess the effect of pioglitazone on 
cold hypersensitivity. 
 
4.3.11  Statistical Analysis 
 Mass, glucose, hotplate, pressure, coldplate, and MCS were compared using a 
repeated measures two-way ANOVA followed by Holm-Sidak multiple comparison 
correction. To compare ZL vs. ZDF, the outcome measures insulin, MG-AGE, HbA1c, 
and area-under-the-curve (AUC; calculated via the trapezoidal method) were analyzed 
using an unpaired, two-tailed t-test. To compare ZL vs. ZDF and vehicle vs. pioglitazone, 
the outcomes HbA1c and AUC were analyzed via a two-way ANOVA followed by Holm-
Sidak multiple comparison correction. Ipsilateral vs. contralateral or pioglitazone vs. 
vehicle comparisons of pERK immunohistochemistry in ZL vs. ZDF were analyzed by 
two-way ANOVA followed by Holm-Sidak multiple comparison correction. A value of 
α=0.05 was used to determine statistical significance. All data were analyzed and 
graphed using Prism 6.0 (GraphPad, La Jolla, CA) and are presented as mean ± SEM. 
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4.4  Results 
4.4.1  The ZDF Rat is a Model of Progressive Painful Diabetic Neuropathy 
 When compared to control heterozygotes or wild-types, only ZDF rats homozygous 
for the fatty (fa/fa) leptin receptor mutation develop cardinal symptoms of glucose-
intolerant diabetes (Clark et al, 1983) including hyperphagia (Saitoh et al, 2007; Otto et 
al, 2011), hyperinsulinemia (Munoz et al, 2001; Sugimoto et al, 2008; Li et al, 2014), 
obesity (Otto et al, 2011), hyperglycemia (Piercy et al, 1999; Otto et al, 2011; Vera et al, 
2012), elevated HbA1c (Sugimoto et al, 2008; Li et al, 2014), and increased MG-AGE 
(Shevalye et al, 2012). In the first experiment we characterized the progression of 
hyperglycemia and pain-like behavior in diabetic ZDF and control ZL rats. As illustrated 
in Figure 1A-C, ZDF had elevated mass [strain x time; F (14, 308) = 8.249; P < 0.0001] 
from 4 to 18 wks [p < 0.01], elevated blood glucose [strain x time; F (14, 308) = 46.31; P 
< 0.0001] from 8 to 18 wks [p < 0.0001], and elevated serum insulin [p = 0.0009] at 19 
wks.  
 Advanced glycation end-products (AGEs) such as methylglyoxal (MG) derived 
hydroimidazolone (MG-H1) are associated with diabetic pain in patients (Sveen et al, 
2013). MG-AGEs result from the accumulation of MG (Illien-Junger et al, 2015), a 
metabolite of glucose found in blood that is elevated in type 2 diabetes (Kender et al, 
2014) and exacerbated in patients and mice with PDN (Bierhaus et al, 2012). Therefore 
we measured MG-AGE levels and hemoglobin glycation in the form of HbA1c, an AGE 
considered by clinicians to be the ‘gold standard’ diagnostic for diabetes (Sacks, 2011). 
Figure 1D indicates that 19 wk old ZDFs had elevated blood levels of MG-AGE [p < 
0.05]. In a separate group of subjects, Figure 1E indicates that 12 wk-old ZDFs had 
elevated blood levels of HbA1c [p < 0.0001]. Thus, consistent with the literature, we 
found that ZDFs exhibited: (1) obesity after weaning that persisted until the conclusion of 
the study; (2) hyperglycemia beginning at 6 wks of age that progressively increased 
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throughout the study; (3) hyperinsulinemia, elevated MG-AGE, and elevated HbA1c 
levels at 12 wks. 
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Figure 4-1. ZDF rats develop a type 2 diabetes phenotype. 
(A) Body mass (n=12) and (B) blood glucose levels (n=12), serum (C) insulin (n=6) 
at 19 wks, (D) methylglyoxal-derived advanced glycation end-products (MG-AGE; 
n=3) at 19 weeks and (E) HbA1c at 12 weeks of age (n=10) in Zucker Diabetic Fatty 
(ZDF) and Zucker Lean (ZL) controls. * p < 0.05, ZDF vs. ZL. 
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 To rigorously evaluate the ZDF rat as a behavioral model of PDN, we measured not 
only evoked responses to noxious stimuli over an extended time course, but also signs 
of affective pain. First, to assess stimulus-evoked hyperalgesia, we measured responses 
to noxious mechanical and thermal stimuli. Figure 2A-B illustrates that ZDFs were 
hypersensitive to a noxious hotplate [strain; F (1, 22) = 14.2; P = 0.0011] at 15, 17, and 
18 weeks of age [p < 0.05], exhibiting an overall decrease in heat response threshold 
from 14 to 18 wks [AUC; p < 0.05]. Figure 2C-D illustrates that ZDFs were 
hyperresponsive to noxious mechanical pressure [strain x time; F (10, 220) = 6.045; P < 
0.0001] from 15 to 18 wks [p < 0.001], exhibiting an overall decrease in pressure 
threshold from 14 to 18 wks [AUC; p < 0.0001]. Figure 2E-F illustrates that ZDFs 
exhibited more hindpaw responses in a coldplate test [strain x time; F (10, 220) = 2.372; 
P = 0.0110] at 18 wks [p < 0.01], with an overall increase from 14 to 18 wks [AUC; p < 
0.001]. 
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Figure 4-2. ZDF rats develop hyperalgesia. 
Paw withdraw responses to (A-B) heat, (C-D) pressure, and (E-F) cold stimuli in ZL 
and ZDF rats. Area under the curve (AUC) analyses for 14-18 wks are shown. n=12 
per group. * p < 0.05, ZDF vs. ZL. 
 
 Preclinical research targeting the mechanisms of PDN primarily relies on stimulus-
evoked behavioral outcomes (Obrosova, 2009). However, PDN symptoms include not 
just pressure and thermal hyperalgesia but also aching, paresthesia/dysesthesia, and 
affective pain (Liberman et al, 2014). To our knowledge there are no reports of affective 
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pain in a rodent model of type 2 diabetes (Lee-Kubli et al, 2014). To address this gap 
and determine whether ZDFs possess the affective-motivational component of PDN that 
is most relevant to diabetic patients, we utilized a mechanical conflict-avoidance system 
(MCS) (Morrow and Harte, 2010; Donahue et al, 2012; Lau et al, 2012) as shown in 
Figure 3A. Figure 3B illustrates that illustrates that during the four training trials when no 
pins were present (0 mm probe height), latency to exit the light chamber was similar 
between ZL and ZDF rats (p > 0.05), indicating no differences in light aversion or learned 
motivation/ability to find the dark chamber. Despite contrasting results in an open field 
test, where we (unpublished findings; R.B. Griggs et al, 2013) and others (Jiménez-
Aranda et al, 2013) found diminished locomotor activity in ZDF, exploration in a novel 
open field environment is not equitable to behavioral training to seek the dark chamber 
in MCS. Raising the probe height produced an increase in the latency to exit the light 
chamber [strain x probe height; F (6, 102) = 4.262; P = 0.0007] in ZL at 4 mm (vs. 1 mm; 
p = 0.0051) and in ZDF at both 3 mm (p < 0.0001) and 4 mm (p < 0.0001) heights, 
indicating aversion to the mechanical stimulus in both control and diabetic rats. 
Importantly, the latency to exit the light chamber was higher in ZDF compared to ZL at 
both 3 mm (p = 0.0493) and 4 mm (p < 0.0001) heights, indicating that diabetes 
potentiates the avoidance of a noxious mechanical stimulus. 
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Figure 4-3. Diabetes increases the avoidance of mechanical probes. 
(A) Diagram of the mechanical conflict avoidance system (MCS) used as a measure 
of affective-motivational pain in ZL and ZDF rats. MCS behavioral testing began at 
17 wks of age and consisted of three stages: familiarization (1 d), training (4 d), and 
testing (3 d). Familiarization: Animals were initially placed in the light chamber and 
allowed free access to explore the entire MCS apparatus. Training: Animals were 
trained to move from the light chamber, through the stimulus chamber with 
mechanical probes set to a height of 0 mm (i.e. no probes), and into the dark 
chamber. Each animal underwent four training trials on each of the four consecutive 
training days. Testing: Animals were placed in the light chamber and allowed to 
cross the stimulus chamber at probe heights of 1 mm, 3 mm, and 4 mm. Each 
animal was tested for 3 trials at each probe height with only one probe height tested 
on each of the three testing days. (B) The latency to exit the light chamber (latency) 
in ZL and ZDF rats is shown for the 4 d of training (left) and 3 d of testing (right). 
The latency was similar in the absence of mechanical probes (probe height = 0 mm) 
during training and at a 1 mm probe height during testing. Raising the testing probe 
height increased the latency in ZL at 3 mm and ZDF at 3 and 4 mm. The latency 
was greater in ZDFs compared to ZLs at the 3 and 4 mm probe height. n=9-10. * p < 
0.05. † p<0.05 vs. ZL at 1mm. ‡ p<0.05 vs. ZDF at 1 mm. 
 
 Central sensitization is defined as the increased responsiveness of nociceptive 
neurons in the central nervous system to their normal or subthreshold afferent input 
(Woolf, 2011). As an example, expression of phosphorylated extracellular signal-
regulated kinase (pERK) in the dorsal horn is exacerbated by light touch stimulation after 
peripheral nerve injury (Morgenweck et al, 2013) or inflammation (Gao and Ji, 2010) but 
not uninjured controls, and is therefore an important marker of spinal central 
sensitization (Gao and Ji, 2009). To test the hypothesis that diabetes results in central 
sensitization, we evaluated noxious pressure-evoked phosphorylation of ERK (pERK) in 
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dorsal horn neurons. We chose pressure as the evoking stimulus because it is a 
hallmark pain modality in PDN patients (Otto et al, 2003). Figure 4A shows that unilateral 
stimulation of the tibial receptive field produced unilateral pERK within the superficial 
laminae of the dorsal horn. pERK was restricted to the side ipsilateral to stimulation and 
was predominantly located within the medial extent of the dorsal horn, respecting 
previously-described somatotopic boundaries of tibial nerve anatomy (Swett and Woolf, 
1985; Corder et al, 2010). Figure 4B shows representative images indicating that pERK 
predominantly colabeled with NeuN, an established immunohistochemical marker for 
neurons (Kim et al, 2009). The percentage of pERK cell-profiles that colabeled with 
NeuN was (mean ± SEM): ZL contralateral (81.5 ± 6.5), ZL ipsilateral (88.3 ± 3.6), ZDF 
contralateral (80.5 ± 3.1), ZDF ipsilateral (92.1 ± 1.3). The degree of colocalization was 
similar between ZL and ZDF at either contralateral [p = 0.93] or ipsilateral [p = 0.89] 
dorsal horns. Figure 4C illustrates that pressure increased pERK in ZL [ipsilateral vs. 
contralateral; p < 0.0001] and ZDF rats [p < 0.0001]. Diabetes exacerbated this increase 
[ZDF vs. ZL; ipsilateral only; p = 0.001], and there was an interaction between Strain and 
Stimulation [F (1, 20) = 8.051; P = 0.0102].  
 
 
Figure 4-4. Diabetes exacerbates noxious pressure-induced activation of 
dorsal horn neurons. 
Pressure-evoked phosphorylation of ERK and colabeling with NeuN in the L4/5 
dorsal horn at 18 wks of age in ZL and ZDF rats. Representative images of pERK 
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(A) in the stimulated (ipsilateral) or unstimulated (contralateral) side and (B) 
colabeling with the neuronal marker NeuN in the medial portion of the ipsilateral 
lumbar dorsal horn after pressure stimulation. (C) Quantification of cell-like profiles 
labeled with pERK in laminae I-II. n=6. † p<0.05 vs. ZL ipsilateral. ‡ p<0.05 vs. ZDF 
ipsilateral. * p<0.05. Scale bars = 100 µm. 
 
4.4.2  Chronic Administration of Oral Pioglitazone Reduces Pathological Signs of 
Diabetes 
 Numerous reports indicate that oral administration of pioglitazone or rosiglitazone 
reduces hyperglycemia in db/db mice (Takahashi et al, 2015), ZDF rats (Piercy et al, 
1999), and humans (Patel et al, 1999; Aronoff et al, 2000; Xu et al, 2015) as well as 
HbA1c levels in ZDF (Watanabe et al, 2015) and diet-induced type 2 diabetes (Ibrahim 
et al, 2015). To confirm that pioglitazone alleviated signs of type 2 diabetes in ZDF, we 
measured blood glucose and HbA1c. The average dose of pioglitazone (mg · kg-1 · d-1) 
received by ZL (35.53 ± 1.94) and ZDF (32.19 ± 2.52) was similar over the 7 wk 
treatment period, and was comparable to previous studies in db/db mice (4 wks of 30 mg 
· kg-1 · d-1) (Takahashi et al, 2015) and ZDF rats (6 wks of 10 mg · kg-1 · d-1) (Watanabe 
et al, 2015). As illustrated in Figure 5A, pioglitazone decreased blood glucose in ZDF [F 
(1, 18) = 16.51; P = 0.0007] but not in ZLs [F (1, 18) = 3.51; P=0.077] from 13 to 19 wks 
of age. Figure 5B illustrates that blood levels of HbA1c were elevated in ZDF rats at 19 
wks of age [p < 0.0001], even greater than observed at 12 wks (Fig 1E). Pioglitazone 
normalized HbA1c levels in ZDF to the level of ZL [p < 0.0001]. 
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Figure 4-5. Pioglitazone reduces pathological signs of type 2 diabetes. 
Effect of vehicle or pioglitazone (administered in food, yellow bar) on blood levels of 
(A) glucose (n=9-10) from 11 to 19 wks and (B) HbA1c (n=9-10) at 19 wks of age in 
ZL and ZDF rats. ‡ p<0.05 vs. both ZL groups. † p<0.05, ZDF Pioglitazone vs. ZDF 
Vehicle. * p<0.05. 
 
4.4.3  Chronic Oral Pioglitazone Inhibits the Development of PDN and Reduces Evoked 
pERK 
 Hyperalgesia develops in ZDF at approximately 14 wks of age (Fig 2). To test the 
hypothesis that pioglitazone prevents the development of hyperalgesia, we initiated its 
administration at 12 wks of age. As illustrated in Figure 6A-B, ZDF exhibited lower heat 
response thresholds as compared to ZL [strain x time; F (8, 144) = 2.039; P = 0.0458] 
from 13 to 19 wks. Pioglitazone temporarily normalized heat thresholds in ZDF [F (1, 17) 
= 22.09; P = 0.0002] from 13 to 15 wks [p < 0.01], and then heat hypersensitivity 
returned at 16 wks. Figure 6C-D illustrates that ZDF exhibited a decrease in pressure 
response thresholds compared to ZL [strain x time; F (8, 144) = 2.178; P = 0.0324] from 
11 to 19 wks [p < 0.05]. Pioglitazone normalized pressure thresholds in ZDF [drug; F (1, 
17) = 104.9; P < 0.0001] throughout the duration of treatment, from 13 to 19 wks [p < 
0.05]. Further studies are needed to investigate the differential effect of pioglitazone on 
heat and noxious mechanical sensitivity. In addition, we speculate that pioglitazone 
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would reduce cold hypersensitivity as we recently reported that pioglitazone reduced the 
development of 63 and reversed 30 hyperresponsivitiy to acetone in the spared nerve 
injury model of neuropathic pain. 
 Because we began pioglitazone administration prior to the development of 
hyperalgesia, further intervention studies are needed to determine if the mechanism of 
pioglitazone antihyperalgesia is independent from its reduction of hyperglycemia. This 
may indeed be the case, since we found that a single intraperitoneal injection of 
pioglitazone, given after the development of hyperalgesia in ZDF, reversed heat 
hypersensitivity without changing blood glucose levels (unpublished data, R.R. Donahue 
et al, 2014). 
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Figure 4-6. Pioglitazone attenuates pain-like behavior. 
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Effect of vehicle or pioglitazone in food (yellow bar) on the development of (A-B) 
heat and (C-D) mechanical hyperalgesia (n=9-10). Pioglitazone inhibits the 
development of heat and mechanical hyperalgesia in ZDF.  ‡ p<0.05 ZDF Vehicle 
vs. all other groups. * p<0.05. 
 
To determine whether chronic pioglitazone treatment reduces spinal nociresponsive 
neuron activation, we quantified pERK after noxious mechanical stimulation of the 
hindpaw. Figure 7A-B illustrates that noxious pressure evoked greater pERK in vehicle-
treated ZDF as compared to ZL [p = 0.0006]. Pioglitazone but not vehicle normalized 
pERK in ZDF [p = 0.011] but not ZL [p = 0.96]. There was an interaction between Strain 
and Drug [F (1, 19) = 6.048; P = 0.0237]. 
 
 
Figure 4-7. Pioglitazone attenuates dorsal horn neuron activation. 
Noxious pressure-evoked pERK in the lumbar superficial dorsal horn of ZL and ZDF 
rats at 19 wks of age following a 7 wk treatment with vehicle or pioglitazone 
administered in chow. (A) Representative images of pERK immunostaining. (B) 
Pioglitazone reduced pERK in ZDFs to the level of ZLs. n=5-6. * p<0.05. Scale bar = 
100 µm. 
 
4.5  Discussion 
4.5.1  ZDFs Develop Multiple Types of Pain-Like Behavior 
 Consistent with previous reports, ZDFs developed mechanical (Roane and Porter, 
1986; Zhuang et al, 1997; Li et al, 2006; Brussee et al, 2008; Sugimoto et al, 2008; Otto 
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et al, 2011; Rong and Ma, 2011; Vera et al, 2012; Galloway and Chattopadhyay, 2013), 
heat (Roane and Porter, 1986; Li et al, 2006; Rong and Ma, 2011; Galloway and 
Chattopadhyay, 2013), and cold hyperalgesia (Rong and Ma, 2011) at 14 to 18 wks of 
age (Otto et al, 2011; Vera et al, 2012; Galloway and Chattopadhyay, 2013), results 
which we replicated in two separate cohorts. In contrast, a comparatively small number 
of ZDF studies report either mechanical hypoalgesia (Shevalye et al, 2012), heat 
hypoalgesia (Sugimoto et al, 2008; Shevalye et al, 2012; Vera et al, 2012), no difference 
in heat (Brussee et al, 2008) or pressure (Piercy et al, 1999) response thresholds, and/or 
pressure hyperalgesia prior to hyperglycemia (Romanovsky et al, 2008). Discrepancies 
in heat responses could be due to differences in the stimulus type: we used a hotplate 
while other studies used an infrared beam directed at the tail (Sugimoto et al, 2008) or 
hindpaw (Brussee et al, 2008; Shevalye et al, 2012; Vera et al, 2012).  
 A recent review of preclinical models of PDN highlights the need to establish indices 
of spontaneous/affective pain (Lee-Kubli et al, 2014). One study used conditioned place 
preference (CPP), an assay that has re-emerged (Sufka, 1994) as a leading preclinical 
measure of tonic pain in rats (King et al, 2009) and mice (He et al, 2012), to reveal 
affective pain in type 1 diabetic STZ mice in the absence of an evoking stimulus 
(Wagner et al, 2014). Here, we discovered that type 2 diabetes exacerbates the 
avoidance of a noxious mechanical stimulus. Unlike CPP, where presumed relief of non-
evoked affective pain reinforces a chamber preference, MCS utilizes the avoidance of an 
evoked stimulus as a measure of the motivational component of pain. Our results 
demonstrate for the first time the existence of a motivational-affective component of PDN 
in a preclinical model of type 2 diabetes. 
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4.5.2  ZDFs Develop Central Sensitization in Spinal Dorsal Horn Neurons 
 The dorsal horn is a key site of nociceptive integration (Basbaum et al, 2009) 
including central sensitization after tissue or nerve injury (Woolf, 2011). A recent 
electrophysiological study in ZDF spinal cord slices indicated that non-noxious 
mechanical stimulation increased afterdischarges and spontaneous activity of dorsal 
horn neurons (Schuelert et al, 2015). However, the authors did not investigate pain-like 
behavior and they analyzed dorsal horn neurons at 32-34 wks, after ZDF aged 26 wks 
are reported to be hypoalgesic (Lee-Kubli et al, 2014). Thus, at this advanced diabetic 
stage, it is unclear whether central sensitization contributed to painful diabetic 
neuropathy. In our study using younger ZDF, we resolved this uncertainty by evaluating 
both behavioral hypersensitivity and stimulus-evoked pERK in the same subjects.  
 We are the first to demonstrate both pain-like behavior and elevated spinal neuron 
activation in ZDF. Both of these results were observed in response to a noxious 
mechanical stimulus, and this fits with the clinical manifestations of PDN: up to 71% of 
patients (Otto et al, 2003) report hyperalgesia in response to application of a similar, 
static, noxious pressure stimulus (Wienemann et al, 2012) used in the current study on 
ZDF. By contrast, Schuelert et al reported that spinal neurons were not sensitized to 
noxious mechanical stimuli (Schuelert et al, 2015). Albeit, our results provide strong 
evidence in support of the hypothesis proposed by Schuelert et al that central 
sensitization contributes to hyperalgesia in type 2 diabetes (Schuelert et al, 2015). If 
true, then therapies aimed at reducing central sensitization could alleviate PDN. Indeed, 
spinal administration of MEK inhibitors, which prevent phosphorylation of ERK, 
attenuated hyperalgesia in db/db (Xu et al, 2014) and STZ (Ciruela et al, 2003) models. 
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4.5.3  Pioglitazone Reduces Pathological Signs of PDN in ZDF by Actions at PPARγ 
 Several lines of evidence lead us to speculate that activation of spinal peroxisome 
proliferator-activated receptor gamma (PPARγ) mediated the antihyperalgesic actions of 
pioglitazone reported here in ZDF. First, spinal sites are rich in PPARγ expression 
(Moreno et al, 2004; Churi et al, 2008; Maeda et al, 2008) and pioglitazone crosses the 
blood-brain barrier (Maeshiba et al, 1997). Second, intrathecal administration of PPARγ 
antagonists inhibits the antihyperalgesic effect of both repeated systemic or single 
intrathecal administration of PPARγ agonists (Churi et al, 2008; Morgenweck et al, 2013; 
Griggs et al, 2015). Alternatively, non-PPARγ mechanisms can be proposed for the 
antihyperalgesic effects of pioglitazone in PDN. Pioglitazone inhibits HMGB1-RAGE 
signaling in spinal neurons (Wang et al, 2014) and reduces plasma RAGE (Ibrahim et al, 
2015), both of which are implicated in the pathogenesis of neuropathic pain in models of 
traumatic nerve injury (Feldman et al, 2012) and PDN (Ren et al, 2012; Hidmark et al, 
2014). Whether pioglitazone reduces the contribution of spinal gliosis and/or HMGB1-
RAGE signaling to PDN remains an important direction of future studies.  
 Our current results suggest that pioglitazone decreases central sensitization to 
reduce PDN in type 2 diabetes. In support of this idea, chronic oral pioglitazone (at the 
same 30 mg · kg-1 · d-1 dose used in the current study) reduced non-noxious stimulus-
induced mechanical allodynia and spinal pERK in a traumatic nerve injury model of 
neuropathic pain (Morgenweck et al, 2013). Our results extend this finding by showing 
that pioglitazone reduces spinal pERK following a different stimulus (noxious pressure) 
and in a different neuropathic pain model that is associated with disease (type 2 
diabetes).  
 Our studies aimed to evaluate whether ZDF exhibited hyperalgesia alongside spinal 
sensitization and whether this could be reduced by a TZD, and therefore the focus was 
not on peripheral mechanisms. However, several studies suggest that pioglitazone can 
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inhibit peripheral mechanisms of chronic pain: 1) PPARγ is expressed in sciatic nerve 
(Yamagishi et al, 2008); 2) TZDs decreased hyperalgesia, proinflammatory cytokine 
expression, and macrophage infiltration in sciatic nerve after nerve injury (Maeda et al, 
2008; Takahashi et al, 2011); 3) Pioglitazone reduced macrophage infiltration and pERK 
in the sciatic nerve of STZ rats (Yamagishi et al, 2008); 4) Pioglitazone reduced pERK in 
sciatic nerve of db/db mice (Dasu et al, 2009); and 5) Rosiglitazone and resolvin D1 
coadministration to the site of hindpaw incision in db/db mice promotes a M2 
macrophage phenotype and reduces mechanical hypersensitivity (Saito et al, 2015). 
Future studies in preclinical models of type 2 PDN could investigate the effect of local 
TZD administration to the peripheral nerve (Takahashi et al, 2011; Hasegawa-Moriyama 
et al, 2012) on: macrophage polarization (Hasegawa-Moriyama et al, 2012); TNFα, 
which is elevated in patients with PDN (Uceyler et al, 2007; Purwata, 2011); nerve 
conduction velocity, which is decreased in type 2 diabetes (Brussee et al, 2008); and 
pain-like behaviors. 
   
4.5.4  Pioglitazone Reduces PDN Independent of its Anti-Hyperglycemic Action 
 Although we found that hyperglycemia preceded pain-like behavior as it does in type 
2 diabetic patients (Abbott et al, 2011), we propose that pioglitazone reduces PDN 
independent of its simultaneous reduction of blood glucose. This is based on several 
lines of evidence. First, pioglitazone and other PPARγ agonists reduce neuropathic pain-
like behavior in normoglycemic animals after various routes of administration including: 
repeated oral (Maeda et al, 2008; Morgenweck et al, 2013) or intraperitoneal (Maeda et 
al, 2008; Takahashi et al, 2011; Hasegawa-Moriyama et al, 2012; Morgenweck et al, 
2013); local injection to the injured sciatic nerve (Takahashi et al, 2011) or incised paw 
(Hasegawa-Moriyama et al, 2012); or a single spinal (Park et al, 2007; Churi et al, 2008; 
Morgenweck et al, 2010; Griggs et al, 2015) or brain (Morgenweck et al, 2010) injection. 
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Second, numerous drugs can reduce PDN without reducing hyperglycemia in patients 
with PDN, including tapentadol (Schwartz et al, 2011) or the FDA-approved PDN 
medications duloxetine and pregabalin (Mendell and Sahenk, 2003; Smith and Argoff, 
2011). Furthermore, the antioxidant taurine (Li et al, 2006), aldose reductase inhibitors 
(Calcutt et al, 2004; Ramos et al, 2007; Obrosova, 2009), insulin growth factor (Zhuang 
et al, 1996; Zhuang et al, 1997), or poly-ADP-ribose inhibitors (Obrosova et al, 2005; 
Obrosova et al, 2008; Drel et al, 2010) reduce hyperalgesia in animal models of PDN 
without inhibiting hyperglycemia. Consistent with these findings, pioglitazone normalized 
peripheral nerve conduction velocities without affecting hyperglycemia in the STZ model 
(Yamagishi et al, 2008). Third, mechanical hyperalgesia that is not associated with 
hyperglycemia has been reported in ZDFs, which suggests that hyperalgesia can be 
independent from blood glucose levels (Romanovsky et al, 2008). Finally, it is important 
to note that normalization of blood glucose alone cannot reverse the neurotoxic effects 
resulting from long-term hyperglycemia (Tomlinson and Gardiner, 2008) that contribute 
to PDN (Vincent et al, 2011).  
 The results from this pretreatment study are clinically important as they suggest that 
pre-diabetic patients could benefit from adjuvant treatment with pioglitazone or an 
alternative PPARγ agonist in addition to recommended lifestyle changes such as diet 
and exercise. This is supported by preclinical studies indicating that TZD treatment prior 
to or coinciding with peripheral nerve injury are quite effective at reducing hyperalgesia 
(Maeda et al, 2008; Takahashi et al, 2011; Morgenweck et al, 2013). Further study is 
needed to definitively dissociate the antihyperglycemic and antihyperalgesic effects of 
targeting PPARγ with pioglitazone. For example, alternative agonists such as 15d-PGJ2 
that alleviate neuropathic pain (Churi et al, 2008) without alteration of glucose or HbA1c 
could be tested in ZDF. Also, we could test a “control” drug that normalizes glucose 
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metabolism without affecting hyperalgesia or investigate whether administration of 
glucose to pioglitazone-treated ZDF could reinstate hyperalgesia.  
 
4.5.5  Conclusions and Future Directions  
The current results are the first to demonstrate in a preclinical model of type 2 
diabetes that pioglitazone prevents the development of not only pain-like behavior but 
also noxious stimulation-evoked central sensitization – within the same subjects. We go 
beyond the use of non-noxious von Frey hairs to evaluate spinal sensitization in ZDF 
(Schuelert et al, 2015) or nerve injury (Morgenweck et al, 2013) by evoking spinal pERK 
and hyperalgesia using a clinically relevant pressure stimulus (Otto et al, 2003). Our 
results extend the potential efficacy of pioglitazone from resolving neuropathic pain after 
traumatic nerve injury to the growing problem of PDN. 
 Alternative strategies using other TZDs or related therapies may bypass the human 
safety risks of pioglitazone (Lewis et al, 2011). First, the non-TZD PPARγ agonists 
FK614 (Minoura et al, 2007), MBX-102 (Chandalia et al, 2009; Gregoire et al, 2009), or 
MDG548 (Lecca et al, 2015) reduce insulin insensitivity, hyperglycemia, and 
inflammation and are neuroprotective (Lecca et al, 2015). Second, TZDs (Geldenhuys et 
al, 2010; Yonutas and Sullivan, 2013) or the novel ligand TT01001 (Takahashi et al, 
2015) reduce diabetic mitochondrial dysfunction by targeting the mitochondrial protein 
mitoNEET, which is thought to alleviate other neurological diseases (Feinstein et al, 
2005; Yonutas and Sullivan, 2013). Finally, a multiple drug strategy, such as 
coadministration of pioglitazone with canagliflozin (Watanabe et al, 2015) or geraniol 
(Ibrahim et al, 2015) might reduce diabetes without the adverse effects of adipocyte 
differentiation, fat deposition, and weight gain associated with pioglitazone-only 
treatment. PDN patients may also benefit from other diabetic drugs such as metformin, 
which reduces peripheral neuropathic pain (Mao-Ying et al, 2014) and PDN in STZ rats 
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(Byrne et al, 2015; Ma et al, 2015), as well as decreases hyperglycemia, HbA1c, and 
MG in patients with type 2 diabetes (Kender et al, 2014). Future clinical studies could 
investigate whether the above treatments or other PPARγ-directed therapies alleviate 
both hyperglycemia and neuropathic pain, as simultaneous inhibition is necessary to 
maximize quality of life in type 2 diabetic patients. 
 
4.6  Supplemental Data & Discussion 
4.6.1  Pioglitazone produces weight gain and hyperphagia.  
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Figure 4-8. Pioglitazone increases food consumption and weight in both ZL 
and ZDF. 
Both (A) mass and (B) food consumption were increased within one week of 
beginning pioglitazone administration.  
 
 In Figure 4-8 we illustrate that chronic oral administration of pioglitazone produced 
an increase in food consumption that presumably led to exacerbated weight gain in both 
ZL and ZDF. Hyperphagia and obesity did not change the average dose received by ZL 
and ZDF during the period of administration (see 0). Weight gain and edema are 
consistent with the known side effects of TZDs. Figure 4-9 illustrates that the same dose 
of pioglitazone (30 mg/kg/d) modestly increased weight gain in nerve injured Sprague-
Dawley rats. It appears that the increase in weight gain is exacerbated by type 2 
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diabetes, as 7 wks of pioglitazone treatment resulted in SNI animals weighing roughly 
450 g while ZDF were almost 700 g. These results indicate that weight gain should be 
monitored during long-term pioglitazone treatment and that future studies could 
investigate ways to reduce TZD-associated weight gain.  
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Figure 4-9. Pioglitazone effect on weight gain in Sprague-Dawley rats after 
traumatic nerve injury. 
Data courtesy of Renee Donahue. 
Pioglitazone administration in food began 7 d prior to spared nerve injury (SNI). (A) 
Pioglitazone modestly increased weight gain at 6-7 weeks after beginning 
administration at the same dose (30 mg/kg/d) used to treat PDN in ZDF. (B) 
However, pioglitazone did not increase the weight when analyzed using area-under-
the-curve calculation for 0 to 42 d after SNI. * p<0.05 Pio 30 vs. Vehicle. † p<0.05 
Pio 30 and Pio 3 vs. Vehicle. 
 
4.6.2  Exploratory locomotor behavior in ZDF decreases as PDN develops 
 In order to measure the effect of diabetes on sedentary behavior we measured 
locomotor activity using an open field photo beam array. Rearing number, rearing 
duration, distance travelled, total beam breaks, and active/resting duration were 
quantified in control ZL and diabetic ZDF rats at 6, 12, and 18 weeks of age. Figure 4-10 
shows that there are no significant differences in any of the activity measures at 6 or 12 
wks but by 18 wks diabetic animals showed decreased activity levels in all measures 
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tested. These results are consistent with decreased locomotor activity in ZDF rats 
(Jiménez-Aranda et al, 2013) and db/db mice (Sharma et al, 2010) at similar stages of 
type 2 diabetes. Five weeks of rosiglitazone treatment (20 mg/kg/d orally) at a similar 
dose to the 30 mg/kg/d of pioglitazone in the current studies did not attenuate 
hypolocomotive behavior in db/db mice. Rosiglitazone did however attenuate 
hyperglycemia (Sharma et al, 2012). These results indicate that alleviating type 2 
diabetes in rodents is not sufficient to reduce the hypolocomotion that may reflect 
affective components of animal behavior.  
 
4.6.3  Mechanisms of PDN 
 Other mechanisms in addition to neuronal central sensitization might drive PDN in 
type 2 diabetes. First, increased expression of NGF (Cheng et al, 2009), pp38 (Cheng et 
al, 2010; Galloway and Chattopadhyay, 2013), Nav1.6 (Ren et al, 2012), Nav1.7 
(Galloway and Chattopadhyay, 2013), TNFα (Cheng et al, 2010; Galloway and 
Chattopadhyay, 2013), and IL-1β (Galloway and Chattopadhyay, 2013) in the lumbar 
DRG of db/db mice and ZDF rats with PDN suggests peripheral pain sensitization. 
Further supporting expressional studies, administration of anti-NGF (Cheng et al, 2009) 
or a p38 kinase antagonist (Cheng et al, 2010) reduced mechanical allodynia in 8 wk old 
db/db mice. Second, PDN is associated with an increase in spinal expression of markers 
of astrocyte (GFAP) (Liao et al, 2011; Dauch et al, 2012; Ren et al, 2012; Xu et al, 2014) 
but not microglia (Ox42) (Liao et al, 2011; Xu et al, 2014) gliosis. Indeed, the astrocyte 
toxin LAA but not the microglial inhibitor minocycline reversed mechanical hyperalgesia 
in db/db mice (Liao et al, 2011). However, our preliminary results in ZDF contrast with 
previous reports indicating upregulation of glial markers in the spinal cord in PDN. Figure 
4-11 illustrates that the expression of microglial and astrocyte activation markers is 
similar in ZL and ZDF at 18 wks of age. Given that this is the first study to investigate 
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glial activation in the spinal cord in ZDF, it is possible that species differences between 
db/db mice and ZDF rats contribute to the lack of upregulation in Iba1 or GFAP in the 
current study. In the future, assessment of functional markers for glial activation could be 
performed to investigate the interplay between neurons and glia in peripheral, spinal, 
and brain areas and to evaluate their contribution to PDN.  
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Figure 4-10. Locomotor activity decreases with age in ZDF. 
General exploratory behavior in an open field activity box was measured in 5 min 
bins for 45 min at 6, 12, and 18 wks of age in ZL and ZDF. The number of rearing 
events, rearing duration, total beam breaks, distance travelled, active duration, and 
resting duration are shown. * p<0.05 ZDF vs. ZL. 
 
 
Figure 4-11. Immunohistochemical quantification of microglial and astrocyte 
markers. 
(A) Representative images of the ipsilateral dorsal horn in ZL and ZDF rats aged 18 
wks from the first experiment characterizing the development of PDN. Quantification 
of (B) the microglial marker Iba1 and (C) the astrocyte marker GFAP revealed no 
significant differences in the expression of gliosis markers in the spinal cord. 
Integrated density was determined by thresholding the images using the default 
algorithm within NIS Elements to reduce background and include positively stained 
cells. Integrated density of the region of interest (ROI) is equal to the product of ROI 
area and mean intensity value. The mean intensity value represents the sum of the 
intensity values for all pixels above the threshold in the ROI divided by the number 
of pixels above threshold within the ROI. This method controls for differences in 
fluorescence background levels between slices and subjects. 
 
 We offer several explanations for our result that pioglitazone did not significantly 
reduce blood insulin levels in diabetic ZDFs: (1) Hyperinsulinemia in ZDFs occurs at an 
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earlier age (Gregoire et al, 2009; Ibrahim et al, 2015; Watanabe et al, 2015) and 
therefore insulin production in diabetic ZDFs may already be diminished in the vehicle 
group; (2) Pioglitazone treatment produces a modest increase in insulin production as 
evidenced by our control ZDFs; or (3) Pioglitazone did not reduce insulin in similarly 
aged diabetic ZDFs (Watanabe et al, 2015); (4) The duration of pioglitazone treatment 
was not long enough to reduce the overcompensation of pancreatic beta cell insulin 
production, although insulin sensitivity was enhanced as evidenced by the reduction in 
hyperglycemia. However, this finding does rule out an alternative mechanism of 
pioglitazone analgesia providing support to the conclusion that antihyperalgesia is 
independent of the metabolic benefits of pioglitazone.  
Pioglitazone may decrease PDN by reducing diabetes-associated inflammation. In 
humans, TNF-α plasma levels and macrophage TNF-α expression are positively 
correlated with diabetic neuropathy-associated pain (Purwata, 2011). TZDs reduce 
proinflammatory factors such as: (1) blood TNF-α in a long-term model of diabetes 
(Qiang et al, 1998) or after methylglyoxal treatment (Hsu et al, 2013); (2) adipose TNF-α 
in ZDFs (Minoura et al, 2007); (3) in vitro production of TNF-α in activated macrophages 
(Jiang et al, 1998); (4) proinflammatory cytokine release in TLR-activated human 
monocytes and db/db mice (Dasu et al, 2009); (5) pioglitazone reduces diabetes-
associated elevations in urinary (Ye et al, 2010) and monocyte (Dasu et al, 2009) 
expression of the chemokine MCP-1/CCL2; (6) glucose induction of TNF-α and MCP-1 
release from rat microglia (Quan et al, 2011) may be diminished by pioglitazone 
reduction of hyperglycemia; and (7) molecules implicated in the generation of pain such 
as proinflammatory cytokines, Nav1.7, and pp38 are elevated in the DRG from diabetic 
ZDF (Galloway and Chattopadhyay, 2013). We speculate that chronic pioglitazone 
treatment decreases the neuroinflammatory state produced by type 2 diabetes, thereby 
reducing PDN.  
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 Separating improvements in hyperglycemia and insulin resistance from analgesic 
effects of PDN treatments is non-trivial. Several lines of evidence make it unclear as to 
whether the correction of hyperglycemia (by treating the underlying insulin resistance in 
type 2 diabetes or by insulin infusion in type 1) results in decreased pain. (1) Localized 
hyperglycemia in the sciatic nerve or DRG induces pain-like behavior and was reversed 
by an aldose reductase inhibitor. This suggests that production of reactive oxygen 
species (ROS), the endpoint of the glucose-polyol pathway, is responsible for pain-like 
hypersensitivity (Dobretsov et al, 2003) rather than the direct neurotoxic effect of glucose 
(Tomlinson and Gardiner, 2008). (2) Taurine, an antioxidant, improves nerve conduction 
velocity and attenuates mechanical and thermal hyperalgesia without affecting 
hyperglycemia (Li et al, 2006). (3) Markers for oxidative or nitrosative stress, which can 
lead to pain, are reduced by Poly(ADP)-ribose polymerase inhibition without eliminating 
hyperglycemia (Obrosova et al, 2005). (4) Hyperglycemia persists when pain-like 
behavior is reduced in STZ (Ramos et al, 2007) and ZDF (Piercy et al, 1999) rats after 
treatment with IGF (Zhuang et al, 1996), IGF-II (Zhuang et al, 1997), or aldose reductase 
inhibitors (Ramos et al, 2007). (5) Pain behavior can persist even after correction of 
hyperglycemia (Lee and McCarty, 1992). Contrasting with the above, studies indicate 
that acute exposure to glucose can produce hyperalgesia (Dobretsov et al, 2001; 
Dobretsov et al, 2003) and glycemic control correlates with pain relief in diabetic patients 
(Oyibo et al, 2002). Nevertheless, treatments such as TZDs and metformin that reduce 
both hyperglycemia and pain-like behavior in preclinical models need further clinical 
investigation.  
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CHAPTER 5:  Methylglyoxal produces pain in type 2 diabetes via sensitization of 
TRPA1 and AC1 
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5.1  Abstract 
 Type 2 diabetic pain remains difficult to treat, in part because the mechanisms that 
lead to painful diabetic neuropathy (PDN) are poorly understood. Metabolic 
dysregulation in diabetes produces an increase in the glucose metabolite methylglyoxal 
(MG) and blood levels of MG correlate with PDN in patients. The current literature led to 
our hypothesis that elevated MG contributes to pain in type 2 diabetes by sensitizing 
peripheral and/or spinal nociceptive neurons via activation of TRPA1 and AC1.   
 We confirmed that methylglyoxal is increased in the db/db mouse model of type 2 
PDN. Intraplantar injection of MG produced multiple types of pain-like behaviors, 
including spontaneous nociceptive responses, mechanical and heat hypersensitivity, and 
conditioned place aversion, a measure of affective pain in preclinical studies. MG also 
triggered spinal nociceptive transmission, as it evoked phosphorylation of ERK and 
increased intracellular calcium in superficial dorsal horn neurons. Pharmacological and 
genetic disruption of TRPA1 attenuated pERK and pain-like behavioral responses to MG 
administration as well as reversed hyperalgesia in db/db mice. Knockout of AC1 
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abolished MG-induced hyperalgesia but not nociceptive responses while the AC1 
inhibitor NB001 attenuated hyperalgesia in db/db mice. Finally, the novel MG 
scavenging peptide GERP10 attenuated hyperalgesia in db/db mice without altering 
hyperglycemia or elevated HbA1c. We conclude that elevated MG in type 2 diabetes 
contributes to PDN through a TRPA1-AC1 dependent pathway. 
 
5.2  Introduction 
 Painful diabetic neuropathy (PDN) is associated with accumulation of methylglyoxal 
(MG), a major metabolite of glycolysis, in the blood in both patients and rodent models 
(Bierhaus et al, 2012). For example, in healthy control subjects blood MG levels are 150-
300 nM (McLellan et al, 1992; Bierhaus et al, 2012) and ~600 nM in diabetic patients, 
though levels are greatly exacerbated in diabetic patients reporting pain (~900 nM). This 
suggests a potential role for MG in the production of pain associated with diabetes.  
 Previous studies indicate that acute administration of MG produces spontaneous 
nociception (Andersson et al, 2013) and evoked heat hypersensitivity in mice (Bierhaus 
et al, 2012). Data from knockout mice suggest activation of transient receptor potential, 
ankyrin subtype 1 (TRPA1) as a mechanism of these effects in primary afferents. 
However, additional measures of evoked and affective pain-like behavior beyond MG-
induced nociception and the use of additional pharmacological and genetic tools in 
preclinical models are needed to assess the contribution of MG and TRPA1 to ongoing 
PDN in type 2 diabetes. 
 A majority of PDN studies focus on the streptozotocin (STZ) model of type 1 diabetes 
(Calcutt et al, 2009). Indeed, using the STZ model or administration of exogenous MG, 
Bierhaus et al showed that MG scavenging compounds (e.g. ALT-711, aminoguanidine) 
or an arginine-rich peptide (i.e. GERP10) reduced MG-associated hypersensitivity 
(Bierhaus et al, 2012). Here we focus on db/db mice (Kodama et al, 1994), a model of 
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type 2 diabetes that is ideal because: (1) type 2 diabetes represents the majority (90%) 
of diabetic patients (World Health Organization) and has a greater incidence of PDN 
compared to type 1 (Van Acker et al, 2009; Abbott et al, 2011); (2) pain mechanisms in 
type 1 versus type 2 likely differ (Schmidt et al, 2003; Schmidt et al, 2004; Kamiya et al, 
2005; Schuelert et al, 2015); (3) it is unknown whether administration of the MG 
scavenger GERP10 will alleviate type 2 PDN as it does in STZ (Bierhaus et al, 2012); 
and (4) STZ may activate TRPA1 to produce peripheral neuropathy and pain prior to the 
development of diabetic hyperglycemia (Andersson et al, 2015) thereby confounding 
conclusions from previous STZ studies investigating the role of TRPA1 in development 
of PDN (Wei et al, 2009; Wei et al, 2010; Koivisto et al, 2012).  
 Several lines of evidence suggest that sensitization of nociceptive neurons in the 
spinal dorsal horn of primary afferents may contribute to painful type 2 diabetes (aka 
PDN) through a TRPA1 mechanism. First, increased phosphorylation of extracellular 
signal-regulated kinase (pERK), a marker for nociresponsive spinal neuron activation (Ji 
et al, 1999; Gao and Ji, 2009), is associated with pain-like hypersensitivity in type 2 
diabetic rats (see Chapter 4: ). Second, inhibition of spinal ERK phosphorylation in db/db 
mice reversed pain-like hypersensitivity (Xu et al, 2014). Third, MG-evoked nociception 
and calcium mobilization in DRG neurons was abolished in TRPA1 knockout mice 
(Eberhardt et al, 2012; Andersson et al, 2013). Fourth, MG-evoked activation of SH-
SY5Y cells was prevented by NMDA receptor inhibition (de Arriba et al, 2006). Along 
these lines, we hypothesized that: (1) MG activation of peripheral TRPA1-positive 
nociceptors induces spinal phosphorylation of ERK (pERK) that is dependent on 
peripheral and/or spinal TRPA1; and (2) elevated MG in type 2 diabetes produces 
painful spinal sensitization as evidenced by exacerbated glutamate- and/or MG-evoked 
calcium responses in spinal slices and dissociated DRG neurons from wild-type and 
db/db mice. 
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 Calcium activated adenylyl cyclase 1 (AC1) (Xia and Storm, 1997) is a key modulator 
of pain plasticity in the central nervous system (Zhuo, 2012). For example, AC1 
mediates spinal LTP and ERK activation induced by capsaicin or glutamate in mice (Wei 
et al, 2006) as well as NMDA-induced pain reinstatement after injury (Corder et al, 
2013). As glutamate and NMDA receptors play a role in both normal and sensitized pain 
transmission, and activation of TRPA1 leads to a rise in intracellular calcium (Eberhardt 
et al, 2012; Ohkawara et al, 2012), we tested the hypothesis that AC1 mediates pain-like 
responses after MG administration and in db/db mice with PDN.  
 
5.3  Materials and Methods 
5.3.1  Subjects 
 Experiments were carried out in accordance with the Institutional Animal Care and 
Use Committee at the University of Kentucky (Approved Protocol # 2009-0486). All 
efforts were made to minimize animal suffering, to reduce the number of animals used, 
and to utilize alternatives to in vivo techniques, in accordance with the International 
Association for the Study of Pain (Zimmermann, 1983) and the National Institutes of 
Health Office of Laboratory Animal Welfare Guide for the Care and Use of Laboratory 
Animals.  
 Animals were housed in a temperature and humidity controlled room on a 12 hour 
light – 12 hour dark cycle with lights on from 07:00 to 19:00. Animals were provided 
water and chow ad libitum. All rats and mice used were male. Male Sprague-Dawley rats 
(CD-IGS, Charles River Laboratories, Inc., Wilmington, MA) weighing 300-450g at the 
time of behavioral procedures were used. TRPA1 knockout (-/-) and wild-type littermates 
(+/+) mice were graciously provided by Dr. Gregory Frolenkov (Department of 
Physiology, University of Kentucky, Lexington, KY), courtesy of Drs. Kelvin Kwan and 
David Corey (Harvard University, Cambridge, MA), and were used to setup a TRPA1 
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knockout colony. AC1-/- and AC1+/+ mice were graciously provided by Dr. Daniel Storm 
(Washington University, Seattle, WA, USA) and were used to setup an AC1 knockout 
colony. Both congenic knockout mouse lines were maintained using a heterozygote 
breeding strategy onto a C57BL/6J (000664, JAX Mice, The Jackson Laboratory, Bar 
Harbor, ME) background. Genotypes were confirmed by PCR. Control (C57BLKS/J; 
BKS) and diabetic (Leprdb; db/db) mice (The Jackson Laboratory, Bar Harbor, ME; Stock 
No. 000642) were aged 6-14 wks. Mice aged 8-12 wks were used for all non-db/db 
studies with C57BL/6J serving as congenic controls.  
  
5.3.2  Drugs & Injections 
 Methylglyoxal (M0252, Sigma-Aldrich, St. Louis, MO) was diluted in 0.9% sterile 
saline for intraplantar injections (0-1000 µg) or aCSF (0-10 mM) for calcium imaging 
studies. NB001 (SML0060, Sigma-Aldrich) was diluted in water for intrathecal injections. 
GEAP10 and GERP10 were graciously provided by Drs. Thomas Fleming and Peter 
Nawroth (University Hospital Heidelberg, Heidelberg, Germany) and diluted in 0.9% 
saline for intraperitoneal injections. For intrathecal (5-10 μL), intraperitoneal (100 µL), 
and intraplantar (5-25 µL) injections un-anaesthetized mice were lightly restrained and a 
30Ga½“ needle attached to a Hamilton microsyringe was used to administer drug 
solutions. Intrathecal injections were performed by puncturing the dura between the 
L5/L6 vertebrae and confirmed by presence of reflexive tail or hindpaw flick as 
previously described (Fairbanks, 2003). 
 Stock solutions of methylglyoxal contain <1% of impurities such as formalin, which is 
known to be an agonist for TRPA1 (McNamara et al, 2007). However, concern that 
contaminates in the Sigma-Aldrich solution used in this study could confound our 
conclusions is mitigated by the finding that electrophysiological results using MG from 
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Sigma-Aldrich and synthesized pure MG were identical in a previous CNS study (Distler 
et al, 2012). 
 
5.3.3  Pain-like Behavior 
 Fluctuations in noise, vibrations, temperature, and other distractors in the behavioral 
testing room were minimized to optimize reliable measurements between cohorts of 
animals tested on different days. Animals were acclimated to the different testing 
apparatuses prior to commencing behavioral studies and for 30-60 min on the day(s) of 
testing. 
 Nociceptive responses were measured by placing the animals within an acrylic 
enclosure immediately following intraplantar injection of saline or methylglyoxal. A mirror 
was positioned below the enclosure to facilitate quantification of spontaneous 
licking/lifting (s) or flinching (#) of the injected hindpaw for five minutes. The seconds of 
licking/lifting and the number of flinches were added together to obtain a combined 
number of nociceptive responses, where one second of licking/lifting or one flinch were 
equated to one nociceptive response.  
 Heat hypersensitivity was assessed by placing the animals on a heated surface (52.5 
± 1 °C) within an acrylic enclosure (Hotplate; Columbus Instruments, Columbus, OH). 
The time until a hindpaw withdraw response (e.g. jumping, licking, flicking) occurred was 
recorded. The animal was immediately removed after the withdraw response or at a 
cutoff of 30 s to avoid tissue injury. Three trials were averaged for each timepoint. 
 Mechanical hypersensitivity was assessed by placing animals within a rectangular 
acrylic box (15x4x4 cm; 3 white opaque walls and 1 clear wall) and stimulating the 
ventral-medial hindpaw plantar surface with an incremental series of 8 von Frey 
monofilaments (Stoelting, Inc., Wooddale, IL) of logarithmic stiffness using a modified 
up-down method (Dixon, 1980; Chaplan et al, 1994). Testing began by applying an 
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intermediate von Frey monofilament (number 4.31, exerts 2.0 g of force) perpendicular 
to the glabrous skin, causing a slight bending. In the case of a positive response 
(withdraw of the paw) a filament exerting less force was applied. In the case of a 
negative response, a filament exerting greater force was applied. The calculated 50% 
withdraw threshold is reported. 
 Conditioned place aversion (CPA) testing was completed using a three-chambered 
acrylic enclosure with manual doors and the time spent in each chamber was quantified 
using a 4 x 16 photobeam array (Place Preference, San Diego Instruments, San Diego, 
CA; http://www.sandiegoinstruments.com/place-preference/). Printed paper was used to 
cover the outside of the clear box so that the middle chamber was grey and the end 
chambers had either vertical or horizontal black and white stripes that were ¾” wide. 
Mice were acclimated to the CPA box on d1-2 and then preconditioning preferences 
were assessed on d3. During conditioning on d4, intraplantar saline injection-pairing in 
the morning was followed by methylglyoxal (300µg) injection-pairing to the opposite 
chamber in the afternoon. On d5, the same conditioning procedure was repeated with 
methylglyoxal injected into the hindpaw that received saline on d4. Drug pairings and the 
hindpaw initially receiving methylglyoxal were counterbalanced. On d6, postconditioning 
preferences were assessed in the absence of any injections.  
 
5.3.4  pERK quantification via immunohistochemistry 
 Animals were injected intraplantar with saline or methylglyoxal, nociceptive 
responses were quantified, and then mice were anesthetized with isoflurane (5% 
induction, 2% maintenance). Ten minutes after intraplantar injection, animals were 
perfused through the left ventricle with room temperature 0.1 M phosphate buffered 
saline (PBS) with heparin (10,000 USP units/L) followed by ice-cold fixative (10% 
phosphate buffered formalin). The lumbar spinal cord was removed and post-fixed 
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overnight in 10% phosphate buffered formalin and then cryoprotected in 30% sucrose in 
0.1 M PBS for several days. Transverse sections (30 μm) from L3-L4 were cut on a 
freezing microtome and collected in 0.1 M PBS. The sections were washed three times 
in 0.1 M PBS and then pretreated with blocking solution (3% normal goat serum and 
0.3% Triton X-100 in 0.1 M PBS) for 1 h. Sections were then incubated in blocking 
solution containing the primary antibody rabbit anti-pERK (1:250, #4370, Cell Signaling 
Technology, Danvers, MA) overnight at room temperature on a slow rocker. The 
sections were washed three times in 0.1M PBS, and incubated goat anti-rabbit 
secondary antibody (1:800, Alexa 568, Molecular Probes, Grand Island, NY) for 90 min, 
washed in 0.1M PBS, 0.01M PBS, then 0.01M PB, and non-sequentially mounted onto 
Superfrost Plus slides, air dried, and cover-slipped with Prolong Gold with DAPI 
mounting medium (Molecular Probes). 
 All images were captured on a Nikon Eclipse TE2000-E microscope using a 10x 
objective and analyzed using NIS-Elements Advanced Research software. We focused 
our quantification of the number of pERK immunopositive cell profiles within lamina I-II, 
where the majority of C-fibers and nociceptive peripheral afferents terminate within the 
dorsal horn (Basbaum et al, 2009; Corder et al, 2010). Each spinal cord slice was 
analyzed by an observer blinded to treatment. 4-6 high quality sections were randomly 
selected for quantification. 
 
5.3.5  Calcium imaging  
 Preparation of adult mouse spinal cord slices. Mice were anesthetized with 5% 
isoflurane and quickly perfused transcardially with 10 ml of ice-cold sucrose-containing 
artificial cerebrospinal fluid (aCSF) (sucrose-aCSF) that contained (in mM): NaCl 95, KCl 
1.8, KH2PO4 1.2, CaCl2 0.5, MgSO4 7, NaHCO3 26, glucose 15, sucrose 50, kynurenic 
acid 1, oxygenated with 95% O2, 5% CO2; pH 7.4. The lumbar spinal cord was rapidly 
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isolated by laminectomy from the cervical enlargement to the cauda equina, placed in 
oxygenated ice-cold sucrose-aCSF, cleaned of dura mater and ventral roots, and super-
glued vertically to a block of 4% agar (Fisher Scientific, Pittsburgh, PA) on the stage of a 
Campden 5000mz vibratome (Lafayette, IN). Transverse slices (450 µm) from lumbar 
segments L3/L4 were cut in ice-cold sucrose-aCSF. 
 Fluorometric Ca2+ measurements. Slices were incubated for 30 min with Fura-2 AM 
(10 μM), pluronic acid (0.1%) in oxygenated aCSF containing (in mM): NaCl 127, KCl 
1.8, KH2PO4 1.2, CaCl2 2.4, MgSO4 1.3, NaHCO3 26, glucose 15 at 37ᵒ C, followed by a 
20 min de-esterification period in normal aCSF. Prior to recording, slices were kept at RT 
in a chamber containing approximately 150 ml of oxygenated aCSF. Slices were 
perfused at 1-2 ml/min with normal aCSF in an RC-25 recording chamber (Warner 
Instruments, Hamden, CT) mounted on a Nikon FN-1 upright microscope fitted with a 
79000 ET FURA2 Hybrid filter set (Nikon Instruments, Melville, NY) and a Photometrics 
CoolSNAP HQ2 camera (Tucson, AZ). Relative intracellular Ca2+ levels were determined 
by measuring the change in ratio of fluorescence emission at 510 nm in response to 
excitation at 340 and 380 nm (200 ms exposure). Paired images were collected at 1-1.5 
seconds/frame. Relative changes in Ca2+ levels were evaluated using Nikon Elements 
software by creating a region of interest over the cell body and calculating the peak 
change in ratio. The peak magnitude of Ca2+ response to 90 s exposure to MG was 
normalized to the Ca2+ response to 1 mM glutamate (10 s). Only cells that displayed a 
consistent response to 1 mM glutamate at the beginning and end of the experiment 
(showing a less than 40% decrease in glutamate-evoked Ca2+ transients) were included 
in this study. 
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5.3.6  Quantification of Methylglyoxal-derived advanced glycation end-products (MG-
AGEs)   
 MG-AGEs were quantified using a competitive ELISA according to the 
manufacturer’s instructions (STA-811, Cell BioLabs, San Diego, CA). This ELISA uses a 
primary antibody that recognizes the hydroimidazolone (H1) moiety created by the 
modification of protein residues by methylglyoxal (Ahmed, 2003). Whole blood taken 
from the left ventricle prior to transcardial perfusions was collected in serum separator 
tubes (SST™, BD, Franklin Lakes, NJ) and allowed to clot for 30 min. Clotted blood in 
SSTs was centrifuged at 5000 x g for 10 min at 4ºC and the serum was transferred to 
fresh microcentrifuge tubes and stored at -80ºC until MG-H1 ELISA analysis. Serum 
samples were diluted in 0.1M PBS to obtain values in the span of the standard curve. 
 
5.3.7  Measurement of blood glucose & HbA1c 
 Mice were lightly restrained in a towel and the distal tail wiped with an alcohol swab. 
A small nick was made at the distal tip of the tail using a #11 scalpel blade. Initial 
bleeding was wiped clean with gauze and subsequent drops of blood were either loaded 
into a room temperature HbA1c cartridge and analyzed using a DCA Vantage Analyzer 
(Siemens, Munich, Germany), or placed on a glucose test strip in duplicate and inserted 
into a glucose monitor (TrueTrack, Walgreens, Deerfield, IL). To avoid perturbations in 
pain-like behavior elicited by fasting or exogenous glucose administration (Dobretsov et 
al, 2001; Dobretsov et al, 2003), non-fasted blood glucose was measured. A random 
blood glucose level greater than 200 mg/dL (11.1 mmol/L) was defined as 
hyperglycemia (Capes et al, 2000; Sacks, 2011). 
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5.3.8  Data analysis and statistics  
 Nociceptive behavior and calcium responses in wild-type rats and mice were 
analyzed using a one-way ANOVA followed by Holm-Sidak multiple comparison 
correction. Nociceptive behavior, pERK immunohistochemistry, blood glucose, and 
HbA1c in wild-type, TRPA1-/-, AC1-/-, and db/db mice were analyzed using a two-way 
ANOVA followed by Holm-Sidak multiple comparison correction. Nociceptive behavior, 
mechanical hypersensitivity, heat hypersensitivity, conditioned place aversion, and blood 
glucose in wild-type, TRPA1-/-, AC1-/-, and db/db mice were analyzed using a repeated 
measures two-way ANOVA followed by a Holm-Sidak multiple comparison correction. 
An alpha value of α=0.05 was used to determine statistical significance. All data were 
analyzed and graphed using Prism 6.0 (GraphPad, La Jolla, CA) and are presented as 
mean ± SEM. 
  
5.4  Results 
5.4.1  Methylglyoxal produces pain-like behavior 
 First we determined whether exogenous intraplantar administration of methylglyoxal 
into the hindpaw is sufficient to produce pain-like behaviors. As illustrated in Figure 1A-
C, methylglyoxal produced dose-dependent nociceptive responses in rats [F(2,9) = 6.87; 
P = 0.015] and mice [F(7,41) = 88.2; p < 0.0001], with 1000 μg of MG producing 
nociceptive responses that lasted for one hour [drug x time; F(15,90) = 3.4; p = 0.0002]. 
As illustrated in Figure 1D-E, methylglyoxal produced hypersensitivity to mechanical 
[drug x time; F(5,85) = 3.54; p = 0.0059] and heat [dose x time; F(15,100) = 5.0; p < 
0.0001] stimuli.   
 To determine an aspect of affective pain we tested whether methylglyoxal produced 
conditioned place aversion. Baseline preconditioning time spent in the saline-paired 
(mean ± SEM; 334.7 s ± 38.9) or methylglyoxal-paired (354.2 s ± 42.35) chambers was 
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similar [p = 0.75], indicating our injection pairings were counterbalanced. 
Postconditioning time spent in the methylglyoxal-paired chamber (273.9 s ± 38.6) was 
less than time spent in the saline-paired chamber (489.6 s ± 49.9) [p = 0.0026], 
indicating avoidance of methylglyoxal administration. As illustrated in Figure 1E, the 
difference scores for saline and methylglyoxal were significantly different [p = 0.021], 
indicating conditioned place aversion to injection of methylglyoxal.  
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Figure 5-1. Exogenous methylglyoxal produces spontaneous, evoked, and 
affective pain-like behavior. 
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Nociceptive behavioral responses in (A) rats (n=3-5) and (B-C) mice (n=3-14) as 
well as evoked (D) mechanical (n=9-10) and (E) heat (n=4-12) thresholds after 
intraplantar (i.pl.) injection of methylglyoxal (MG). (E) Difference scores (post minus 
pre conditioning) for conditioned place aversion testing using two days of i.pl. MG 
(300 μg) injections in mice (n=8). ★ p<0.05 vs. Saline. # p<0.05, MG 10 μg vs. 
Saline. † p<0.05, MG 30 μg vs. Saline. ‡ p<0.05 MG 100 μg vs. Saline. 
 
5.4.2  Methylglyoxal activates spinal neurons to produce PDN 
 Previous studies indicate methylglyoxal activates dorsal root ganglia neurons via 
TRPA1 to produce nociception (Eberhardt et al, 2012; Andersson et al, 2013). However, 
whether elevated methylglyoxal in type 2 diabetes sensitizes spinal neurons remains 
unknown. Therefore we tested the hypothesis methylglyoxal activates nociresponsive 
neurons in the spinal cord dorsal horn. Figure 2A illustrates that intrathecal injection of 
methylglyoxal produces hindpaw mechanical hypersensitivity at 30-120 min [p < 0.05] 
with a significant Drug by Time interaction [F(6,36) = 4.712; p = 0.0012]. 
 
 
Figure 5-2. Methylglyoxal activates nociceptive neurons in the spinal cord 
dorsal horn to produce pain-like behavior. 
Data courtesy of Renee Donahue. I formulated the hypothesis, designed the 
experiment, and analyzed the data.  
(A) Mechanical sensitivity before and after intrathecal (i.t.) injection of MG (n=4). ★ 
p<0.05 vs. Saline. 
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5.4.3  TRPA1 mediates spinal sensitization and pain in type 2 diabetes 
 Phosphorylated extracellular signal-regulated kinase (pERK) in the spinal cord dorsal 
horn (Ji et al, 1999; Zhuang et al, 2005) is a marker of nociresponsive neuron activation 
(Gao and Ji, 2009) and stimulus-evoked central sensitization (Morgenweck et al, 
2013)(Griggs et al, 2015, under review at Journal of Pain), which is defined as the 
increased responsiveness of nociceptive neurons in the central nervous system to their 
normal or subthreshold afferent input (Woolf, 2011). To evaluate methylglyoxal-induced 
spinal sensitization we measured the number of cell profiles displaying pERK in the 
superficial dorsal horn after MG hindpaw administration. To determine the contribution of 
peripheral and/or spinal TRPA1 we administered MG in wild-type and TRPA1 knockout 
(-/-) mice, or after administration of intrathecal vehicle or HC030031, a TRPA1 inhibitor, 
to wild-type mice.  
 Figure 3A-B shows that MG injection increased pERK in wild type [p < 0.0001], but 
not TRPA1-/- [p = 0.95] mice [drug x strain; F(1,11) = 48.41; p < 0.0001] as well as in 
wild-type mice with intrathecal (i.t.) vehicle [p < 0.0001] but not HC [p = 0.088] 
administration [drug x drug; F(1,12) = 67.02; p < 0.0001]. As illustrated in Figure 3C, 
methylglyoxal produced nociception in wild-type [vs. saline; p < 0.0001] but not TRPA1-/- 
[p = 0.77] mice [F(1,14) = 44.66; p < 0.0001] as well as in wild-type mice with i.t. vehicle 
[p < 0.0001] administration [drug x drug; F(1,19) = 29.57; p < 0.0001]. Importantly, 
although MG produced modest nociceptive behavior in HC-treated mice [vs. HC Saline; 
p = 0.0026], nociceptive response was significantly less than that in vehicle-MG mice [p 
< 0.0001]. Figure 3D illustrates that, compared to saline, methylglyoxal decreased 
withdraw latency to heat in wild-type but not TRPA1-/- mice [strain x time; F(5,45) = 
10.67; p < 0.0001]. Compared to TRPA1-/-, methylglyoxal produced heat hypersensitivity 
in wild-types at 30 min [p < 0.0001]. As illustrated in Figure 3E, intrathecal administration 
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of HC030031 reversed heat hypersensitivity in diabetic db/db but not control BKS mice 
[F(5,30) = 7.088; p = 0.0002] from 15-45 min [p < 0.05].  
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Figure 5-3. TRPA1 mediates methylglyoxal-induced spinal nociceptive neuron 
activation and hyperalgesia in painful diabetic neuropathy. 
To determine whether activation of spinal neurons is dependent upon TRPA1 we 
injected methylglyoxal (MG; i.pl.) in wild-type mice alongside intrathecal (i.t.) 
HC030031 (HC) or in TRPA1 knockouts and measured phosphorylated ERK 
(pERK), a marker of nociceptive neuron activation, in the L4-L5 spinal cord. (A) 
Representative dorsal horn images ipsilateral to injection of saline or MG. 
Quantification of (B) pERK+ cells, (C) nociceptive responses, or (D) hotplate 
behavior after i.pl. saline or MG injection in animals treated with with i.t. vehicle or 
HC (10 μg), or in wild-type (+/+) or TRPA1 knockout (-/-) mice. pERK, nociceptive 
responses, and heat hyperalgesia were abolished after pharmacological or genetic 
inhibition of TRPA1. (E) Heat thresholds in control BKS and diabetic db/db mice 
after i.t. injection of the TRPA1 antagonist (10 μg) at 10 wks of age. ★ p<0.05 vs. all 
other groups. # p<0.05 vs. db/db Vehicle.  
 
5.4.4  AC1 facilitates methylglyoxal-induced hypersensitivity 
 Our finding that activation of TRPA1 by methylglyoxal resulted in subsequent heat 
hypersensitivity is puzzling, considering TRPA1 primarily responds to cold (Story et al, 
2003), mechanical (Kwan et al, 2009), or chemical  (Bautista et al, 2005; McNamara et 
al, 2007; Trevisani et al, 2007; Eberhardt et al, 2012) stimuli. However, previous studies 
suggest a functional link between TRPA1 and TRPV1 containing primary afferents 
(Fischer et al, 2014; Spahn et al, 2014; Weng et al, 2015), a phenomena that might be 
mediated by AC1 (Spahn et al, 2014). Therefore we tested the hypothesis that AC1 
mediates pain-related behaviors in wild-type (WT) and AC1 knockout (AC1-/-; KO) mice 
after methylglyoxal administration, as well as in BKS and db/db mice with pretreatment 
with the AC1 inhibitor NB001.  
 Figure 4A illustrates that, compared to saline, methylglyoxal produced nociceptive 
responses [drug; F(1,14) = 193.6; p < 0.0001] in wild-type [vs. saline; p < 0.0001] and 
AC1-/- [p < 0.0001] mice. Saline or methylglyoxal-induced responses were similar in 
wild-type and AC1-/- mice [p = 0.99]. As illustrated in Figure 4B, compared to saline 
injection methylglyoxal produced heat hypersensitivity in wild-type mice [drug in WT; 
F(5,30) = 8.72; p < 0.0001] at 30-60 min [p < 0.001] but not in AC1-/- [drug in KO; 
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F(5,30) = 1.12; p = 0.37]. Compared to AC1-/-, methylglyoxal produced heat 
hyperalgesia in wild-types at 30 min [p = 0.03]. As illustrated in Figure 4C, intraplantar 
methylglyoxal injection had no effect on mechanical thresholds in AC1-/- at any timepoint 
measured [F(5,35) = 0.575; p = 0.72]. As illustrated in Figure 4D, intrathecal injection of 
the AC1 inhibitor NB001 had no effect on heat thresholds in control BKS mice [F(1,6) = 
0.05; p = 0.83]. However, NB001 significantly attenuated heat hyperalgesia in db/db 
mice overall [F(1,6) = 7.35; p = 0.035] and at 45 min [p = 0.044]. 
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Figure 5-4. AC1 mediates methylglyoxal-induced hyperalgesia in painful 
diabetic neuropathy. 
(A) Nociceptive, (B) hotplate, and (C) mechanical behavioral responses after 
intraplantar injection of saline or methylglyoxal in wild-type C57BL6J (+/+) or AC1 
knockout (-/-) littermates. (D) Heat thresholds after intrathecal (i.t.) injection of the 
AC1 inhibitor NB001 (1.5 μg) in BKS and db/db mice at 13 wks of age. # p<0.05 as 
shown. ★ p<0.05 vs. all other groups. 
 
5.4.5  Methylglyoxal scavenging reduces pain-like behavior in type 2 diabetes 
 We reasoned that if methylglyoxal is producing pain in type 2 diabetes, then 
strategies that reduce elevated methylglyoxal in diabetic subjects would alleviate pain-
like behavior. Recently, the novel peptide GERP10 and its control GEAP10 were 
administered to methylglyoxal or streptozotocin treated mice. GERP10 peptide, which 
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contains ten repeats of the amino acid arginine that favors formation of MG-H1 residues 
(Allaman et al, 2015), but not GEAP10 (instead containing non-reactive alanine) was 
shown to reduce hyperalgesia and serum methylglyoxal levels (Bierhaus et al, 2012). 
Here we extended this experiment to the db/db model of type 2 diabetes, which 
progressively develop mechanical (Liao et al, 2011; Ren et al, 2012; Xu et al, 2014) and 
thermal (Xu et al, 2014) hypersensitivity as well as elevated blood MG (Bierhaus et al, 
2012). As illustrated in Figure 5A, db/db mice developed heat hyperalgesia [F(4,112) = 
11.49; p < 0.0001] at 7-10 wks of age [p < 0.0001] but were not hyperalgesic at 6 wks [p 
= 0.60]. As illustrated in Figure 5B-C, db/db mice had elevated blood glucose [F(4,112) = 
9.092; p < 0.0001] at 6-10 wks [p < 0.0001] and increased MG-H1 AGE at 10 wks [p = 
0.03]. As illustrated in Figure 5D, a single intraperitoneal injection of GERP10 but not 
GEAP10 increased heat thresholds in db/db mice [F(1,13) = 7.49; p = 0.02] without 
altering thresholds in BKS controls [F(1,13) = 0.134; p = 0.72]. GERP10 attenuation of 
heat hyperalgesia in db/db mice lasted for several days. As illustrated in Figure 5E-F, 
blood glucose [p < 0.0001] and HbA1c [p < 0.0001] were elevated in db/db compared to 
BKS mice 7 d after injection of the control peptide GEAP10. GERP10 did not alter blood 
glucose [F(1,12) = 0.1; p = 0.76] or HbA1c [F(1,8) = 1.49; p = 0.26] levels.  
 
143 
6 7 8 9 1 0
0
2 0 0
4 0 0
6 0 0
8 0 0
A g e  (w k s )
B
lo
o
d
 G
lu
c
o
s
e
 (
m
g
/d
L
)


 

6 7 8 9 1 0
0
5
1 0
1 5
2 0
A g e  (w k s )
H
o
tp
la
te
 p
a
w
 w
it
h
d
ra
w
 l
a
te
n
c
y
 (
s
)




C 5 7 B L K S
d b /d b
0
5
1 0
1 5
2 0
i.p . in je c t io n  o f 1  m g  p e p t id e
H
o
tp
la
te
 p
a
w
 w
it
h
d
ra
w
 l
a
te
n
c
y
 (
s
)
B L 1 .5 h 3 h 3 d 5 d 7 d1 d
B K S  +  G E A P
B K S  +  G E R P
d b /d b  +  G E A P
d b /d b  +  G E R P
  

M
e
th
y
lg
ly
o
x
a
l 
(µ
g
 /
 m
L
 s
e
ru
m
)
B
K
S
d
b
/d
b0 .0
0 .5
1 .0
1 .5
2 .0

0
2 0 0
4 0 0
6 0 0
8 0 0
B
lo
o
d
 G
lu
c
o
s
e
  
(m
g
 /
 d
L
)
G E A P
G E R P
B K S d b /d b
0
2
4
6
8
1 0
1 2
H
b
A
1
c
 (
%
)
G E A P
G E R P
B K S d b /d b
A C
D E F
B
 
Figure 5-5. The methylglyoxal scavenger GERP10 reduces painful diabetic 
neuropathy. 
Measurement of (A) heat thresholds, (B) blood glucose, and (C) serum 
methylglyoxal (11 wks of age) in BKS and db/db mice. (D) Heat thresholds, (E) 
blood glucose, and (F) blood HbA1c levels after a single intraperitoneal (i.p.) 
injection of the methylglyoxal scavenging peptide GERP10 (1 mg) or its control 
GEAP10 (1 mg) in BKS or db/db mice at 10-11 wks of age. ★ p<0.05 vs. all other 
groups.  
 
5.5  Discussion 
5.5.1  Methylglyoxal contributes to painful type 2 diabetes 
 Our current results are the first to show a number of related findings with regard to 
the spinal contribution of methylglyoxal to pain in diabetes. First, i.pl. administration of 
exogenous MG produces spontaneous nociceptive behavior in both mice and rats. 
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Second, MG produced transient, stimulus-evoked mechanical and heat hypersensitivity 
and negative affect as evidenced by conditioned place aversion. Third, we show that 
administration of MG to the spinal cord produces behavioral hypersensitivity, suggesting 
that spinal sites of action are involved in diabetic pain. Fourth, activation of spinal 
neurons and behavioral hypersensitivity depends upon both TRPA1 and AC1. Fifth, 
inhibition of spinal TRPA1 or AC1 attenuates pain-like behavior in db/db mice. Finally, 
scavenging of systemic methylglyoxal by GERP10 alleviates pain in a model of type 2 
diabetes.  
 We provide evidence that the nociceptive response to MG is dose-dependent, occurs 
in rats, and persists for one hour at the highest dose tested (1000 µg). The level of 
nociceptive responses in mice were comparable to a previously used dose (18 µg; i.pl. ) 
(Andersson et al, 2013). Nociception occurs rapidly, within several seconds, suggesting 
direct modulation (i.e. activation/depolarization) of primary afferent nociceptors. Indeed, 
MG produced a calcium response in cell culture (after transfection with human TRPA1) 
(Eberhardt et al, 2012; Ohkawara et al, 2012; Andersson et al, 2013) and mouse 
peripheral DRG neurons (Eberhardt et al, 2012; Andersson et al, 2013). This is in 
contrast to the notion that MG sensitizes nociceptors through a process mediated by 
keratinocytes, that could result in evoked hypersensitivity (Kwan et al, 2009).   
   Hindpaw administration of MG produced peripheral sensitization to further 
mechanical or heat stimulation that lasted for approximately one hour. Evoked 
hypersensitivity followed the initial chemical-induced spontaneous nociceptive responses 
and was maintained beyond the period of spontaneous pain-like responses. One 
explanation is suggested by previous findings, where MG mobilized calcium in isolated 
DRG neurons (Eberhardt et al, 2012; Andersson et al, 2013) to activate a substantial 
portion of polymodal nociceptors (Eberhardt et al, 2012), presumably contributing to the 
mechanical and heat hypersensitivity indicated by the current results. Evoked 
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hypersensitivity also occurs after hindpaw administration of the TRPV1 agonist 
capsaicin, both in humans (Simone et al, 1987; Simone et al, 1989) and rodents 
(Gilchrist et al, 1996). With capsaicin, initial spontaneous responses are mediated 
peripherally while the longer-lasting stimulus-dependent sensitization is due to a spinal 
mechanism (Zhang et al, 2006; Willis, 2009). These results taken together suggest that 
MG produces pain-like behavioral sensitization at least through a peripheral, if not also 
spinal, mechanism akin to activation of TRPV1 afferents. This hypothesis is further 
supported by our finding that intrathecal MG administration produced long-lasting 
mechanical hypersensitivity.  
 Strategies to block the effects of endogenous MG reveal its role in maintaining pain-
like behavior in type 2 diabetes. It is clear that increases in circulating MG are 
associated with diabetes (Bierhaus et al, 2012; Kong et al, 2014). Further increases in 
circulating MG are associated with PDN (Bierhaus et al, 2012) and raising the 
intracellular MG concentration in freshly isolated DRG neurons from 1.5 µM to 2.2 µM 
(after 90 s application of 3 mM MG) induces neuronal activation (Eberhardt et al, 2012). 
Although these are examples of the effects of free (unbound) MG, MG-derived advanced 
glycation end-products (AGE), such as the formation of methylglyoxal-hydroimidazolone 
(MG-H1) moiety created by the modification of reactive protein residues by 
methylglyoxal (Ahmed, 2003), also contribute to painful neuropathy. AGEs such as MG-
derived hydroimidazolone (MG-H1) are associated with diabetic pain in patients (Sveen 
et al, 2013) and result from the accumulation of free MG (Illien-Junger et al, 2015). 
These results suggest that even modest increases in global or local MG could contribute 
to painful sensitization.  
 Here we demonstrate that a single systemic administration of the free MG 
scavenging peptide GERP10 attenuates painful type 2 diabetes in db/db mice. We 
contribute to the growing body of work indicating that inhibition of MG, after exogenous 
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MG administration, in the STZ type 1 diabetes model (Bierhaus et al, 2012), and in type 
2 diabetic db/db mice (current results) reduces pain-like behavior. This is in line with 
other methods of blocking MG, including administration of aminoguanidine or ALT-711 
(Bierhaus et al, 2012), or by systemic overexpression of GLO1 (Bierhaus et al, 2012). 
Future studies are needed to determine whether GERP10 could alleviate painful 
diabetes in humans.  
 The major metabolic enzyme for MG, glyoxalase 1 (GLO1), plays a role in generating 
painful diabetes. For example, reduced GLO1 expression and activity is associated with 
pain in type 1 and type 2 patients (Skapare et al, 2013) as well as mice injected with MG 
or STZ (Jack et al, 2011; Bierhaus et al, 2012; Jack et al, 2012). Alternatively, 
administration of the GLO1 inhibitor Sr-p-Bromobenzylglutathionecyclopentyl diester 
(every 2nd day for 2 weeks, i.p. 50 mg/kg) resulted in hot, cold, pressure, and light-touch 
hypersensitivity (Andersson et al, 2013). Pain-like hypersensitivity presumably occurred 
via pharmacologically increasing endogenous MG, but elevated MG was not confirmed 
(Andersson et al, 2013). Finally, overexpression of GLO1 reduced painful diabetes in 
STZ (Bierhaus et al, 2012) and prevented MG-derived AGE formation (Berner et al, 
2012). These results suggest that decreased GLO1 activity alone is sufficient to produce 
pain and that restoration of GLO1 activity could be beneficial for reducing the 
contribution of free MG and MG-AGEs to painful diabetes.  
 
5.5.2  Methylglyoxal requires TRPA1 to produce painful diabetes 
 MG activates human (Eberhardt et al, 2012; Ohkawara et al, 2012), rat (Eberhardt et 
al, 2012), and mouse TRPA1 in both heterologous cell culture (Eberhardt et al, 2012; 
Ohkawara et al, 2012) and sensory neurons isolated from rodent DRGs (Eberhardt et al, 
2012; Koivisto et al, 2012; Andersson et al, 2013). For the first time we report that either 
pharmacological inhibition or genetic knockout of TRPA1 abolished pain-related 
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responses (spontaneous nociceptive behavior and spinal pERK) and subsequent 
evoked behavioral hypersensitivity (hotplate). Along these lines, calcium influx or 
nociceptive behavior is abolished in cells (Eberhardt et al, 2012) or mice (Andersson et 
al, 2013) lacking TRPA1, respectively. Furthermore, the pain-like behavior that occurs 
after pharmacologically raising MG levels by repeated administration of the GLO1 
inhibitor BrBz in wild-type mice is absent in TRPA1 knockouts (Andersson et al, 2013). 
These results taken together provide strong evidence that MG activates TRPA1 to 
produce pain. 
 There are many lines of evidence that support the hypothesis that tonic activation of 
TRPA1 contributes to neuropathic pain in diabetes. (1) Intrathecal Chembridge-5861528 
(TRPA1 antagonist; CHEM) attenuates pain-like hypersensitivity in STZ rats (Wei et al, 
2010). (2) Inhibition of TRPA1 prevents the loss of intraepidermal nerve fibers that 
occurs after STZ-induced diabetes (Koivisto et al, 2012). (3) Activation of spinal TRPA1 
by cinnemaldehyde (Wei et al, 2011) or methylglyoxal (current results) produces 
hindpaw hypersensitivity. (4) Spinal administration of CHEM reduces secondary 
hyperalgesia produced by intraplantar formalin or capsaicin (Wei et al, 2011). (5) 
Intrathecal TRPA1 inhibition reduces hypersensitivity after spinal nerve ligation, an 
alternative model of painful neuropathy (Wei et al, 2011). (6) TRPA1 modulates dorsal 
horn neuron responsivity in naïve wild-type rats (Kosugi et al, 2007). It is clear that both 
peripheral and spinal TRPA1 contribute to pain-like behavior in multiple pain models.  
 In the current study, we provide two additional experimental results that support the 
hypothesis that tonic MG produces painful diabetes through spinal TRPA1. First, 
blockade of spinal TRPA1 with HC reduces both nociceptive behavior and spinal pERK 
in response to peripheral MG administration. We suggest that activation of TRPA1 
afferents by MG produces release of endogenous TPRA1 agonists in the spinal cord that 
induce subsequent evoked hypersensitivity in a feed forward process, probably through 
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sensitization of spinal nociresponsive neurons. We favor this over the alternative 
explanation that MG activates TRPA1 located in spinal dorsal horn neurons, as there is 
no convincing evidence from the literature that suggests TRPA1 is expressed in dorsal 
horn neurons. This idea is supported by studies showing spinal release of reactive 
oxygen species or arachidonic acid derivatives such as 4-hydroxynonenal that drive pain 
through TRPA1 (Koivisto et al, 2013). Second, spinal inhibition of TRPA1 attenuated 
heat hypersensitivity in db/db mice. This further suggests that endogenous activation 
and/or sensitization of TRPA1 mediates painful diabetes. Future studies could 
investigate whether spinal inhibition of MG, or overexpression of the MG detoxification 
enzyme glyoxalase 1 (GLO1), would also alleviate PDN.  
 The above findings indicate that sustained activation of spinal and/or peripheral 
TRPA1 contributes to painful diabetes. However, our enthusiasm for this mechanism is 
tempered by two studies that the STZ model in studies of diabetic pain is an 
inappropriate model for studying the role of TRPA1. First, there is a dissociation between 
the reduction of evoked hypersensitivity and the lack of conditioned place preference, a 
measure of the reward associated with pain relief, produced by spinal TRPA1 
antagonism in STZ or SNI (Wei et al, 2013). Second, STZ directly activates TRPA1 to 
cause peripheral neuropathy that precedes STZ-induced type 1 diabetes (Andersson et 
al, 2015). Behavioral hypersensitivity produced by STZ was delayed in TRPA1 
knockouts, suggesting that TRPA1 mediates rapid sensitization and degeneration of 
peripheral afferents following STZ administration. This confounds TRPA1 antagonist 
studies in STZ, because now these results could be interpreted as the antagonist is 
blocking STZ-evoked hypersensitivity and neuropathy rather than MG-evoked painful 
diabetes.  
 The mode of activation of TRPA1 by MG is covalent and produces long-lasting 
sensitization TRPA1-containing neurons. MG reacts with lysine and arginine residues to 
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form H1 residues, as well as facilitating the formation of disulfide bonds between 
reactive cysteines. Cys 621, Cys 641, and Cys 665 have been identified by site-directed 
mutagenesis to be critical for MG activation of TRPA1 (Eberhardt et al, 2012), as 
mutation of these residues abolished MG-induced calcium responses. Another study 
provided somewhat conflicting results, whereas mutation of these same cysteine 
residues to serines inhibited responses to AITC but not MG (Andersson et al, 2013). 
However, MG-evoked calcium responses are diminished by the disulfide bond breaker 
DTT (Eberhardt et al, 2012), indicating indeed reactive cysteines are involved. We 
hypothesize that the cell type of heterologous expression may explain the discrepancy. 
In any case, the publication of the crystal structure of TRPA1 indicated that TRPA1 
channel function could be regulated by these same three critical cysteine residues (621, 
641, 665) (Paulsen et al, 2015). In addition to cysteines, MG forms adducts with lysine 
and arginine residues. Indeed, mutation of lysine 710 to glutamine reduced MG-evoked 
responses (Andersson et al, 2013). Modification of proteins in this manner is also 
referred to as advanced glycation end products (AGEs), which, along with their cognate 
receptor RAGE, are implicated in the pathogenesis of painful diabetes (Toth et al, 2008; 
Yao and Brownlee, 2010). In addition to sensitization of TRPA1, MG may contribute to 
PDN through AGE-RAGE signaling, as RAGE specifically recognizes MG-derived AGEs 
(Xue et al, 2014), but this remains a future direction.    
 
5.5.3  MG induces cross-modality sensitization to heat via a TRPA1-AC1 pathway 
 TRPA1 is activated by cold (Story et al, 2003), mechanical (Kwan et al, 2009), and 
chemical  (Bautista et al, 2005; McNamara et al, 2007; Trevisani et al, 2007; Eberhardt 
et al, 2012) stimuli. Here, activation of TRPA1 by MG led to hypersensitivity, an effect 
that was abolished by TRPA1 knockout. In mice, TRPA1 is expressed in small, mostly 
unmyelinated, peptidergic peripheral DRG neurons (C/Aδ) and predominantly 
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colocalizes with TRPV1 (Story et al, 2003; Bautista et al, 2005; Kobayashi et al, 2005; 
Garcia-Anoveros and Duggan, 2007). Functional studies indicated that MG produced a 
calcium response in 72% of capsaicin (prototypical TRPV1 agonist) responsive DRG 
neurons (Andersson et al, 2013), suggesting that 72% of TRPV1 fibers also express 
TRPA1. Furthermore, sensitization of TRPA1 in peripheral neurons is suggested to fine 
tune mechanical sensitivity (Kwan et al, 2009; Brierley et al, 2011). Considering these 
lines of evidence, it is not surprising that TRPA1-dependent activation of a substantial 
portion of C-mechanoheat sensitive afferents by MG (Eberhardt et al, 2012) would result 
in sensitization to subsequent mechanical or heat stimulation.  
 At least three possible scenarios may explain this TRPA1-TRPV1 sensitization: (1) It 
is indirect, where sensitization occurs via TRPA1-dependent depolarization of 
nociceptors lowering the activation/response threshold; (2) It is mediated by direct 
interaction of TRPA1 and TRPV1 (Fischer et al, 2014) or through a scaffolding protein 
such as Tmem100 that was previously implicated in persistent pain (Weng et al, 2015); 
or (3) Sensitization is produced by stimulation of secondary messengers such as AC1, 
as cAMP activation of PKA can result in phosphorylation-dependent sensitization of 
TRPV1 (Spahn et al, 2014). Here we present evidence that AC1 plays a critical role in 
mechanoheat sensitization after MG administration, but not in the spontaneous 
responses produced by direct activation of TRPA1 nociceptors.  
 We are the first to implicate AC1 and its sensitization by an MG-TRPA1 mechanism 
in diabetic pain. We suggest that AC1 mediates spinal sensitization, because intrathecal 
administration of NB001 attenuated heat hypersensitivity in db/db mice. However, 
nociceptive responses evoked by peripheral MG administration in the current results, 
pERK induced by application of capsaicin or glutamate to spinal slices (Wei et al, 2006), 
and pERK after peripheral injection of formalin (Wei et al, 2006) were similar in wild-type 
and AC1 knockout mice. This suggests that AC1 is not necessary for acute activation of 
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nociceptive neurons, even after activation of TRPA1 with an alternative agonist such as 
formalin. We can conclude, however, that AC1 is required for subsequent 
hypersensitivity to both non-noxious mechanical and noxious heat stimuli as well as 
painful spinal sensitization in type 2 diabetes. If indeed AC1 activity is upregulated in 
painful diabetes, then a future study could investigate whether intrathecal forskolin-
induced cAMP production is exacerbated in db/db mice compared to their non-diabetic 
controls. 
 
5.5.4  Conclusions toward treatments for painful diabetes 
 Our results are the first study to implicate AC1 in the maintenance of painful type 2 
diabetes. Furthermore, we confirm that TRPA1 mediates MG-induced nociception and 
extend these results to indicate MG evokes both hypersensitivity and affective pain. 
Finally, we provide further evidence that strategies aiming to inhibit the MG-related effect 
on painful neuropathy in diabetes, such as GERP10, are effective at reducing type 2 
diabetic pain-like behavior.  
 Our results suggest that blocking TRPA1 in peripheral and spinal nociceptive 
neurons could be a strategy for alleviating painful diabetes. To this end several groups 
are developing new TRPA1 antagonists. Glenmark pharmaceuticals (Mumbai, India) 
holds several U.S. patents on various molecules that act as TRPA1 antagonists. 
Although the structure has not been revealed, one such molecule presumably covered 
by a Glenmark patent, GRC-17536, underwent a Phase 2a clinical trial with sites in 
India, Germany, Czech Republish, and United Kingdom in patients with painful diabetic 
neuropathy. GRC reduced average pain intensity and was determined safe, although the 
complete results have not yet been released 
(https://clinicaltrials.gov/ct2/show/study/NCT01726413). Preclinical studies presented in 
abstract form that preceded this clinical trial indicated GRC to be a potent and selective 
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TRPA1 antagonist (Anupindi et al, 2010), but we were unable to find peer-reviewed 
publications on this molecule. In addition, new compounds that block TRPA1 activity are 
being developed by rational drug design using structure-activity relationships based on 
the prototypical TRPA1 antagonist discovered in 2007, HC030031 (Preti et al, 2015), 
which we used to block TRPA1 in the current studies.  
 Thus, approaches that minimize availability of MG to produce sensitization 
(Andersson et al, 2013), MG-AGEs (Sveen et al, 2013), or directly activate TRPA1 
(Eberhardt et al, 2012; Ohkawara et al, 2012) or Nav1.8 (Bierhaus et al, 2012) could 
benefit patients with painful diabetes. For example, the type 2 diabetes drug metformin 
reduces plasma MG and increases GLO1 activity in peripheral blood mononuclear cells 
from type 2 diabetic patients (Kender et al, 2014); however, whether metformin reduces 
diabetic pain in humans as it does in STZ rats (Byrne et al, 2015; Ma et al, 2015) 
remains unknown. Our manuscript under review at Journal of Pain indicates that the 
PPARγ agonist pioglitazone reduced PDN and spinal sensitization in type 2 diabetic rats 
that exhibited increased MG-AGEs. A future direction of our lab is to determine whether 
pioglitazone could reduce the MG-AGE formation, TRPA1 sensitization, and pain. 
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CHAPTER 6:  Overall Discussion and Supplemental Data 
 
6.1  Summary 
The results discussed herein suggest multiple ways of targeting methylglyoxal or 
PPARγ to alleviate the neuropathic pain associated with type 2 diabetes. I began by 
discussing the background information that is necessary to understand preclinical pain 
research and the growing problem of painful type 2 diabetes. Next I showed published 
evidence in Chapter 2: that gabapentin produces conditioned place preference in rats 
with traumatic nerve injury, an important finding indicating that: 1) systemic injection of 
an analgesic drug is sufficient to produce conditioned place preference in rodents 
suggesting rapid alleviation of pain; and 2) I validated the use of conditioned place 
preference (or aversion as shown in section 5.4.1 ) to assess an aspect of motivational-
affective pain in rodents. Below I propose several additional studies to utilize novel 
assays to assess motivational-affective pain in preclinical type 2 diabetes.  
I presented another publication indicating that PPARγ agonists rapidly reduce 
nociceptive and neuropathic pain-like behaviors through a non-genomic, astrocyte-
related mechanism in Chapter 3: . In addition to rapid analgesia, my manuscript under 
review at the Journal of Pain shows that genomic PPARγ mechanisms also mediate 
inhibition of type 2 diabetic neuropathic pain and associated sensitization of spinal 
nociresponsive neurons. These results, along with unpublished studies shown below, 
indicate a differential effect of acute versus chronic administration of PPARγ agonists 
such as pioglitazone on Fos and/or pERK markers of painful central sensitization in the 
setting of nerve injury or type 2 diabetes. Furthermore, data below suggest that 
pioglitazone is sufficient to both prevent and reverse pain associated with type 2 
diabetes, independent of its glucose lowering effect. Below I speculate on how 
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pioglitazone, through a PPARγ-dependent or independent mechanism, may alleviate 
neuropathic pain.  
Finally, in Chapter 5: I implicated methylglyoxal in the generation and maintenance of 
pain associated with type 2 diabetes. I showed that methylglyoxal is sufficient to produce 
nociceptive, evoked, and affective pain-like behavior. The production of pain evoked by 
methylglyoxal requires TRPA1 and AC1, as knockout of these proteins in normal, non-
diabetic mice or administration of their pharmacological inhibitors to db/db mice 
alleviated pain-like behaviors. Several lines of investigation pointed toward a spinal 
mode of action, whereby activation of dorsal horn nociresponsive neurons produces 
pain-like behavior. I showed that inhibition of methylglyoxal using the scavenging peptide 
GERP10 alleviated hypersensitivity in diabetic db/db mice. Future directions outlined 
below propose to target glyoxalase 1, the catabolic enzyme for methylglyoxal, in order to 
reduce the contribution of methylglyoxal to neuropathic pain in type 2 diabetes.  
 
6.2  How does type 2 diabetes lead to painful neuropathy? 
 I propose that pre-diabetic conditions in type 2 diabetes lead to peripheral insulin 
resistance feeding forward to an increase in blood glucose that results in chronic glucose 
neurotoxicity. This causes permanent changes in somatosensory processing that cannot 
be reversed by glucose management alone. I also believe the mechanisms of PDN differ 
in type 1 versus type 2 models of diabetes and this is supported by simultaneous studies 
of type 1 and type 2 diabetic models (Schmidt et al, 2003; Schmidt et al, 2004; Kamiya 
et al, 2005; Schuelert et al, 2015). Although there has been extensive research into the 
streptozotocin-induced type 1 diabetic model in both mice and rats this method fails to 
investigate mechanisms of pain in type 2 diabetes, and type 2 diabetes has greater 
prevalence in the human diabetic patient population. The greater number of publications 
studying pain in STZ compared to ZDF or db/db is disproportionate to the prevalence of 
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type 1 diabetes (just 10%) and is inappropriate with the recent publication indicating that 
STZ activates nociceptors through agonist action at TRPA1 (Andersson et al, 2015). 
Therefore more work is needed to replicate studies in STZ models using models specific 
to painful type 2 diabetes.  
 
6.2.1  Motivational-affective pain in models of painful type 2 diabetes 
 We are the first to show negative affect in type 2 diabetes using MCS. We also 
provide evidence using CPP that gabapentin, a common treatment for PDN (Wodarski et 
al, 2009; Rauck et al, 2013), alleviates affective pain in SNI, an alternate model of 
neuropathic pain. Therefore we propose to investigate in a reverse translation study 
whether administration of gabapentin reverses affective pain in type 2 diabetes. This 
could be accomplished in several models including MG-induced CPA in wild-type mice, 
MCS in ZDF, or CPP in db/db or ZDF. As we are the first to measure negative affect in a 
model of type 2 diabetes using MCS, we attempted to extend this finding to an 
alternative model of type 2 diabetes using a complementary assay. We began to test the 
hypothesis that systemic gabapentin would produce conditioned place preference in 
diabetic db/db mice.  
 Figure 6-1 illustrations preliminary results (n=8) indicating baseline preconditioning 
preferences in db/db mice. As shown, db/db spent the majority of time in the center (C) 
grey neutral chamber, as opposed to exploration of the pairing chambers on the left (L) 
and right (R) of the center chamber. This is in contrast to the normal preconditioning 
preferences in non-diabetic sham or SNI rats (see Figure 2-3), where the majority of the 
time is spent in the white or black pairing chambers. Because diabetic animals at this 
stage of diabetes exhibit decreased exploratory locomotor activity (see Figure 4-10) and 
the mice were initially placed in the center chamber to assess initial preferences, it is not 
surprising that the majority of time was spent in the neutral start chamber. CPP could be 
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performed at an earlier age, when locomotor activity is not diminished, however this is 
unadvisable because db/db mice do not exhibit behavioral hyperalgesia until several 
weeks after hyperglycemia begins. Therefore an alternative approach to assess affective 
pain in type 2 diabetes would be to use a two-chamber CPP apparatus, the MCS assay, 
or test the hypothesis that gabapentin administration reverses MG-induced CPA in wild-
type mice.  
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Figure 6-1. Preliminary preconditioning results in db/db mice using CPP. 
Time spent in the left (L), center (C), and right (R) chambers in a conditioned place 
preference assay using a three-chamber box. Mice were placed into the center, 
neutral chamber to begin assessment of preconditioning baseline. The db/db mice 
failed to explore the left and right drug-pairing chambers during preconditioning.  
 
6.2.2  Inhibition of TRPA1 to reduce painful type 2 diabetes 
 Our current results implicate spinal TRPA1 in the mediation of pain-like behavior 
associated with type 2 diabetes. Therefore we propose several strategies of inhibiting 
TRPA1 in order to reduce painful diabetes. First, reduction of endogenous activation of 
TRPA1 by methylglyoxal in type 2 diabetes could be achieved by masking agonist 
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binding sites using antibodies. This was demonstrated in a previous study where a 
TRPA1 antibody blocked calcium mobilization induced by AITC (Lee et al, 2014). This 
could prevent the tonic activation of TRPA1 by compounds such as methylglyoxal and 4-
HNE that are endogenously generated in diabetes (Koivisto et al, 2012). Second, we 
could prevent the TRPA1-dependent sensitization of TRPV1 in nociceptors by blocking 
their interaction through modulation of the peptide Tmem100. A recent study showed 
that the Tmem100 mediates an optimal interaction of TRPA1 with TRPV1 that 
contributes to pain after injury. The authors developed a mutant peptide, Tmem100-Q3 
that facilitates a strong interaction between TRPA1 and TRPV1 thereby inhibiting pain. 
Strikingly, a cell permeable peptide mimicking the 3Q region of Tmem100-3Q had a 
similar effect of reducing pain sensitization in vivo (Weng et al, 2015). Therefore we 
hypothesize that administration of this Tmem100-Q3 peptide derivative would alleviate 
painful type 2 diabetes by blocking the cross-sensitization between TRPA1 and TRPV1 
in peripheral nociceptors.  
 Previous studies show a dissociation between evoked and non-evoked pain 
measures. The TRPA1 antagonist HC reduced evoked hypersensitivity, but failed to 
produce conditioned place preference in STZ or SNI after spinal administration (Wei et 
al, 2013) or in CFA after systemic administration (Okun et al, 2011). As affective pain is 
mediated by CNS and PNS mechanisms, it is possible that reducing TRPA1 activity 
peripherally is necessary to produce CPP, similar to studies showing peripheral lidocaine 
induces CPP in inflammatory (Okun et al, 2011) or incisional (Navratilova et al, 2012) 
models. Therefore we propose a future study to test the hypothesis that peripheral nerve 
block inhibits CPA to intraplantar methylglyoxal administration. Alternatively, the ability of 
TRPA1 antagonists to produce CPP or reduce MCS-related pain behavior could be 
tested in ZDF or db/db. This experiment could inform whether activation of nociceptors 
by MG is sufficient to produce negative affect. 
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 Increased methylglyoxal in diabetes is known to sensitize sensory neurons through 
TPRA1 (Wei et al, 2009; Koivisto et al, 2012; Wei et al, 2013). Similarly, in the 
streptozotocin model of type 1 diabetes, drugs such as HC-030031 and Chembridge-
586152 inhibit stimulus-dependent pain-like behavior (Wei et al, 2010; Koivisto et al, 
2012) but not ongoing aversion in the CPP paradigm (Wei et al, 2013). Therefore we 
wanted to test the hypothesis that TRPA1-dependent activation of peripheral sensory 
neurons in the dorsal root ganglia is potentiated by type 2 diabetes. Figure 6-2 illustrates 
that AITC (TRPA1 agonist; 100μM) stimulation produced DRG neuron responses in both 
ZL and ZDF as evidenced by ratiometric Fura-2 calcium imaging. Neuronal cells were 
identified by their response to K+ and capsaicin (100μM) (data not shown). The 
percentage of the DRG neurons that responded to AITC, and therefore were peripheral 
neurons putatively containing TRPA1, was 35-38%. This is in line with previous 
functional expression studies (Kobayashi et al, 2005; Hjerling-Leffler et al, 2007). The 
response in ZL and ZDF was similar, indicating that painful type 2 diabetes did not alter 
TRPA1-dependent activation of peripheral nociceptors. This suggests that TRPA1 
sensitization in peripheral neurons may not mediate the pain associated with type 2 
diabetes. 
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Figure 6-2. TRPA1-dependent calcium response in DRG neurons from ZL and 
ZDF. 
Data courtesy of Suzanne Doolen. I formulated the hypotheses, designed the 
experiments, and analyzed the data.  
Neurons were dissociated from L4/5 dorsal root ganglia harvested from control (ZL) 
and diabetic (ZDF) rats. Quantification of (A) peak height, (B) peak height as a % of 
the response to potassium, and (C) percentage of the cells analyzed that responded 
to AITC. There was no difference between ZL and ZDF responses in any of the 
parameters measured.  
 
 Next we tested the hypothesis that MG would produce an exacerbated pain 
response when administered to diabetic db/db mice. Figure 6-3 illustrates that 
intraplantar methylglyoxal produces equal nociceptive response in control BKS and 
diabetic db/db. An alternative approach to this result revealing an absence of peripheral 
TRPA1 sensitization in painful type 2 diabetes is to further investigate the role of spinal 
TRPA1 in naïve animals. As such, we propose to test the hypothesis that the activation 
of spinal neurons by MG is attenuated by TRPA1 inhibition. This is based upon several 
results: (1) MG-induced nociceptive behavior and pERK in the dorsal horn was inhibited 
by intrathecal HC and TRPA1 genetic knockout; (2) spinal administration of HC reduced 
painful type 2 diabetes in db/db mice; and (3) MG activation of DRGs is absent in 
TRPA1-/- mice (Eberhardt et al, 2012). 
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Figure 6-3. Nociceptive behavior after MG administration in type 2 diabetic 
mice. 
Nociceptive response after intraplantar methylglyoxal (MG; 3 μg) administration in 
control BKS and type 2 diabetic db/db mice at age 11 wks. There was no difference 
in BKs and db/db mice in nociceptive response evoked by i.pl. MG.  
 
 Several possible results exist for the proposed experiment that TRPA1 inhibition 
reduces MG-evoked spinal neuron activation. The TRPA1 antagonist HC030031 could 
reduce the MG-induced response indicating that TRPA1 plays a role in spinal neuron 
activation. Alternatively, the results could indicate that inhibition of presumably 
presynaptic TRPA1 in the dorsal horn is not sufficient to reduce MG-evoked calcium 
responses. This provides for the possibility that MG activates post-synaptic neurons 
directly, independent of its effects on TRPA1. A clue comes from previous work, where 
MG was shown to activate Nav1.8 in primary afferents (Bierhaus et al, 2012). Care must 
be taken in the experimental design so that spinal neurons are not exposed to MG more 
than once, as MG covalently binds to lysine, arginine, or cysteine residues within TRPA1 
and therefore it is reasonable to suspect that this produces long-lasting sensitization that 
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could alter the efficacy of the HC antagonist during future MG stimulation (see 5.5.2 ). 
This is supported by a study showing the calcium response to a low dose of MG is 
biphasic, suggesting sustained sensitization of TRPA1 (Koivisto et al, 2012). These 
studies could be performed using dorsal root stimulation (DRS) to begin to separate pre 
versus post synaptic activation of neurons by MG. A possible expected result is that MG 
activates post synaptic neurons independent of TRPA1, while pre synaptic effects are 
indeed regulated, at least in part, by TRPA1. DRS studies could test this idea. 
 
6.2.3  AC1 and mechanisms of spinal sensitization  
 In addition to the pERK evidence presented herein, studies are needed to further 
investigate functional spinal sensitization in models of type 2 diabetic pain. One 
approach is to test the hypothesis that glutamate evoked neuron activation, by using a 
combination of calcium imaging and electrophysiological studies, is exacerbated in the 
spinal cord dorsal horn from ZDF or db/db. A similar approach is to use methylglyoxal as 
the activation stimulus. We predict that spinal neuron responses would be greater in 
ZDF or db/db compared to their respective controls, which would be consistent with 
previous results from our colleagues in inflammatory and nerve injury models (Doolen et 
al, 2012; Corder et al, 2013). Follow-up studies could test whether GERP10, HC, 
pioglitazone, or NB001 inhibits glutamate- or methylglyoxal-evoked spinal sensitization.  
 Another approach is to bypass the downstream targets of methylglyoxal in diabetes 
by testing whether spinal inhibition of MG directly could reduce painful type 2 diabetes. 
As spinal inhibition of TRPA1 attenuated heat hypersensitivity in db/db mice, but not 
calcium mobilization induced by TRPA1 activation ex vivo, one method to clarify the role 
of spinal MG in PDN would be to test whether inhibition of MG in the spinal cord would 
reduce painful diabetes. Our results suggest that endogenous activation and/or 
sensitization of TRPA1 in the spinal cord, presumably on presynaptic terminals, 
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facilitates evoked hypersensitivity. Therefore if elevated MG is contributing to this 
process, then intrathecal administration of GERP10 (or other MG scavenging 
compound) would reduce behavioral hypersensitivity in db/db mice.  
 Contrary to the results above that suggests that sensitization of peripheral TRPA1 
does not mediate PDN, we show pain-like behavior is reduced by spinal inhibition of 
both TRPA1 and AC1 in db/db mice and in AC1-/- after MG administration. This leads us 
to speculate that there is an upregulation of AC1 activity, or the AC1 system is primed 
and that endogenous activation of TRPA1 by MG produces pain through revealing this 
calcium-dependent AC1 sensitization. Along this line of thinking, there would be no 
difference between control and diabetic animals in the calcium response mediated by 
artificial activation of DRG neurons with AITC (as above). However, we would speculate 
that the production of cAMP would be greater in diabetic animals after TRPA1 activation, 
indicating a primed AC1 system. Since we suspect that activation of TRPA1 produces 
sensitization of AC1, and that this sensitization leads to a potentiated cAMP, one 
possible mechanism of the generation of heat hypersensitivity in type 2 diabetes is PKA-
dependent phosphorylation/sensitization of TRPV1 (Spahn et al, 2013). To test this we 
could stimulate DRG neurons with MG or saline followed by capsaicin in the presence or 
absence of NB001 pretreatment. Several results are possible in this experiment. First, 
we predict that initially stimulating the DRGs with MG (as opposed to saline) would 
potentiate the response to capsaicin, revealing a functional link between TRPA1 and 
TRPV1. Second, we predict that inhibition of AC1 with NB001 would reduce the 
capsaicin-evoked calcium response subsequent to MG stimulation, indicating that MG 
sensitizes TRPV1 through AC1.  
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6.3  Methylglyoxal and glyoxalase 1 in painful type 2 diabetes 
6.3.1  Developing a chronic model of MG-induced PDN  
 To test the hypothesis that methylglyoxal is sufficient to produce diabetic-like pain a 
chronic administration model is needed. Several reports indicate that a diabetic-like 
phenotype develops after repeated or chronic administration of MG to rodents, but pain-
like behavior in these models has not been tested. A recent review of modeling type 2 
diabetes in rodents suggested that a major culprit of diabetic dysfunction is MG, and 
suggested chronic MG administration as a suitable model for type 2 diabetes (Dornadula 
et al, 2015). A chronic MG model may better model the type 2 diabetic condition when 
compared to intraplantar MG administration, because MG is elevated in the plasma 
rather than at local sites such as at subcutaneous nociceptors in the dermis or 
epidermis. Therefore we summarize a few chronic MG studies as a basis for future 
experimentation.  
 Intraperitoneal administration of methylglyoxal (17.25 mg/kg) produced a modest 
increase in tissue MG concentrations 3 h after administration and increased plasma MG 
within 5-15 min (Dhar et al, 2010). Coadministration with the MG scavenging compound 
Alagebrium (100 mg/kg) attenuated increases in MG. Both i.p. and i.v. (50 mg/kg) 
administration of MG acutely resulted in decreased glucose tolerance. MG 
administration decreased the levels of GSH and increased D-Lactate, indicating that the 
glyoxalase system was activated by exogenous MG administration (see Figure 1-2). 
Plasma MG levels remained elevated two fold at 2 h after administration, although 
further timepoints were not assessed. This result suggests that repeated (e.g. twice 
daily) i.p. injection of MG could be sufficient to increase circulating and tissue 
concentrations of MG and possibly induce a pain-like phenotype.   
 Chronic MG treatment by addition to the drinking water (50-75 mg/kg/d) in Wistar 
(control, W) and Goto-Kakizaki (nonobese type 2 diabetes, GK) aged 6 months (young, 
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control, C) or 14 months (aged, A) resulted in impaired glucose tolerance and increased 
MG (Rodrigues et al, 2014). Results are shown in the figure below adapted from the 
manuscript. Kidney immunohistochemical expression of AGEs and RAGE appeared 
greater in the GKC and in the W and GK rats that were aged or treated with MG, 
indicating that MG induces the AGE-RAGE system. 
 Chronic minipump infusion (60 mg/kg/d) for 28 d in Sprague-Dawley rats resulted in 
changes in fasting plasma glucose (33% increase), insulin (60% decrease), and GSH 
(50% decrease). Glucose and GSH were also lowered in pancreatic, skeletal muscle, 
and adipose tissues. Impaired oral glucose tolerance and fasting measures were 
alleviated by the MG scavenger and AGE breaker Alagebrium (Dhar et al, 2011).  
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Figure 6-4. Diabetic measures after chronic administration of methylglyoxal.  
Adapted from (Rodrigues et al, 2014). 
Methylglyoxal (MG) is elevated in a type 2 diabetes model (GK), in aged (A) rats, or 
after administration of exogenous MG in drinking water. [KEY: Wistar (W), Goto-
Kakizaki (GK), young Control (C), Aged (A), methylglyoxal administered (MG)]. 
Blood glucose in (A) fasted or (B) at 2 h in an oral glucose tolerance test. (C) Serum 
methylglyoxal levels are shown.  
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 Based on the above findings, we attempted to test the hypothesis that chronic 
administration of MG using Alzet minipumps would produce pain-like mechanical and/or 
heat hypersensitivity. Figure 6-5 illustrates the effect of MG minipump administration on 
blood glucose, weight, and behavioral hypersensitivity. After 7 d of MG administration we 
found no difference in mechanical or heat thresholds. It should be noted that all mice in 
the high dose (100 mg/kg/d) had removed their minipumps by the second week of the 
experiment. By the third week almost all the mice subjected to MG administration had 
removed their minipumps. All of the minipumps in the saline mice remained implanted at 
week 3. We speculate that chronic release of MG in the subcutaneous space along the 
lumbar dorsal region cause an irritation or hypersensitivity that resulted in scratching and 
eventual removal of the minipumps. Minipump MG administration by Dhar et al as 
described was also subcutaneous, but at a lower dose of 60 mg/kg/d using a larger 
minipump (2ML4) and the experiment was performed in rats over a 28 d administration 
period. The authors anecdotally reported no inflammatory response associated with the 
minipump implant (Dhar et al, 2011), but it is unclear whether any minipumps had been 
removed during the experiment. We suspect that species or dose differences could 
explain the aversive effect of MG minipumps in our study. It remains a future direction for 
us to develop a chronic model of MG-induced pain through minipump, daily injections, or 
drinking water administration of MG in mice and rats.  
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Figure 6-5. Pain-like sensitivity is unchanged by MG minipump administration. 
Alzet minipumps (#2004) were implanted subcutaneously in the dorsal-lumbar 
region. Concentrations in the minipump were calculated to deliver 0 (saline vehicle), 
1, 30, or 100 mg/kg/d of methylglyoxal (MG). (A) Blood glucose was measured 
immediately following implant. (B) Weight, (C) mechanical, and (D) heat 
hypersensitivity were monitored before (BL; baseline) and at several timepoints 
following minipump implant. Chronic administration of MG for one week did not 
affect weight gain or evoked pain-like behaviors. (n=8) 
 
6.3.2  Manipulating GLO1 expression/function to reduce painful diabetes 
 Several lines of evidence suggest that the activity and/or expression of GLO1 
regulates the contribution of MG to painful diabetes. (1) Both type 1 and type 2 diabetic 
patients whose neuropathy symptom score was rated as severe, compared to moderate 
or mild ratings, exhibited decreased blood Glo1 activity (Skapare et al, 2013). (2) Aging 
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impairs GLO1 expression and function and impairs wound healing, which can be 
restored by administration of aminoguanidine (Fleming et al, 2013). (3) Strain differences 
in the copy number variants of Glo1 results in protection from STZ-induced diabetic 
neuropathy in BALB/cByJ mice compared to BALB/cJ mice, in which GLO1 expression 
is decreased tenfold (Jack et al, 2012). (4) GLO1 polymorphisms regulate GLO1 activity 
(Peculis et al, 2013), but a link between SNPs and diabetic pain risk has not been 
established. (5) Repeated administration of BrBz resulted in behavioral hypersensitivity 
to mechanical, heat, and cold stimulation (Andersson et al, 2013). (6) GLO1 
overexpression reduced STZ-mediated hypersensitivity (Bierhaus et al, 2012). The 
above findings indicate that strategies aiming to increase GLO1 activity in type 2 
diabetes could potentially alleviate pain.  
 We propose several methods to overexpress GLO1 by both systemic and targeted 
vectors. (1) Somatic gene transfer using the pCMV-Neo overexpression vector for GLO1 
(i.p. injection in db/db mice) provided to us by our colleagues Thomas Fleming and Peter 
Nawroth. (2) AAV overexpression of GLO1 by insertion of the pCMV-Neo 
overexpression cassette into an AAC serotype. Local injections to the spinal cord, brain, 
or peripheral nerve could be used to determine the site of MG-related hyperalgesia 
and/or affective pain. For example, we hypothesize that overexpression of GLO1 
peripherally would reduce hyperalgesia and affective pain, as negative pain affect 
requires both the central and peripheral nervous systems (Qu et al, 2011). (3) Cross 
BAC-GLO1-transgenic mice (Distler and Palmer, 2012; Distler et al, 2012; Distler et al, 
2013) with a transgenic mouse that has neuronal promoter-driven CRE to specifically 
overexpress GLO1 in neurons.  
 A method alternative to overexpression of GLO1 could be promoting degradation of 
methylglyoxal using substances in addition to already known MG scavengers and AGE 
breakers. For example, we hypothesize that administration of glutathione would facilitate 
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MG degradation, even in type 2 diabetes where GLO1 activity is low, by providing a 
surplus of the required cofactor for GLO1. Glutathione has antioxidant properties and 
could also act to scavenge ROS, prevent MG-AGE formation, and ameliorate 
mitochondrial dysfunction, all mechanisms that contribute to PDN. 
 
6.4  Mechanisms of PPARγ-related analgesia 
6.4.1  The rapid effects on pain by PPARγ agonists 
 Three of our findings led us to conclude that PPARγ agonists exhibit non-genomic, 
possibly receptor-independent effects on pain-like behavior. First, we found that both 
rosiglitazone and pioglitazone attenuate mechanical hyperalgesia in rats with nerve 
injury within five to ten minutes of intrathecal administration. Second, the rapid 
antihyperalgesic effect was unchanged by the translation inhibitor anisomycin, whereas 
the antihyperalgesic effects at sixty to ninety minutes were reduced by anisomycin. 
Third, pioglitazone attenuated heat hyperalgesia in ZDF and db/db mice within one hour 
of administration. We suspect that PPARγ mediates this rapid effect as the PPARγ 
antagonist GW9662 inhibited pioglitazone antihyperalgesia in SNI within thirty minutes of 
administration. However, several of these timepoints are in the ambiguous time frame 
between anisomycin insensitive (10 min) and sensitive (60 min) periods, so future 
studies could seek to determine the antihyperalgesic effect of pioglitazone at rapid 
timepoints in alternative pain models or in transgenic animals where PPARγ has been 
temporally and/or spatially eliminated. 
 The exact mechanism by which pioglitazone rapidly reduces pain in nociceptive 
(intraplantar capsaicin and methylglyoxal administration), diabetic (ZDF and db/db 
models), or nerve injury conditions still remains unknown. We provide correlative 
evidence that pioglitazone reduces markers of central sensitization. Acute pioglitazone 
administration reduces astrocyte activation within one hour (section 3.4.9 ). Chronic 
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administration of pioglitazone reduces both activation of glia in SNI (Morgenweck et al, 
2013) as well as inhibits spinal neuron sensitization to noxious pressure in painful type 2 
diabetes (section 4.4.3 ) and non-noxious light-touch in SNI (see Figure 6-6 below). But, 
these latter findings were in chronic administration scenarios, and new data below 
reveals that acute administration of pioglitazone does not alter stimulus-evoked markers 
of neuronal sensitization in the spinal cord (as evidenced by light-touch evoked Fos and 
pERK).  
 A growing body of evidence suggests that the mechanisms of pioglitazone analgesia 
are different between acute (rapid) and chronic (sustained) administration. For example, 
acute administration of pioglitazone did not reduce light-touch evoked pERK or Fos in 
SNI (Figure 6-7 below), even though chronic administration in both diabetic and nerve 
injury models reduced stimulus-evoked pERK. Similarly, pioglitazone did not reduce 
spinal Fos expression associated with capsaicin injection (see Figure 3-6). Furthermore, 
although acute intrathecal pioglitazone rapidly reduced evoked mechanical 
hypersensitivity, it failed to produce CPP in SNI rats (Figure 6-8 below). In fact, we found 
that sham rats exhibited CPP to intrathecal pioglitazone while preferences in SNI rats 
were unchanged by pioglitazone conditioning. This finding that uninjured animals 
perceived pioglitazone as rewarding is puzzling because we see no effect of pioglitazone 
on sensory thresholds in sham or naïve animals. However, it could be that the activation 
of reward pathways in sham animals by pioglitazone is diminished after peripheral nerve 
injury, although this is unfounded speculation.  
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Figure 6-6. Chronic pioglitazone administration reduces light touch-evoked 
pERK. 
Adapted from (Morgenweck et al, 2013). 
Representative images of phosphorylated ERK (p-ERK) in spared nerve injury rats 
that were administered (A) saline or (B) pioglitazone for seven weeks. (C) 
Pioglitazone reduced p-ERK in the dorsal horn evoked by light touch stimulation of 
the sural receptive field of the injured hindpaw using a cotton swab.  significantly 
different from “0” (unpaired). n = 5-8. 
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Figure 6-7. Acute pioglitazone does not reduce evoked spinal pERK or Fos in 
SNI rats. 
Two weeks after SNI surgery rats were injected i.p. with either saline vehicle or 
pioglitazone (100 mg/kg) one hour prior to stimulation of the injured hindpaw as 
described above. Rats were perfusion-fixated and processed for 
immunohistochemical staining of phosphorylated ERK (pERK) and expression of 
Fos in the lumbar dorsal horn. (A) Quantification of ipsilateral and contralateral 
pERK in vehicle animals. (B) Quantification of ipsilateral pERK in vehicle or 
pioglitazone animals (n=3-4). (C-F) Representative images of pERK in the indicated 
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groups. (G) Quantification of ipsilateral and contralateral Fos in vehicle animals. (H) 
Quantification of ipsilateral Fos expression in vehicle or pioglitazone animals (n=8). 
(I-L) Representative images of Fos expression in the indicated groups. Light-touch 
stimulation of the injured hindpaw in SNI rats produced an increase in pERK and 
expression of Fos in the spinal dorsal horn ipsilateral to stimulation. Pretreatment 
with pioglitazone prior to stimulation did not change evoked pERK or expression of 
Fos.  p<0.05 vs. ipsilateral. 
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Figure 6-8. Pioglitazone produces conditioned place preference in sham but 
not SNI rats. 
 (A) Mechanical withdraw thresholds in sham and SNI rats before injury (BL), before 
the CPP preconditioning (PRE), and after CPP postconditioning (POST). (B) 
Preconditioning and postconditioning time spent in the saline or pioglitazone paired 
chamber. (C) Difference scores (preconditioning time spent in chamber minus 
postconditioning time spent in chamber) for sham and SNI rats are shown.  p<0.05 
vs. preconditioning in B or vs. sham saline in C. n=6-8. 
 
6.4.1.1  pERK and Fos 
 Evidence from our pioglitazone studies indicate that pERK and Fos markers of spinal 
sensitization are differentially affected by acute versus chronic administration. With 
regard to these pERK and Fos studies, we did not perform colabeling with neuronal or 
glial markers. The cell type where pERK and Fos are labeled via immunohistochemistry 
is unclear as is the excitatory or inhibitory nature these cells. Therefore it is possible that 
pioglitazone produced activation of inhibitory neurons or increased the phosphorylation 
of ERK (pERK) or expression of Fos in glial cells, even though those glial cells may have 
been contributing to the anti-hypersensitive effect of pioglitazone. pERK has previously 
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been shown to be expressed in glial cells (Gao and Ji, 2010), along with activity-
dependent phosphorylation of other MAPK in nerve injury (Tsuda et al, 2004; Ji et al, 
2009) or diabetes (Daulhac et al, 2006). ERK activation is suggested to facilitate pain (Ji, 
Gereau et al. 2009) and several studies suggest that PPARγ agonists may inhibit ERK 
phosphorylation. For example, activated PPARγ prevents MEK, the MAPK kinase 
upstream of ERK, from phosphorylating ERK (Burgermeister, Chuderland et al. 2007, 
Burgermeister and Seger 2007), although contrary to the finding that increased pERK is 
associated with decreased PPARγ expression in a microbial sepsis model (Kaplan et al, 
2010). PPARγ reduces ERK phosphorylation after TNFα or IFNγ stimulation (Lombardi, 
Cantini et al. 2008, Lombardi, Cantini et al. 2009) and administration of these cytokines 
in vivo can directly mediate hyperalgesia (Tsuda, Masuda et al. 2009, Gruber-
Schoffnegger, Drdla-Schutting et al. 2013). Taken together, our results and the literature 
indicate a direct interaction between PPARγ and the MAPK pathway (Gardner et al, 
2005).  
 
6.4.1.2  Cytokines and chemokines 
 Rapid analgesia after pioglitazone administration may result from decreased 
chemokine/cytokine release. For example, reduction of neuropathic pain is associated 
with a decrease in MCP1/CCL2 (Gao, Zhang et al. 2009) or TNFα (Ohtori, Takahashi et 
al. 2004), which can contribute to astrocyte pain sensitization (Zhang, Berta et al. 2011) 
and spinal LTP (Gruber-Schoffnegger, Drdla-Schutting et al. 2013). Repeated PPARγ 
activation reduces TNFα in the spinal cord and DRG after nerve injury (Maeda, Kiguchi 
et al. 2008) and decreases astrocyte TNFα release after inflammatory activation in vitro 
(Storer, Xu et al. 2005). Furthermore, pioglitazone rapidly decreases astrocyte TNFα 
release in vitro (Gurley, Nichols et al. 2008). As cytokines can directly and quickly 
modulate the responsivity of nociceptive neurons, reduction of their release by TZDs is 
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one possible mechanism of rapid analgesia. Furthermore, increased TNFα is associated 
with pain in diabetic patients (Purwata, 2011). 
  
6.4.1.3  mitoNEET 
 Receptor-independent functions of PPARγ agonists at mitochondria was first 
proposed ten years ago by Feinstein and colleagues (Feinstein et al, 2005). 
Mitochondrial dysfunction resulting in alterations in calcium homeostasis contributes to 
hyperactivity of sensory processing (Flatters, 2015), painful neuropathy (Fernyhough 
and Calcutt, 2010; Barrière et al, 2012; Verkhratsky and Fernyhough, 2014), and 
neurodegenerative disease (Feinstein et al, 2005; Geldenhuys et al, 2010; Yonutas and 
Sullivan, 2013). TZDs (Geldenhuys et al, 2010; Yonutas and Sullivan, 2013) or 
exogenous ligands such as TT01001 (Takahashi et al, 2015) reduce diabetic 
mitochondrial dysfunction by targeting the mitochondrial protein mitoNEET. Functional 
and expressional evidence indicate that pioglitazone binds to and stabilizes mitoNEET 
within the outer mitochondrial membrane (Bolten et al, 2007; Paddock et al, 2007), 
making mitoNEET a potential target for the rapid antihyperalgesic effect of TZDs. 
Therefore we hypothesize that pioglitazone or other TZDs act at mitoNEET to rapidly 
restore calcium homeostasis in PDN (Latham et al, 2009; Cao et al, 2011; Todorovic and 
Jevtovic-Todorovic, 2014; Verkhratsky and Fernyhough, 2014) or after experimental 
traumatic nerve injury and that this could be a mechanism of acute PPARγ agonist 
analgesia.  
 
6.4.1.4  GPR40 
 The rapid effects of pioglitazone could be mediated by “off-target” effects at GPR40, 
a G-protein coupled receptor recently implicated in the regulation of hyperalgesia 
associated with formalin, CFA, SNL, and stroke (Nakamoto et al, 2012; Nakamoto et al, 
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2013; Harada et al, 2014; Karki et al, 2015; Nakamoto et al, 2015). Activation of GPR40 
by endogenous (e.g. DHA, polyunsaturated fatty acids) and exogenous (GW9508) 
ligands reduces inflammatory (Nakamoto et al, 2012; Nakamoto et al, 2013), 
neuropathic (Karki et al, 2015), and post-stroke (Harada et al, 2014) pain. Analgesic 
effects were inhibited by the GPR40 antagonist GW1100. GPR40 is expressed in POMC 
and β-endorphin neurons in the hypothalamus (Nakamoto et al, 2013), serotonergic and 
noradrenergic neurons in the RVM and LC (Nakamoto et al, 2015), and neurons but not 
glia in the spinal cord (Karki et al, 2015). Therefore both functional and expressional 
evidence implicate GPR40 in various pain models. Furthermore, calcium mobilization 
produced by rosiglitazone is abolished by siRNA knockdown of GPR40, suggesting that 
TZDs may also activate GPR40 (Gras et al, 2009). This is intriguing, given the notion 
that GPR40 functions to facilitate descending inhibition (Harada et al, 2014; Karki et al, 
2015; Nakamoto et al, 2015), that TZDs may activate GPR40, and TZDs rapidly inhibit 
hypersensitivity. Both inflammatory (carrageenan and CFA) and nerve injury (SNL) 
models increase the expression of GRP40 in the spinal cord (Karki et al, 2015). There’s 
even evidence that activation of GPR40 by GW9508 increases the expression of Fos 
after injury even with simultaneous reduction of formalin nociception (Nakamoto et al, 
2013; Nakamoto et al, 2015), which would explain the lack of effect of pioglitazone on 
Fos expression in capsaicin and SNI models – pioglitazone decreased Fos in 
nociceptive neurons while simultaneously increasing Fos in inhibitory neurons resulting 
in no net change in Fos expression. Finally, hyperalgesia after injury and decreased 
endogenous activity of GPR40 in the descending inhibitory system, either through 
decreased expression of GPR40 or lesser availability of endogenous PUFA agonists, is 
associated with changes in GFAP (Harada et al, 2014) further supporting the interplay of 
pioglitazone, GPR40, and astrocytes. Thus GPR40 is an intriguing candidate for the 
regulation of rapid analgesia produced by TZDs.  
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6.4.1.5  TRP channels 
 PPARγ agonists may reduce hypersensitivity via interactions with TRP channels. 
15d-PGJ2 activates TRPA1 by covalent modification of reactive cysteine residues (Cruz-
Orengo et al, 2008; Takahashi et al, 2008; Weng et al, 2012). Peripheral administration 
of 15d-PGJ2 results in immediate nociceptive behavior and calcium mobilization in 
TRPA1 containing DRG neurons. Paradoxically, although 15d-PGJ2 activates TRPA1 to 
produce immediate nociception, we and others have shown that 15d-PGJ2 reduces 
evoked hypersensitivity in an inflammatory pain model (Morgenweck et al, 2010; Alves 
et al, 2011). These antihyperalgesic effects are thought to be mediated by PPARγ, as 
they are blocked by a PPARγ antagonist. However, a possible mechanism of the rapid 
analgesic effects of PPARγ agonists such as 15d-PGJ2 is through the acute 
desensitization of TRPA1 (Weng et al, 2012). Indeed, rosiglitazone is suggested to 
directly inhibit TRP channels (Majeed et al, 2011), suggesting a possible mechanism for 
the rapid inhibition of pain produced by TZDs. A future direction is to test the hypothesis 
that the antihyperalgesic effect of pioglitazone is abolished in TRPA1 or TRPV1 
knockouts, which would suggest that TRP channels play a role in the rapid analgesic 
effect of both endogenous and exogenous PPARγ agonists.  
 
6.4.2  How does pioglitazone reduce painful type 2 diabetes? 
 Therapeutic management of hyperglycemia does not always reverse PDN (Calcutt, 
2002), indicating the need for dual therapies that treat both the hyperglycemia and 
insulin desensitization as well as the neuronal mechanisms that contribute to pain. Here 
we show that chronic oral administration of pioglitazone reduced both hyperglycemia 
and hypersensitivity in ZDF. One could conclude that the mechanism of analgesia is 
mediated by normalizing blood glucose and therefore reducing the neurotoxic effects of 
hyperglycemia on nociceptive processing. However, Figure 6-9 illustrations that acute 
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administration of pioglitazone rapidly increased heat response thresholds (within one 
hour) in both db/db mice and ZDF rats but not in their respective normoglycemic 
controls. Furthermore, pioglitazone reduced hypersensitivity without changing blood 
glucose. This result provides strong evidence that the reduction of PDN by pioglitazone 
is not mediated through its role as an insulin-sensitizer, but likely facilitated by one of the 
rapid action mechanisms described above. 
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Figure 6-9. Effect of acute systemic pioglitazone on heat hyperalgesia and 
blood glucose in type 2 diabetes models. 
Data courtesy of Renee Donahue and Tommaso Iannitti. 
Pain-like heat withdraw latencies and blood glucose were measured before and 
after intraperitoneal (i.p.) injection of saline or pioglitazone (Pio) in rat and mouse 
models of type 2 diabetes. Heat sensitivity is shown in (A) control ZL and (B) 
diabetic ZDF rats (n=4-5) as well (C) control BKS and (D) diabetic db/db mice (n=8-
16). Glucose levels are shown in (E) control ZL and (F) diabetic ZDF rats (n=4-5) as 
well (G) control BKS and (H) diabetic db/db mice (n=8-16). Acute administration of 
pioglitazone attenuated heat hypersensitivity without changing blood glucose levels 
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within 2 hrs of administration.  high, † high and medium, ‡ high, medium, low dose 
Pio significantly different (p<0.05) from Saline.  
 
 We provide evidence that pioglitazone may alleviate painful type 2 diabetes through 
a methylglyoxal mechanism. Not only did acute administration of pioglitazone rapidly 
attenuate heat hyperalgesia in type 2 diabetic mice and rats, but it also acutely reduced 
MG-evoked nociception and hyperalgesia. Figure 6-10 illustrates that systemic or spinal 
administration of pioglitazone reduced MG-evoked nociceptive behavior. These data 
indicate that spinal administration of pioglitazone is more effective than systemic 
administration at reducing peripherally evoked nociception. We conclude that 
pioglitazone reduced the contribution of MG to pain-like behavior in type 2 diabetes 
through a spinal mechanism. I speculate that chronic administration of pioglitazone could 
act as an AGE breaker (Rahbar et al, 2000) to reduce PDN in ZDF.  
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Figure 6-10. Pioglitazone reduces MG-evoked pain-like behavior. 
Data in Panels A, C, D courtesy of Renee Donahue. I formulated the hypotheses, 
designed the experiments, and analyzed the data.  
(A) Intraperitoneal (100 mg/kg; mice) or (B) intrathecal (300 μg; rats) administration 
of pioglitazone but not saline vehicle 30 min prior to intraplantar methylglyoxal (100 
μg) reduced nociceptive responses in wild-type animals (n=3-4). Nociceptive licking, 
lifting, and flinching were quantified for the first five minutes after intraplantar 
administration of methylglyoxal (MG). Intraperitoneal administration of pioglitazone 
(100 mg/kg; mice) reduced (C) mechanical and (D) heat hyperalgesia.  p<0.05, # 
p<0.05 vs. Veh-Saline, $ p<0.05 vs. i.p. pioglitazone + i.pl. methylglyoxal.  
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 Enough evidence exists for us to speculate that pioglitazone inhibits the development 
of tolerance to the endogenous opioid system that normally acts to inhibit pain after 
injury. Corder et al established that behavioral hypersensitivity after inflammatory, nerve, 
or incisional injury recovers due to the body’s endogenous opioid system. They showed 
that endogenous mu opioid receptors mediate the restoration of normal sensory 
thresholds (Corder et al, 2013) by administration of opioid receptor antagonists. In the 
setting of type 2 diabetes, ZDF rats became hyposensitive to morphine after a prolonged 
period of behavioral hypersensitivity, suggesting that the ability of the body to recover 
from injury in diabetes is impaired, possibly due to impaired G-protein coupling of the mu 
opioid receptor (Otto et al, 2011). Therefore strategies that mitigate changes in the 
endogenous opioid system could be beneficial pain therapies. To this end, a recent 
study showed that pioglitazone delayed the behavioral tolerance that develops after 
repeated morphine administration (de Guglielmo et al, 2014; Ghavimi et al, 2014). This 
effect was reduced by GW9662 inhibition of PPARγ or by Cre recombinase knockout of 
PPARγ in nestin-positive neurons. reduced the effect of pioglitazone on delaying 
tolerance to morphine (de Guglielmo et al, 2014). Therefore we suggest that pain in type 
2 diabetes occurs by desensitization of and/or tolerance to the body’s endogenous pain 
inhibitory system, and speculate that chronic oral administration of pioglitazone reduced 
the development of hyperalgesia by mitigating (in the case of mechanical pressure 
hyperalgesia) or delaying (in the case of heat hyperalgesia) endogenous opioid 
tolerance. This hypothesis could help explain why pressure hyperalgesia was completely 
prevented by pioglitazone, while the onset of heat hyperalgesia was delayed several 
weeks but not abolished.  
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6.5  Conclusions 
 Figure 6-11 summarizes this work. My working model is that hyperglycemia and 
decreased GLO1 activity in type 2 diabetes leads to accumulation of methylglyoxal. 
Methylglyoxal tonically activates TRPA1 in vivo, priming the AC1 system resulting in 
peripheral and spinal sensitization through a yet to be determined mechanism, but I 
speculate that cAMP/PKA and TRPV1 as well as spinal plasticity mechanisms are 
involved. This proposed pathway of pain in type 2 diabetes can be altered at many 
different junctions to reduce pain sensitization. MG is inhibited by GERP10 and by 
pioglitazone, probably through activation of PPARγ activation, although PPARγ-
independent mechanisms could be involved in TZD analgesia. Inhibition of TRPA1 and 
AC1 activity through pharmacologic and genetic methods reduced spinal sensitization 
and pain. I propose a multitude of future studies to further investigate this overall 
mechanism. (1) Overexpression and inhibition of GLO1 activity as well as chronic MG 
administration as tools to manipulate MG levels either systemically or within specific 
tissues such as the spinal cord dorsal horn. (2) Inhibition of MG by alternative 
scavenging compounds such as ALT-711, AG, and GSH. (3) CHEM inhibition of TRPA1 
or using dorsal root stimulation, Tmem100 cell permeable peptide, blocking antibodies, 
and TRPV1 knockouts (-/-) to investigate the interplay between TRPA1 and TRPV1. (4) 
Investigate the mechanism of rapid pioglitazone antihyperalgesia through TRP channels, 
mitoNEET, or GPR40. (5) Use electrophysiology and CPP to uncover the mechanisms 
of MG-dependent spinal sensitization and affective pain, respectively.  
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Figure 6-11. Overall schematic of the current results and future directions. 
Working model of the contribution of methylglyoxal to pain in type 2 diabetes and 
inhibition of such pain mechanisms by pioglitazone. KEY: Line Arrows 
activation/production; Line Dots inhibition; Dark Blue drugs/interventions/tools; 
Black proteins/molecules/processes; Light Blue models/assays; Purple future 
studies; Red conditions. Abbreviations can be found in the Appendix. 
 
 Type 2 diabetes is a growing problem in the United States and throughout the world. 
Pain associated with type 2 diabetes is a complex process involving both peripheral and 
central sensitization. My results in combination with the literature provide evidence that 
this pain cannot be reversed by management of blood glucose and insulin dysfunction 
alone. Therefore I reasoned that the known antihyperalgesic and antihyperglycemic 
effects of TZDs could be combined to reduce painful type 2 diabetes. I provide the first 
preclinical evidence that pioglitazone reduces hyperglycemia and pain-like behavior 
associated with type 2 diabetes. The antihyperalgesic influence of pioglitazone in type 2 
diabetes is independent of its glucose lowering effect because acute administration of 
pioglitazone reversed hypersensitivity without changing blood glucose. I show that acute 
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pioglitazone rapidly reduces astrocyte gliosis but not markers of neuronal activation, and 
therefore provide insight into future studies determining the exact mechanisms by which 
pioglitazone rapidly reduces neuropathic pain, a phenomena we showed in several 
models including nociception induced by capsaicin and methylglyoxal, traumatic nerve 
injury, and type 2 diabetes. Drugs such as pioglitazone and other TZDs that inhibit 
glucose neurotoxicity, are anti-inflammatory, reduce gliosis, improve insulin signaling 
and glucose metabolism, and reduce pain are likely to provide a greater benefit to 
patients than treating the symptoms of pain or hyperglycemia independently.  
 In preclinical pain studies it is important to include measures of negative affect. This 
work highlights the importance of measuring “pain” in rodents using mechanical conflict 
avoidance and conditioned place preference/aversion assays, in addition to stimulus-
evoked measures of hypersensitivity. For the first time we show negative affect in a 
model of type 2 diabetes and implicate methylglyoxal in the generation of this 
motivational-affective pain in diabetes.  Measurement of evoked and non-evoked, 
affective pain in preclinical studies will be essential to enhance the translation of new 
analgesic drugs. 
 We extend previous studies investigating the effects of methylglyoxal on peripheral 
nociceptors and in the STZ model of type 1 diabetes by showing methylglyoxal induces 
spinal sensitization and pain-like behavior that is dependent upon TRPA1 in painful type 
2 diabetes. We identified a new target in painful type 2 diabetes, AC1, and suggest 
future studies aiming to reduce the methylglyoxal-TRPA1-AC1 sensitization pathway. 
We show for the first time that blocking methylglyoxal by administering GERP10 has 
long-lasting antihyperalgesia after a single dose. Finally, we indicate that pioglitazone 
reduces methylglyoxal-evoked pain and suggest future studies to investigate this 
mechanism. We conclude that both PPARγ and methylglyoxal represent promising 
targets for reducing the pain associated with type 2 diabetes. 
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APPENDIX 
 
Description of abbreviations used. 
Abbreviation  Description  
15d 15d-PGJ2, endogenous prostaglandin PPARγ agonist 
AC1 adenylyl cyclase 1, calcium activated enzyme that produces cAMP 
AG aminoguanidine, methylglyoxal scavenger and AGE breaker 
AGE advanced glycation end-product 
ALT-711 alagebrium, methylglyoxal scavenger and AGE breaker 
ANOVA analysis of variance, statistical test 
BKS C57BLK6S, mouse strain that is a control for db/db mice 
BrBz S-p-bromobenzylglutathioine cyclopentyl diester, GLO1 inhibitor 
cAMP cyclic adenosine monophosphate 
CHEM Chembridge-5861528, TRPA1 antagonist derived from HC 
CIG ciglitazone, PPARγ agonist 
CPA conditioned place aversion 
CPP conditioned place preference 
db/db Lepr-/- mouse model of type 2 diabetes 
DH dorsal horn 
DRG dorsal root ganglia sensory neuron 
DRS dorsal root stimulation 
DTT dithiothreitol, disulfide bond reducing agent 
GEAP control peptide containing 10 repeats of G,E,A,P amino acids 
GERP MG scavenging peptide containing 10 repeats of G,E,A,P amino acids 
GFAP glial fibrillary acidic protein, an astrocyte marker 
GLO1 glyoxalase 1, primary enzyme involved in MG detoxification 
GLO2 glyoxalase 2, secondary enzyme involved in MG detoxification 
GSH glutathione, GLO1 cofactor 
H1 hydroimidazolone residue 
i.p. intraperitoneal 
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i.pl. intraplantar 
i.t. intrathecal 
IASP International Association for the Study of Pain 
Iba1 ionized calcium-binding adapter molecule 1, a microglia marker 
MCS mechanical conflict avoidance system 
MG methylglyoxal 
MG-AGE methylglyoxal-derived advanced glycation end-product 
PDN painful diabetic neuropathy 
pERK phosphorylated extracellular signal-regulated kinase 
Pio pioglitazone, TZD PPARγ agonist 
PKA protein kinase A, activated by cAMP 
PPARγ peroxisome proliferator-activated receptor gamma 
PUFA polyunsaturated fatty acids 
Rosi rosiglitazone, TZD PPARγ agonist 
s.c. subcutaneous 
SEM standard error of the mean 
STZ streptozotocin model of type 1 diabetes 
TRPA1 Transient Receptor Potential cation channel A1 
TRPV1 Transient Receptor Potential cation channel V1 
TZD thiazolidinedione, structural class of PPARγ agonists 
vF von Frey, method of determining mechanical sensitivity 
ZDF Zucker Diabetic Fatty rat (fa/fa) model of type 2 diabetes 
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IASP definitions of terms used to describe pain phenomena. 
TERM  DEFINITON 
Allodynia Pain due to a stimulus that does not normally provoke pain. 
Hyperalgesia Increased pain from a stimulus that normally provokes pain. 
Hypoalgesia Diminished pain from a stimulus that normally provokes pain. 
Paresthesia An abnormal sensation, whether spontaneous or evoked. 
Dysesthesia An unpleasant abnormal sensation, whether spontaneous or 
evoked. 
Hyperesthesia Increased sensitivity to stimulation, excluding the special senses. 
Hypoesthesia Decreased sensitivity to stimulation, excluding the special senses. 
Neuropathic Pain Pain caused by a lesion or disease of the somatosensory nervous 
system. 
Neuropathy A disturbance of function or pathological change in a nerve: in one 
nerve, mononeuropathy; in several nerves, mononeuropathy 
multiplex; if diffuse and bilateral, polyneuropathy. 
Nociception The neural process of encoding noxious stimuli. 
Nociceptive 
Neuron 
A central or peripheral neuron of the somatosensory nervous 
system that is capable of encoding noxious stimuli. 
Nociceptive Pain Pain that arises from actual or threatened damage to non-neural 
tissue and is due to the activation of nociceptors. 
Nociceptive 
Stimulus 
An actually or potentially tissue-damaging event transduced and 
encoded by nociceptors. 
Nociceptor A high-threshold sensory receptor of the peripheral somatosensory 
nervous system that is capable of transducing and encoding 
noxious stimuli. 
Noxious 
Stimulus 
A stimulus that is damaging or threatens damage to normal tissues. 
Central 
Sensitization 
Increased responsiveness of nociceptive neurons in the central 
nervous system to their normal or subthreshold afferent input. 
Peripheral 
Sensitization 
Increased responsiveness and reduced threshold of nociceptive 
neurons in the periphery to the stimulation of their receptive fields. 
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